

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

The United Kingdom Research study into Ethnicity And COVID-19 outcomes in Healthcare workers (UK-REACH): Protocol for a prospective longitudinal cohort study of healthcare and ancillary workers in UK healthcare settings

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-050647
Article Type:	Protocol
Date Submitted by the Author:	01-Mar-2021
Complete List of Authors:	Woolf, Katherine; University College London, Research Department of Medical Education Melbourne, Carl; University of Leicester, Genetic Epidemiology Research Group, Department of Health Sciences Bryant, Luke; University of Leicester, Department of Respiratory Sciences Guyatt, Anna; University of Leicester, Genetic Epidemiology Research Group, Department of Health Sciences McManus, Ian; University College London, Research Department of Medical Education Gupta, Amit; Oxford University Hospitals NHS Foundation Trust Free, Robert; University of Leicester, Department of Respiratory Sciences; NIHR Leicester Biomedical Research Centre Respiratory Diseases Nellums, Laura; University of Nottingham, Division of Epidemiology and Public Health Carr, Sue; University Hospitals of Leicester NHS Trust; General Medical Council John, Catherine; University of Leicester, Department of Health Sciences Martin, Christopher; University of Leicester, Department of Respiratory Sciences; University Hospitals of Leicester NHS Trust, Department of Infection and HIV Medicine Wain, Louise; University of Leicester, Department of Health Sciences; NIHR Leicester Biomedical Research Centre Respiratory Diseases Gray, Laura; University of Leicester, Department of Respiratory Sciences Modhwadia, Vishant; University of Leicester, Department of Respiratory Sciences Abrams, Keith; University of York, Centre for Health Economics Tobin, Martin; University of Leicester, Genetic Epidemiology Research Group, Department of Health Sciences; NIHR Leicester Biomedical Research Centre Respiratory Diseases, Glenfield Hospital Khunti, Kamlesh; University of Leicester, Department of Respiratory Sciences; University Hospitals of Leicester, Department of Respiratory Sciences; University Hospitals of Leicester NHS Trust, Department of Infection and HIV Medicine

Keywords: COVID-19, Public health < INFECTIOUS DISEASES, MENTAL HEALTH

SCHOLARONE™ Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

The United Kingdom Research study into Ethnicity And COVID-19 outcomes in Healthcare workers (UK-REACH): Protocol for a prospective longitudinal cohort study of healthcare and ancillary workers in UK healthcare settings

Katherine Woolf*¹, Carl Melbourne*², Luke Bryant*³, Anna L Guyatt², Chris McManus¹, Amit Gupta⁴, Robert C Free^{3,9}, Laura Nellums⁵, Sue Carr^{6,7}, Catherine John², Christopher A Martin^{3,8}, Louise V Wain^{2,9}, Laura J Gray², Claire Garwood³, Vishant Modhwadia³, Keith Abrams ¹⁰, Martin D Tobin^{2,9}, Kamlesh Khunti¹¹, Manish Pareek^{3,8**} on behalf of the UK-REACH Study Collaborative Group+

Affiliations

- 1 Research Department of Medical Education, University College London Medical School, Gower Street, London WC1E 6BT, UK.
- 2 Department of Health Sciences, University of Leicester, University Road, Leicester, LE1 7RH, UK.
- 3 Department of Respiratory Sciences, University of Leicester, Leicester, LE1 7RH, UK.
- 4 Oxford University Hospitals NHS Foundation Trust, Headley Way, Headington, Oxford OX3 9DU, UK.
- 5 Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, City Hospital Campus, Hucknall Road, NG5 1PB, UK.
- 6 University Hospitals Leicester NHS Trust, Level 3, Balmoral Building, Leicester Royal Infirmary, Infirmary Square, Leicester, LE1 5WW, UK.
- 7 General Medical Council, 3BH, 350 Euston Rd, London NW1 3JN, UK.
- 8 Department of Infection and HIV Medicine, University Hospitals of Leicester NHS Trust, Leicester, LE1 5WW, UK.
- 9 National Institute for Health Research Leicester Biomedical Research Centre Respiratory, Glenfield Hospital, Leicester, LE3 9QP UK.
- 10 Centre for Health Economics, University of York, York, UK.
- 11 Diabetes Research Centre, University of Leicester, Leicester LE5 4PW, UK

UK-REACH Study Collaborative Group (*Work Package 2 collaborators):

Manish Pareek (Chief investigator)*, Amani Al-Oraibi, Amit Gupta**, Anna Guyatt, Carl Melbourne*, Catherine John*, Christopher A Martin*, I Chris McManus*, Chris Orton, Claire Garwood*, David Ford, Edward Dove, Fatimah Wobi, Janet Hood, Kamlesh Khunti*, Katherine Woolf*, Keith Abrams*,

^{*}Joint first authors; **Corresponding author manish.pareek@leicester.ac.uk

Laura J Gray*, Laura Nellums*, Louise V Wain*, Lucy Teece, Luke Bryant*, Martin Tobin,* Mayuri Gogoi, Osama Hassan, Robert C Free*, Ruby Reed-Berendt, Sue Carr*, Vishant Modhwadia*.

Abstract

Introduction

The COVID-19 pandemic has resulted in significant morbidity and mortality, and devastated economies globally. Among groups at increased risk are healthcare workers (HCWs) and ethnic minority groups. Emerging evidence suggests HCWs from ethnic minority groups are at increased risk of adverse COVID-19-related outcomes. To date there has been no large-scale analysis of these risks in UK HCWs or ancillary workers in healthcare settings, stratified by ethnicity or occupation, and adjusted for confounders. This paper reports the protocol for a prospective longitudinal questionnaire study of UK HCWs, as part of the UK-REACH programme (The United Kingdom Research study into Ethnicity And COVID-19 outcomes in Healthcare workers).

Methods and analysis

A baseline questionnaire with follow-ups at 4 and 8 months will be administered to a national cohort of UK HCWs and ancillary workers in healthcare settings, and those registered with UK healthcare regulators. With consent, data will be linked to health records with 25 year follow-up.

Univariate associations between ethnicity and clinical COVID-19 outcomes, physical and mental health, and key confounders/explanatory variables will be tested. Multivariable analyses will test for associations between ethnicity and key outcomes adjusted for the confounder/explanatory variables. Multilevel models will model changes over time by ethnic group, facilitating understanding of absolute and relative risks in different ethnic groups, and generalisability of findings.

Ethics and dissemination.

The study is approved by Health Research Authority (reference 20/HRA/4718), and carries minimal risk. We aim to manage the small risk of participant distress about questions on sensitive topics by clearly participant information that the questionnaire covers sensitive topics and there is no obligation to answer these or any other questions, and by providing support organisation links. Results will be disseminated with reports to Government and papers submitted to pre-print servers and peer reviewed journals.

Registration details.

Trial ID: ISRCTN11811602

STRENGTHS AND LIMITATIONS OF THIS STUDY

- National, UK-wide, study, aiming to capture variety of healthcare worker job roles including ancillary workers in healthcare settings.
- Longitudinal study including three waves of questionnaire data collection, and linkage to administrative data over 25 years, with consent.
- Unique support from all major UK healthcare worker regulators, relevant healthcare worker organisations, and a Professional Expert Panel to increase participant uptake and the validity of findings.
- Potential for self-selection bias and low response rates, and the use of electronic invitations and online data collection makes it harder to reach ancillary workers without regular access to work email addresses.

INTRODUCTION

COVID-19 has spread rapidly across the world, causing significant morbidity and mortality, and devastating health economies in many countries. Healthcare workers (HCWs) have been identified as being at increased risk of SARS-CoV-2 infection and adverse outcomes,(1-3) as have individuals from ethnic minority groups.(2, 4-13) Emerging evidence suggests that ethnic minority groups may also be at greater risk of long-term COVID-19 sequelae.(4) HCWs and individuals from ethnic minority groups may also be at increased risk of COVID-19-related poor mental health outcomes, including anxiety, depression and post-traumatic stress.(14-19)

There are concerns that HCWs from ethnic minority groups are at particular risk of SARS-CoV-2 infection and adverse COVID-19 outcomes compared to white HCWs (3, 20, 21) However, the quality of data relating to COVID-19 outcomes in HCWs remains poor, with no large representative studies of the risk of COVID-19 infection or adverse outcomes in healthcare workers or ancillary workers in healthcare settings (hereafter "HCWs") stratified by ethnicity or occupation type, controlling for potential confounders.

To address this, UK-REACH (United Kingdom Research study into COVID-19 outcomes in Healthcare workers) will rapidly examine differences in COVID-19 diagnosis, clinical outcomes (diagnosis, hospitalisation, ICU admission), professional roles, and well-being among ethnic minority and white HCWs through a unique large database analysis (rapid linkage and analysis of anonymised professional registration and National Health Service (NHS) datasets), longitudinal cohort study, legal/ethical analysis, and qualitative work packages. This work will provide information on very short-term outcomes and produce rapid actionable outputs, as well as enabling investigations of the medium/long-term effects of COVID-19 on HCWs in future studies through the linkage and cohort study. This protocol describes the UK-REACH longitudinal cohort study.

Research Question

What is the impact of COVID-19 on the physical and mental health of ethnic minority HCWs compared to white HCWs in the short term and the longer term?

Aims

To examine the relationship between ethnicity and COVID-19-related mental and physical health outcomes through the establishment of a novel longitudinal cohort study of HCWs, including recruitment from the membership bodies and professional registers for different healthcare roles, providers of facilities management, and directly from UK healthcare settings.

To study changes in health outcomes, social circumstances and professional roles of HCWs of different ethnicities, over the course of the COVID-19 pandemic and to characterise longer-term outcomes and consequences.

To measure differences in the impact of COVID-19 infection and working during the pandemic on physical and mental health in a multi-ethnic group of HCWs in the UK.

Objectives

To survey HCWs at baseline to collect data on demographics, job role, attitudes to work and work climate, social and living circumstances, values and personality, and physical and mental health.

To collect baseline biological samples for future analysis in a subsample of consenting participants.

To conduct follow-up surveys and samples over 12 months in order to capture changes over subsequent COVID-19 pandemic waves.

To link survey data to participant healthcare records, with consent.

METHODS AND ANALYSIS

Study design

National prospective longitudinal cohort study in all four nations of the United Kingdom.

Setting

Healthcare workers and ancillary workers in healthcare settings within the UK.

Participants

Inclusion criteria

Age ≥ 16 years;

Living in the UK;

Healthcare worker or ancillary worker in a UK healthcare setting OR Registered with the following UK healthcare professional regulatory bodies: the General Medical Council (GMC), Nursing and Midwifery Council (NMC), General Dental Council (GDC), Health and Care Professions Council (HCPC), General Optical Council (GOC), General Pharmaceutical Council (GPC) or the Pharmaceutical Society of Northern Ireland (PSNI);

Willing and able to give informed consent.

Exclusion criteria

Age <16 years;

Living outside the UK;

Not a healthcare worker or ancillary worker in a healthcare setting AND not regulated by one of the professional regulatory bodies listed above;

Unwilling and/or unable to give informed consent.

Sample size

We aim to recruit at least 32,000 HCWs (66% from ethnic minority groups). See Figure 1 for the study flow chart. The proposed sample will approximately comprise:

- 10,000 doctors
- 10,000 nurses, midwives and nursing associates
- 4,000 ancillary workers
- 2,000 allied health professionals
- 2,000 ambulance workers
- 2,000 pharmacists and pharmacy technicians
- 1,000 dentists and dental care professionals
- 1,000 optometrists and dispensing opticians

Whilst the above numbers represent our target numbers for recruitment, we will welcome participants working in other roles within healthcare settings. We may adapt target sample sizes for subgroups following initial response, to ensure we have appropriate representation of ethnic minority participants in each job role.

This sample size has been pragmatically chosen to allow for adequate representation of all ethnic groups within all job-role categories. Based on general population prevalence estimates (11) producing conservative power estimates, we anticipate at least 80% (statistical) power to detect modest effects of ethnicity (RR \geq 1.5) for more prevalent outcomes (e.g. COVID-19 diagnosis) and larger effects (RR \geq 2) for rarer outcomes (e.g. mortality). Power calculations will be reviewed to reflect changing rates of infection.

Recruitment

Recruitment will be via several routes, and will be incentivised by the inclusion of a prize draw for those who complete the questionnaire:

- i) Email, letter, and/or text message invitations from healthcare professional regulators. The records and registrations with the GMC, NMC, GDC, HCPC, GOC, GPC, PSNI will be used as a sampling frame. Where possible, we will utilise demographic data routinely collected by regulators to oversample for people identifying as being from ethnic minority backgrounds. We will endeavour to sample representatively across age groups, sex/gender, job roles, and other characteristics, in order to maximise the generalisability of our findings. Regulators will send invitations and reminders on behalf of the principal investigator. Alongside these invites regulators will also promote the study through their social media channels as the invites go out.
- ii) Targeted advertisement to key staff groups through healthcare organisations. We will advertise the study through the general communication channels of regulators, professional bodies (e.g. Royal College of Midwives, Royal College of General Practitioners), Health Education bodies, and other relevant organisations (e.g. the British Medical Association, the British Association of Physicians of Indian Origin (BAPIO), The Filipino Nurses Association United Kingdom). This will include promotion through newsletters, web pages, email communications and banners on self-service portals (for example, on the NHS Electronic Staff Record portal used for accessing payslips).
- iii) General publicity of the study via print and broadcast media, social media for the study and other relevant organisations, and posters or flyers in workplaces, as relevant to participant staff groups.
- Direct invitation and recruitment via UK healthcare providers.

 UK healthcare providers, including at least 30 NHS Hospital Trusts, will advertise to potential participants by email, text, mail, verbally, or through posters/flyers. Trusts will be selected to represent a range of geographical areas (to include England, Scotland, Wales, and Northern Ireland). We will aim to recruit from both large teaching hospitals and smaller community healthcare trusts, and will take into consideration regional ethnic diversity when selecting trusts. We will also utilise a study infographic to promote recruitment through NHS trusts. Recruitment of ancillary staff has been facilitated by Serco at specific trusts, through utilisation of content handouts and posters which have been cascaded by contractors on site.

Invitations and advertisements will direct staff via a weblink and/or QR code to the study recruitment site. In the case of direct recruitment through UK healthcare settings, potential participants will be supported to join with the help of suitably trained members of the local research team where appropriate. Reminders will also be sent to improve recruitment to the study.

Data collection

See Figure 2 for the study timeline.

To gain informed consent, potentially interested participants will have the opportunity to read the UK-REACH participant information sheet (PIS) online via a web application, or in person with a member of the local research team, before deciding if they would like to take part. Potential participants will be asked to register for a UK-REACH account (https://uk-reach.org/) by entering an email address and password, then will be asked to sign an online consent form. To complete registration, participants will be asked to provide personal details including name, date of birth, and address. Participants will be considered enrolled into the study after completing the registration process, and giving their electronic consent on a secure web page. They will be assigned a unique identifier at this point. This will be securely retained in an electronic database at the University of Leicester, which will also function as an enrolment log.

Once translation has been undertaken and checked, we will make study materials (PIS and consent form) available in alternative languages commonly used by workers in healthcare settings as required. These will be made available on the UK-REACH website.

After consenting to participation in the study, participants will be asked to complete a baseline online questionnaire on demographics, job role and other work circumstances, location of work/residence, interaction with COVID-19 patients (including access to personal protective equipment, social and living circumstances, discrimination and harassment, values and personality, and physical and mental health (see Measures, below). This questionnaire will be accessible via the study website, and support to complete the questionnaire will also be available from the study team. Some identifiable data (e.g. name, DOB, address) will be collected during registration and/or the questionnaire to facilitate secure data linkage (see Data linkage, below).

Participants will be invited to complete the baseline questionnaire between December 2020 and January 2021. Participants will have the option of completing two further questionnaires, one at approximately 4 months from baseline and one at approximately 8 months from baseline. Consent will be requested to follow up participants for up to 25 years (subject to funding), and during this time serial questionnaire data will be collected, and periodic linkage with healthcare records will take place (see Data linkage, below).

Data linkage

Participants will be asked to provide consent for the study to follow their health by extracting information from their past and future NHS health care records (including NHS number), any COVID-19 related records, and from "COVID-19 symptom study" websites or apps (22) if they use them.

Initially, questionnaire and personal data, for which consent has been given, will be electronically transferred to University of Leicester, and stored separately on secure servers. A study ID for each participant together with identifiable data will be sent to NHS Wales Informatics Service in order to acquire the list of NHS numbers/Community Health Index (CHI) number (for Scotland)/Health and

Care number (for Northern Ireland) in partnership with the relevant UK NHS data providers. Study ID and NHS/CHI/H&C number will then be used to link to healthcare records by the relevant data provider across the UK. De-identified records will be sent directly to the Secure Anonymised Information Linkage databank (SAIL, https://saildatabank.com), retaining Study ID. Separately, study ID and corresponding questionnaire data will be sent from the University of Leicester to SAIL. These datasets will be linked within SAIL to provide the complete dataset. Interim analysis of unlinked questionnaire data will be performed at the University of Leicester using pseudonymised datasets. All linked data analysis will take place within SAIL.

Questionnaire design

The questionnaires will be designed by the study team with input from the Professional Expert Panel (PEP) - see Patient and Public Involvement, below. Where possible, previously used and/or validated measures are being used. The study team will devise measures where none are available.

The baseline questionnaire will ask about participants' current experiences and attitudes, as well as collecting some retrospective data about participants' experiences and attitudes at the start of the pandemic and/or pre-pandemic. Follow-up questionnaires will repeat outcome measures, and may include new items relevant to the progression of the pandemic. The data dictionary (https://www.uk-reach.org/data-dictionary) contains the source(s) for each question. The baseline questionnaire is included as an Appendix.

Patient and public involvement

The UK-REACH team have worked closely with national and local organisations representing ethnic minority HCWs, who have been closely involved in identifying the research questions, deciding the study methodology, and are included either as members of the study delivery team or collaborators. They are also part of the Stakeholder group (see Supplementary Information for list of organisations) that will meet monthly to monitor study progress and research outputs, and provide advice to the research team on study delivery and progress. This group will also be central in disseminating the research findings. Alongside the high-level national organisation input into this stakeholder group, we will have representation from ethnic minority HCWs, including those who have contracted COVID-19 (mild to severe), to provide feedback on our work and how it should be disseminated. Members of our stakeholder/public engagement group will also sit on the Scientific Committee to ensure there is a seamless flow of information from the research team and the public engagement/stakeholder group. In addition we are working closely with the Centre for BME Health (Leicester, UK) to ensure that we are working to engage staff from a range of ethnic groups.

A Professional Expert Panel (PEP) will provide feedback on UK-REACH study materials and sampling methodology such as surveys, questionnaires, and interview and focus group topic guides. The PEP is made up of individuals who work within a healthcare setting from a range of ethnic backgrounds, occupational backgrounds, and genders. Staff have unique insight related to their professions or ethnic groups and are, therefore, in a position to provide advice and lived experience related to certain aspects of the project. The aim is for the PEP to draw on their experiences when providing their comments to ensure research instruments are at optimum suitability for study participants. The PEP meets virtually on a bi-monthly basis via Microsoft Teams. Study items/documents for discussion are circulated a week in advance of the PEP meeting and the group's Chair and Co-chair (PEP members who both volunteered to take on the role) moderate the meeting. UK-REACH team members are present in order to answer study-specific queries, and so only enter the discussions to

do so. The PEP also interacts with the study team between meetings via email with any additional feedback.

Primary outcome measures

Clinical COVID-19 outcomes

Participants will be asked to self-report COVID-19 infection, defined as either a positive SARS-CoV-2 polymerase chain reaction (PCR) or antibody test, or as self-reported suspected infection; the latter will be particularly relevant for those reporting historic illness early in the pandemic before widespread availability of testing.

Those reporting COVID-19 illness will be asked about: date of onset, the nature of symptoms experienced and their duration, and hospitalisation (including any time spent in intensive care). Corroboration of the details of these outcomes will be possible using linked electronic healthcare records (see "Measures obtained via data linkage", below).

General health

This will be measured using the EQ-5D-5L instrument(23) (https://euroqol.org/), which contains five dimensions on mobility, self-care, usual activities, pain and discomfort, and anxiety and depression, plus an overall self-report of health.

Mental health

This will be measured using the Patient Health Questionnaire-2 (PHQ-2)(24) for depression, the Generalised Anxiety Disorder-2 (GAD-2)(25) scale for anxiety, a three-item abbreviated version of the PCL-6 scale for post-traumatic stress disorder,(26) a three-item abbreviated version of the UCLA Loneliness scale, (27) and an Office for National Statistics question about overall life satisfaction.(28) Participants will also be asked key questions from the Utrecht Work Engagement Scale (29) and the GMC National Training Survey questions on burnout(30) (from the Copenhagen Burnout Inventory (31)).

Questionnaire measures

Ethnicity

In this study we will ask participants to self-identify the ethnic group with which they most identify using the 18 UK Census 2011 Categories.(32) The questionnaire also asks the ethnic group of any partner and of parents.

We will then collapse these 18 categories into five main ethnic categories also defined within the Census (Black, Asian, Mixed, Other, White). We will further collapse them into two groups which we will refer to as "white" (White British, White Irish, White Gypsy or Traveller, White Other) and "ethnic minority" (all other ethnic groups). There is currently considerable debate about the categorisation of people using ethnic groups, and in particular, the grouping of people who do not identify as white into a single category. There is also considerable debate and controversy about the words used to describe such a broad and heterogeneous grouping, with terms such as "people of colour", "Black Asian and Minority Ethnic" or "BAME" used. In our choice of terms we have followed the BMJ who in their special edition on Racism in Medicine use the term "ethnic minority" as one that is most likely to be understood by our study population.(33) We fully acknowledge that broad ethnic groupings can mask important ethnic and cultural differences, and where possible we will use more refined ethnic groupings, while also acknowledging the heterogeneity within them.

Nationality, religion, and languages

Country of birth, nationality, parents' country of birth, grandparents' country of birth (born in UK / not born in UK), age learned English (if second language), language(s) spoken at home (currently and as a child), religion, religiosity, ethnic identity.

Other demographics and education

Age, gender, sex, marital status, highest level of education completed, year and country of primary professional qualification (if applicable), highest level of education achieved by parents.

Work

Job role(s), sector(s), grade and specialty (for doctors), NHS band (for other HCWs), registered field of practice (nurses); work location(s); whether currently working, reasons for not working (if applicable); hours worked in a typical week; frequency of night shifts; contact with patients (with and without COVID-19), colleagues and others (remotely, face-to-face with social distancing, with physical contact); time spent travelling to and from work, modes of transport; access to, use of, and training to use personal protective equipment (PPE); exposure to aerosol-generating procedures; NHS COVID-19 risk assessment experiences; feelings about raising a clinical concern at work, perceptions of fairness of organisation with regards career progression; redeployment as a result of the pandemic, patient exposure, training and supervision in redeployed role (if applicable); proportion of colleagues of same ethnicity to self, proportion of colleagues who are white; work engagement.

Home and social life

Household composition (numbers, ages, relationship to participant) and sharing of accommodation; number of household members travelling using public transport or in jobs that bring them into close contact with others; childcare and support "bubbles"; length of time at current address; type and size of accommodation including amount of shared space and access to safe outdoor space; numbers of social contacts (remotely, face to face with social distancing, with physical contact), proportion of friends of the same ethnic group to self.

Harassment and discrimination

Experiences of discrimination in day-to-day life; discrimination at work and whether made a complaint (if applicable).

Physical health, mental health, and wellbeing

Height, weight, smoking and alcohol use, physical activity at work, general physical activity, change in lifestyle since start of pandemic, healthcare experience in 2019 (GP consultations and hospital admittance), flu vaccine uptake, medication, health conditions and pregnancy, quality of life, general anxiety, depression, post-traumatic stress disorder (PTSD), loneliness, and general life satisfaction.

COVID-19 experiences and beliefs

COVID-19 exposure, testing and test positivity; symptoms experienced, plus their severity and longevity, including diagnosis of long-COVID (if applicable); behaviour changes due to COVID-19; concern, knowledge and beliefs about COVID-19; COVID-19 information sources; enjoyment of first national lockdown (Spring 2020), COVID-19 vaccine trial participation; COVID-19 vaccination intention including offers, uptake (including vaccine brand), or reasons for refusal, and vaccine beliefs.

Trait and state psychological measures

'Big five' personality traits, locus of control, health locus of control, risk taking, burnout, personal need for structure.

Open-ended questions

The baseline questionnaire will include three open-ended free-text questions: "What are your thoughts on why people from ethnic minorities working in health and care have been more severely affected by COVID-19?", "How do you see society changing as a result of COVID-19?", "How do you see your own future changing as a result of COVID-19?".

Evaluation questions

Views on the length of the questionnaire and on its usefulness for understanding ethnicity and COVID-19.

Measures obtained via data linkage

Data linkage will be used to corroborate COVID-19 clinical outcomes (acute infection, antibody positivity), major comorbidities and patterns of healthcare use.

Biological sampling

At baseline we will also seek consent to re-contact participants in the future for DNA sampling and sampling related to immune profiling although we will submit an amendment to implement this sampling and detail the specifics relating to this at the time of submitting the amendment.

Statistical analysis

Descriptive statistics will be calculated for the primary outcome measures, and for ethnicity and key confounder/explanatory variables.

Univariate associations between ethnicity and primary outcome measures, and between ethnicity and key confounders/explanatory variables calculated using chi-squared tests for categorical variables, and t-tests and analyses of variance for continuous measures, with non-parametric equivalents used as appropriate for ordinal variables. This will enable the examination of the behavioural, social, and clinical phenotypes of the cohort in relation to the patterns of demographics, job role, attitudes to work and work climate, social and living circumstances, values and personality, and physical and mental health by ethnicity.

Using baseline data, multivariable analyses will test for associations between ethnicity and key outcomes, adjusted for the confounder/explanatory variables found to have a statistically significant univariate association with either ethnicity or the primary outcome variable(s), with interactions included as appropriate. Using follow-up data, multilevel models will be used to model changes over time by ethnic group.

Models will fit ethnicity as both a binary indicator (ethnic minority versus white) and as a categorical variable based on ONS categorisation of ethnicity, with the white group used as the reference group.

ETHICS AND DISSEMINATION

Ethical approval

The study has been approved by the Health Research Authority (Brighton and Sussex Research Ethics Committee; ethics reference: 20/HRA/4718).

Ethical considerations

Whilst this study is low risk, the questionnaire covers sensitive topics around COVID-19, ethnicity (including issues of discrimination and harassment), and mental health, and these could be distressing to participants. We aim to manage this risk by clearly indicating on the PIS that the questionnaire covers sensitive topics and that participants are under no obligation to answer these, or indeed any other, questions, and provide links to support organisations.

Participant confidentiality

The participants will be identified only by a unique identifier in the main research database. Identifiable information (name, date of birth, address etc) will be stored in a separate secure database, and will be accessed only by a small number of authorised staff at the University of Leicester who require access to administer the study. All documents will be stored securely, and only be accessible by study staff and authorised personnel. The study will comply with the Data Protection Act, which requires data to be anonymised as soon as it is practical to do so. Any dissemination of study findings will follow best-practice guidelines for deductive disclosure. Only aggregate data will included in publications.

Discontinuation/withdrawal of participants from study

Participants who wish to withdraw from the cohort study will be asked to determine the desired level of withdrawal from the study as described by the two options below. We will keep a record of consent for all participants to manage re-contact and for future audit. We will accept signed withdrawal forms from participants or, if they are unable to complete a withdrawal form themselves, from someone acting on the participant's behalf. At the present time, withdrawal forms will be completed electronically, but signed written forms will also be accepted when it is feasible to securely receive and store these. The options that participants will be given if they wish to withdraw:

Option 1 - No further contact: we would no longer contact the participant, but would have the participant's permission to continue to obtain information by accessing their health records in the future.

Option 2 – No further contact or access: we would no longer contact the participant or obtain information from the participant's health records in the future.

If participants withdraw from UK-REACH, then any data and samples already collected will remain and be used in the study. Information and data will continue to be collected about participants' health from central NHS records, hospital records, and participants' GPs, unless participants state otherwise on the withdrawal form.

Description of data flow

See Figure 3 for a description of the data flow.

Dissemination plan

Quarterly reports in months 3, 6, 9, and 12 summarising recruitment progress and initial findings on relationship between ethnicity, COVID-19 diagnosis and outcomes, physical/mental well-being, and professional and social factors. Brief reports will be produced and submitted for review by the stakeholder group (see Supplementary material for details), PEP, Study Steering Committee and the UK Government's Scientific Advisory Group for Emergencies (SAGE). Papers submitted to peer reviewed journals and pre-print servers.

DATA SHARING STATEMENT

To access data or samples produced by the UK-REACH study, the working group representative must first submit a data and material request form to the **Data Access Committee** (DAC) providing details for all manuscript proposals. The DAC will establish priorities for core and ancillary projects. For ancillary studies outside of the core deliverables, the **Steering Committee** will make final decisions once they have been approved by the **Core Management Group** and the DAC. Decisions on granting the access to data/materials will be made within eight weeks. Third party requests from outside the Project will require explicit approval of the Steering Committee once approved by the Core Management Group and the DAC.

AUTHORS CONTRIBUTIONS

MP conceived of the idea and led the application for funding with input from MT, KK, ICM, KW, RF, LN, SC, KRA, LG, AG and CJ. The survey was designed by KW, MP, ICM, CMel, CJ, AG, LN, CAM and RF. Online consent and survey tools were developed by LB. KW wrote the first draft of the manuscript with input from MP and all co-authors. All authors approved the submitted manuscript.

ACKNOWLEDGEMENTS

This work is carried out with the support of BREATHE -The Health Data Research Hub for Respiratory Health [MC_PC_19004] in partnership with SAIL Databank. BREATHE is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK.

We wish to acknowledge the PEP group and the STAG group (see Supplementary material), and SERCO, as well as the following people for their support in organising the email invites from the regulatory bodies: Kerrin Clapton and Andrew Ledgard (General Medical Council), Caroline Kenny (Nursing and Midwifery Council), David Teeman and Lisa Bainbridge (General Dental Council), My Phan and John Tse (General Pharmaceutical Council), Angharad Jones (General Optical Council), Katherine Timms and Charlotte Rogers (The Health and Care Professions Council) and Mark Neale (Pharmaceutical Society of Northern Ireland).

FUNDING STATEMENT

UK-REACH is supported by a grant from the MRC-UK Research and Innovation (MR/V027549/1) and the Department of Health and Social Care through the National Institute for Health Research (NIHR) rapid response panel to tackle COVID-19. Core funding was also provided by NIHR Biomedical Research Centres.

ALG was funded by internal fellowships at the University of Leicester from the Wellcome Trust Institutional Strategic Support Fund (204801/Z/16/Z) and the BHF Accelerator Award (AA/18/3/34220). CJ holds a Medical Research Council Clinical Research Training Fellowship (MR/P00167X/1). KA is supported by Health Data Research (HDR) UK and as a NIHR Senior Investigator Emeritus (NF-SI-0512-10159). KK and LJG are supported by the National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands (ARC EM). KK, MP, and RCF are supported by the NIHR Leicester Biomedical Research Centre (BRC). CAM is an NIHR Academic Clinical Fellow (ACF-2018-11-004). LBN is supported by an Academy of Medical Sciences Springboard Award (SBF005\1047). MP is supported by a NIHR Development and Skills Enhancement Award. MDT holds a Wellcome Trust Investigator Award (WT 202849/Z/16/Z) and an NIHR Senior Investigator Award. KW holds an NIHR Career Development Fellowship (CDF: CDF-2017-10-008). LVW holds a GSK/British Lung Foundation Chair in Respiratory Research (C17-1).

The views expressed in the publication are those of the author(s) and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health and Social Care.

This research was funded in whole, or in part, by the Wellcome Trust [WT204801/Z/16/Z and WT 202849/Z/16/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

COMPETING INTERESTS STATEMENT

SC is Deputy Medical Director of the General Medical Council, UK Honorary Professor, University of Leicester. KK is Director of the University of Leicester Centre for Black Minority Ethnic Health, Trustee of the South Asian Health Foundation, Chair of the Ethnicity Subgroup of SAGE and Member of Independent SAGE. LVW receives grant funding from GSK and Orion, outside of the submitted work. KA has served as a paid consultant, providing unrelated methodological and strategic advice, to the pharmaceutical and life sciences industry generally and has received unrelated research funding from Association of the British Pharmaceutical Industry, European Federation of Pharmaceutical Industries & Associations, Pfizer, Sanofi and Swiss Precision Diagnostics. He is a Partner and Director of Visible Analytics Limited, a healthcare consultancy company.

WORD COUNT

REFERENCES

- 1. Office for National Statistics. Coronavirus (COVID-19) related deaths by occupation, England and Wales: deaths registered between 9 March and 28 December 2020 2021 [Available from: <a href="https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/causesofdeath/bulletins/coronaviruscovid19relateddeathsbyoccupationenglandandwales/deathsregisteredbetween9marchand28december2020#deaths-involving-covid-19-among-men-and-women-health-and-socialcare-workers."
- 2. Mutambudzi M, Niedwiedz C, Macdonald EB, Leyland A, Mair F, Anderson J, et al. Occupation and risk of severe COVID-19: prospective cohort study of 120 075 UK Biobank participants. Occupational and Environmental Medicine. 2020:oemed-2020-106731.

- 3. Levene LS, Coles B, Davies MJ, Hanif W, Zaccardi F, Khunti K. COVID-19 cumulative mortality rates for frontline healthcare staff in England. British Journal of General Practice. 2020;70(696):327-8.
- 4. Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond SI, et al. Epidemiology of post-COVID syndrome following hospitalisation with coronavirus: a retrospective cohort study. medRxiv. 2021:2021.01.15.21249885.
- 5. Khanijahani A. Racial, ethnic, and socioeconomic disparities in confirmed COVID-19 cases and deaths in the United States: a county-level analysis as of November 2020. Ethnicity & Health. 2020:1-14.
- 6. Khunti K, Singh AK, Pareek M, Hanif W. Is ethnicity linked to incidence or outcomes of covid-19? BMJ. 2020;369:m1548.
- 7. Kirby T. Evidence mounts on the disproportionate effect of COVID-19 on ethnic minorities. The Lancet Respiratory Medicine. 2020;8(6):547-8.
- 8. Platt L, Warwick R. COVID-19 and Ethnic Inequalities in England and Wales*. Fiscal Studies. 2020;41(2):259-89.
- 9. Webb Hooper M, Nápoles AM, Pérez-Stable EJ. COVID-19 and Racial/Ethnic Disparities. JAMA. 2020;323(24):2466-7.
- 10. Nazroo J, Murray K, Taylor H, Bécares L, Field Y, Kapadia D, et al. Rapid Evidence Review: Inequalities in relation to COVID-19 and their effects on London. University of Manchester, The Ubele Initiative, University of Sussex; 2020.
- 11. Sze S, Pan D, Nevill CR, Gray LJ, Martin CA, Nazareth J, et al. Ethnicity and clinical outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine. 2020;29-30:100630.
- 12. Pan D, Sze S, Minhas JS, Bangash MN, Pareek N, Divall P, et al. The impact of ethnicity on clinical outcomes in COVID-19: A systematic review. EClinicalMedicine. 2020;23.
- 13. Clift AK, Coupland CAC, Keogh RH, Diaz-Ordaz K, Williamson E, Harrison EM, et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ. 2020;371:m3731.
- 14. Sahebi A, Nejati B, Moayedi S, Yousefi K, Torres M, Golitaleb M. The prevalence of anxiety and depression among healthcare workers during the COVID-19 pandemic: An umbrella review of meta-analyses. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2021:110247.
- 15. Galli F, Pozzi G, Ruggiero F, Mameli F, Cavicchioli M, Barbieri S, et al. A Systematic Review and Provisional Metanalysis on Psychopathologic Burden on Health Care Workers of Coronavirus Outbreaks. Frontiers in Psychiatry. 2020;11(1001).

- 16. Greene T, Harju-Seppänen J, Adeniji M, Steel C, Grey N, Brewin CR, et al. Predictors and rates of PTSD, depression and anxiety in UK frontline health and social care workers during COVID-19. medRxiv. 2020;2020.10.21.20216804.
- 17. Iob E, Frank P, Steptoe A, Fancourt D. Levels of Severity of Depressive Symptoms Among At-Risk Groups in the UK During the COVID-19 Pandemic. JAMA Network Open. 2020;3(10):e2026064-e.
- 18. Iob E, Steptoe A, Fancourt D. Abuse, self-harm and suicidal ideation in the UK during the COVID-19 pandemic. The British Journal of Psychiatry. 2020;217(4):543-6.
- 19. Wanigasooriya K, Palimar P, Naumann DN, Ismail K, Fellows JL, Logan P, et al. Mental health symptoms in a cohort of hospital healthcare workers following the first peak of the COVID-19 pandemic in the UK. BJPsych Open. 2020;7(1):e24.
- 20. Trivedy C, Mills I, Dhanoya O. The impact of the risk of COVID-19 on Black, Asian and Minority Ethnic (BAME) members of the UK dental profession. British Dental Journal. 2020;228(12):919-22.
- 21. Martin CA, Patel P, Goss C, Jenkins DR, Price A, Barton L, et al. Demographic and occupational determinants of anti-SARS-CoV-2 IgG seropositivity in hospital staff. Journal of Public Health. 2020.
- 22. Drew DA, Nguyen LH, Steves CJ, Menni C, Freydin M, Varsavsky T, et al. Rapid implementation of mobile technology for real-time epidemiology of COVID-19. Science. 2020;368(6497):1362-7.
- 23. Herdman M, Gudex C, Lloyd A, Janssen MF, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research. 2011;20(10):1727-36.
- 24. Löwe B, Kroenke K, Gräfe K. Detecting and monitoring depression with a two-item questionnaire (PHQ-2). Journal of Psychosomatic Research. 2005;58(2):163-71.
- 25. Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. General Hospital Psychiatry. 2016;39:24-31.
- 26. Lang AJ, Wilkins K, Roy-Byrne PP, Golinelli D, Chavira D, Sherbourne C, et al. Abbreviated PTSD Checklist (PCL) as a guide to clinical response. General hospital psychiatry. 2012;34(4):332-8.
- 27. Hughes ME, Waite LJ, Hawkley LC, Cacioppo JT. A Short Scale for Measuring Loneliness in Large Surveys:Results From Two Population-Based Studies. Research on Aging. 2004;26(6):655-72.
- 28. Surveys using our four personal well-being questions: A guide to what surveys include the four ONS personal well-being questions: Office for National Statistics; 2018 [Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/wellbeing/methodologies/surveysusingthe40fficefornationalstatisticspersonalwellbeingquestions.

- 29. Schaufeli WB, Bakker AB, Salanova M. The Measurement of Work Engagement With a Short Questionnaire: A Cross-National Study. Educational and Psychological Measurement. 2006;66(4):701-16.
- 30. General Medical Council National training surveys 2019: Initial findings report. General Medical Council, 2019.
- 31. Kristensen TS, Borritz M, Villadsen E, Christensen KB. The Copenhagen Burnout Inventory: A new tool for the assessment of burnout. Work & Stress. 2005;19(3):192-207.
- Jons 1
 2016.

 ace: BMJ; 2020 [A\
 /02/13/navjoyt-ladher 32. Harmonised Concepts and Questions for Social Data Sources, Primary Principles: Ethnic Group. Government Statistical Service; 2016.
- 33. Ladher N. Let's talk about race: BMJ; 2020 [Available from: https://blogs.bmj.com/bmj/2020/02/13/navjoyt-ladher-lets-talk-about-race/.

Figure captions

Figure 1: Study flowchart

Figure 2: UK-REACH Work package 2 timeline as of 4th February 2021. Dates are shown across the bottom from October 2019 to July 2021. The COVID-19 outbreak began in the UK in January 2020 with numbers of daily hospital admissions due to COVID-19 shown by the lower orange line for Wave one and Wave two. Vaccinations began in December 2020 and are shown by the green line for daily vaccinations. Lockdowns are shown by horizontal red bars, the first national lockdown beginning on March 23^{rd} 2020, the second on November 5^{th} , and the third of January 5^{th} 2021. Lockdowns differed somewhat in timing between England, Wales, Scotland and Northern Ireland. Tiered local restrictions were in place in various regions of the UK between lockdowns, shown in yellow. Questionnaire 1 of Work package 2 began to be distributed on December 4th onwards and is being distributed until the end of March 2021. Questionnaire 1 asks about current events and working conditions, as well as retrospectively about events and working conditions pre-Covid in 2019, about early Covid responses in the first months of 2021, and about events during the first national lockdown. Questionnaire 2 will be distributed four months after registration for questionnaire 1 and therefore will be distributed between April and June 2021. Questionnaire 2 asks primarily about current working conditions, and changes to other aspects of participants' lives captured in Questionnaire 1, including key measures of physical and mental health. With consent, the questionnaire data will be linked to electronic healthcare record data.

Figure 3: Data flow diagram. Solid lines with a circle indicate identifiable data flows for linkage purposes only. Solid lines with an arrow indicate anonymous outputs. Dashed lines indicate deidentified data. After consenting to join UK-REACH, participants provide limited personal identifiable information (PII) which are stored in a secure location at the University of Leicester, alongside study ID. Questionnaire data (including study ID but not alongside the aforementioned PII) are stored in a different secure location at the University of Leicester. Participants provide consent for the study to follow their health by extracting information from electronic health records. Relevant PII for each participant will be securely transferred to NHS Wales Informatics Service (alongside the UK-REACH study ID) in order to acquire NHS number/Community Health Index (CHI) number (for Scotland)/Health and Care number (for Northern Ireland). NHS/CHI/H&C number will then be used to link to healthcare records by the relevant data provider across the UK. De-identified health records will be sent directly to the Secure Anonymised Information Linkage databank (SAIL, https://saildatabank.com), retaining Study ID but excluding PII. Questionnaire data (including study ID) will be sent from the University of Leicester to SAIL. These datasets will be linked within SAIL to provide the complete dataset. Interim analysis of unlinked questionnaire data will be performed at the University of Leicester using pseudonymised datasets. All linked data analysis will take place within SAIL. The above diagram and style was interpreted by Anna Guyatt and Chris Orton from an initial data flow diagram created and provided by Andy Boyd at the University of Bristol. It has been repurposed and amended to illustrate data flows specific to the UK-REACH project.




Figure 1: Study flowchart 116x65mm (300 x 300 DPI)




Figure 2: UK-REACH Work package 2 timeline as of 4th February 2021. Dates are shown across the bottom from October 2019 to July 2021. The COVID-19 outbreak began in the UK in January 2020 with numbers of daily hospital admissions due to COVID-19 shown by the lower orange line for Wave one and Wave two. Vaccinations began in December 2020 and are shown by the green line for daily vaccinations. Lockdowns are shown by horizontal red bars, the first national lockdown beginning on March 23rd 2020, the second on November 5th, and the third of January 5th 2021. Lockdowns differed somewhat in timing between England, Wales, Scotland and Northern Ireland. Tiered local restrictions were in place in various regions of the UK between lockdowns, shown in yellow. Questionnaire 1 of Work package 2 began to be distributed on December 4th onwards and is being distributed until the end of March 2021. Questionnaire 1 asks about current events and working conditions, as well as retrospectively about events and working conditions pre-Covid in 2019, about early Covid responses in the first months of 2021, and about events during the first national lockdown. Questionnaire 2 will be distributed four months after registration for questionnaire 1 and therefore will be distributed between April and June 2021. Questionnaire 2 asks primarily about current working conditions, and changes to other aspects of participants' lives captured in Questionnaire 1, including key measures of physical and mental health. With consent, the questionnaire data will be linked to electronic healthcare record data.

108x60mm (300 x 300 DPI)




Figure 3: Data flow diagram. Solid lines with a circle indicate identifiable data flows for linkage purposes only. Solid lines with an arrow indicate anonymous outputs. Dashed lines indicate de-identified data. After consenting to join UK-REACH, participants provide limited personal identifiable information (PII) which are stored in a secure location at the University of Leicester, alongside study ID. Questionnaire data (including study ID but not alongside the aforementioned PII) are stored in a different secure location at the University of Leicester. Participants provide consent for the study to follow their health by extracting information from electronic health records. Relevant PII for each participant will be securely transferred to NHS Wales Informatics Service (alongside the UK-REACH study ID) in order to acquire NHS number/Community Health Index (CHI) number (for Scotland)/Health and Care number (for Northern Ireland). NHS/CHI/H&C number will then be used to link to healthcare records by the relevant data provider across the UK. De-identified health records will be sent directly to the Secure Anonymised Information Linkage databank (SAIL, https://saildatabank.com), retaining Study ID but excluding PII. Questionnaire data (including study ID) will be sent from the University of Leicester to SAIL. These datasets will be linked within SAIL to provide the complete dataset. Interim analysis of unlinked questionnaire data will be performed at the University of Leicester using pseudonymised datasets. All linked data analysis will take place within SAIL. The above diagram and style was interpreted by Anna Guyatt and Chris Orton from an initial data flow diagram created and provided by Andy Boyd at the University of Bristol. It has been repurposed and amended to illustrate data flows specific to the UK-REACH project.

108x60mm (300 x 300 DPI)

SUPPLEMENTARY INFORMATION

List of Members of UK-REACH Stakeholder Group (STAG) as at January 2021

- 1. General Medical Council (GMC)
- 2. Nursing and Midwifery Council (NMC)
- 3. General Dental Council (GDC)
- 4. General Pharmaceutical Council (GPC)
- 5. Royal College of Psychiatrists (RCPsych)
- 6. Royal College of Obstetricians and Gynaecologists (RCOG)
- 7. Royal College of Midwives (RCM)
- 8. NHS Confederation
- 9. British Association of Physicians of Indian Origin (BAPIO)
- 10. Sudan Doctors' Union -UK Branch
- 11. Association of Pakistani Physicians of Northern Europe (APPNE)
- 12. South Asian Health Foundation (SAHF)
- 13. Health Education England (HEE)
- 14. General Optical Council (GOC)
- 15. Filipino Nurses Association UK (FNAUK)
- 16. Pharmaceutical Society of Northern Ireland (PSNI)
- 17. Health and Care Professions Council (HCPC)
- 18. NHS England & Improvement
- 19. British Medical Association (BMA)
- 20. Medical Association of Nigerians Across Great Britain (MANSAG)

List of Members of UK-REACH Professional Expert Panel (PEP) as at January 2021

Susie Lagrata (co-Chair), Nurse.

Padmasayee Papineni (co-Chair), Doctor.

Sandra Kazembe, Nurse.

Tatiana Monteiro, Domestic worker.

Juliette Mutumiyana, Doctor.

Satheesh Mathew, Doctor.

Amir Burney, Doctor.

Ahmed Hashim, Doctor.

Tiffanie Harrison, Nurse.

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No.
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what	2
		was done and what was found	_
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4,5
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	5,6
		(b) For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8-10
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods	8-10
		if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	10
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	10
		(b) Describe any methods used to examine subgroups and interactions	10
		(c) Explain how missing data were addressed	NA
		(d) If applicable, explain how loss to follow-up was addressed	NA
		(e) Describe any sensitivity analyses	NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	NA
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	NA
		(b) Indicate number of participants with missing data for each variable of interest	NA
		(c) Summarise follow-up time (eg, average and total amount)	NA
Outcome data	15*	Report numbers of outcome events or summary measures over time	NA
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear	NA

		which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	NA
		(c) If relevant, consider translating estimates of relative risk into absolute	NA
		risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
Discussion			
Key results	18	Summarise key results with reference to study objectives	NA
Limitations	19	Discuss limitations of the study, taking into account sources of potential	NA
		bias or imprecision. Discuss both direction and magnitude of any potential	
		bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives,	NA
		limitations, multiplicity of analyses, results from similar studies, and other	
		relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	NA
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study	13
		and, if applicable, for the original study on which the present article is based	

^{*}Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.

BMJ Open

The United Kingdom Research study into Ethnicity And COVID-19 outcomes in Healthcare workers (UK-REACH): Protocol for a prospective longitudinal cohort study of healthcare and ancillary workers in UK healthcare settings

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-050647.R1
Article Type:	Protocol
Date Submitted by the Author:	02-Aug-2021
Complete List of Authors:	Woolf, Katherine; University College London, Research Department of Medical Education Melbourne, Carl; University of Leicester, Genetic Epidemiology Research Group, Department of Health Sciences Bryant, Luke; University of Leicester, Department of Respiratory Sciences Guyatt, Anna; University of Leicester, Genetic Epidemiology Research Group, Department of Health Sciences McManus, Ian; University College London, Research Department of Medical Education Gupta, Amit; Oxford University Hospitals NHS Foundation Trust Free, Robert; University of Leicester, Department of Respiratory Sciences; NIHR Leicester Biomedical Research Centre Respiratory Diseases Nellums, Laura; University of Nottingham, Division of Epidemiology and Public Health Carr, Sue; University Hospitals of Leicester NHS Trust; General Medical Council John, Catherine; University of Leicester, Department of Health Sciences Martin, Christopher; University of Leicester, Department of Respiratory Sciences; University Hospitals of Leicester NHS Trust, Department of Infection and HIV Medicine Wain, Louise; University of Leicester, Department of Health Sciences; NIHR Leicester Biomedical Research Centre Respiratory Diseases Gray, Laura; University of Leicester, Department of Respiratory Sciences Modhwadia, Vishant; University of Leicester, Department of Respiratory Sciences Abrams, Keith; University of York, Centre for Health Economics Tobin, Martin; University of Leicester, Genetic Epidemiology Research Group, Department of Health Sciences; NIHR Leicester Biomedical Research Centre Respiratory Diseases, Glenfield Hospital Khunti, Kamlesh; University of Leicester, Department of Respiratory Sciences; University Hospitals of Leicester, Department of Respiratory Sciences; University Hospitals of Leicester NHS Trust, Department of Infection and HIV Medicine

Primary Subject Heading :	Infectious diseases
Secondary Subject Heading:	Public health, Health services research
Keywords:	Public health < INFECTIOUS DISEASES, MENTAL HEALTH, COVID-19

SCHOLARONE™ Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

The United Kingdom Research study into Ethnicity And COVID-19 outcomes in Healthcare workers (UK-REACH): Protocol for a prospective longitudinal cohort study of healthcare and ancillary workers in UK healthcare settings

Katherine Woolf*1, Carl Melbourne*2, Luke Bryant*3, Anna L Guyatt², Ian Chris McManus¹, Amit Gupta⁴, Robert C Free³,9, Laura Nellums⁵, Sue Carr⁶,7, Catherine John², Christopher A Martin³,8, Louise V Wain²,9, Laura J Gray², Claire Garwood³, Vishant Modhwadia³, Keith Abrams¹0, Martin D Tobin²,9, Kamlesh Khunti¹¹, Manish Pareek³,8** on behalf of the UK-REACH Study Collaborative Group+

*Joint first authors; **Corresponding author manish.pareek@leicester.ac.uk

Affiliations

- 1 Research Department of Medical Education, University College London Medical School, Gower Street, London WC1E 6BT, UK.
- 2 Department of Health Sciences, University of Leicester, University Road, Leicester, LE1 7RH, UK.
- 3 Department of Respiratory Sciences, University of Leicester, Leicester, LE1 7RH, UK.
- 4 Oxford University Hospitals NHS Foundation Trust, Headley Way, Headington, Oxford OX3 9DU, UK.
- 5 Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, City Hospital Campus, Hucknall Road, NG5 1PB, UK.
- 6 University Hospitals Leicester NHS Trust, Level 3, Balmoral Building, Leicester Royal Infirmary, Infirmary Square, Leicester, LE1 5WW, UK.
- 7 General Medical Council, 3BH, 350 Euston Rd, London NW1 3JN, UK.
- 8 Department of Infection and HIV Medicine, University Hospitals of Leicester NHS Trust, Leicester, LE1 5WW, UK.
- 9 National Institute for Health Research Leicester Biomedical Research Centre Respiratory, Glenfield Hospital, Leicester, LE3 9QP UK.
- 10 Centre for Health Economics, University of York, York, UK.
- 11 Diabetes Research Centre, University of Leicester, Leicester LE5 4PW, UK

UK-REACH Study Collaborative Group (*Work Package 2 collaborators):

Manish Pareek (Chief investigator)*, Amani Al-Oraibi, Amit Gupta**, Anna L Guyatt, Carl Melbourne*, Catherine John*, Christopher A Martin*, Ian Chris McManus*, Chris Orton, Claire

Garwood*, David Ford, Edward Dove, Fatimah Wobi, Janet Hood, Kamlesh Khunti*, Katherine Woolf*, Keith Abrams*, Laura J Gray*, Laura Nellums*, Louise V Wain*, Lucy Teece, Luke Bryant*, Martin Tobin,* Mayuri Gogoi, Osama Hassan, Robert C Free*, Ruby Reed-Berendt, Sue Carr*, Vishant Modhwadia*.

Abstract

Introduction

The COVID-19 pandemic has resulted in significant morbidity and mortality, and devastated economies globally. Among groups at increased risk are healthcare workers (HCWs) and ethnic minority groups. Emerging evidence suggests HCWs from ethnic minority groups are at increased risk of adverse COVID-19-related outcomes. To date there has been no large-scale analysis of these risks in UK HCWs or ancillary workers in healthcare settings, stratified by ethnicity or occupation, and adjusted for confounders. This paper reports the protocol for a prospective longitudinal questionnaire study of UK HCWs, as part of the UK-REACH programme (The United Kingdom Research study into Ethnicity And COVID-19 outcomes in Healthcare workers).

Methods and analysis

A baseline questionnaire will be administered to a national cohort of UK HCWs and ancillary workers in healthcare settings, and those registered with UK healthcare regulators, with follow-up questionnaires administered at 4 and 8 months. With consent, questionnaire data will be linked to health records with 25 year follow-up.

Univariate associations between ethnicity and clinical COVID-19 outcomes, physical and mental health, and key confounders/explanatory variables will be tested. Multivariable analyses will test for associations between ethnicity and key outcomes adjusted for the confounder/explanatory variables. We will model changes over time by ethnic group, facilitating understanding of absolute and relative risks in different ethnic groups, and generalisability of findings.

Ethics and dissemination.

The study is approved by Health Research Authority (reference 20/HRA/4718), and carries minimal risk. We aim to manage the small risk of participant distress about questions on sensitive topics by clearly participant information that the questionnaire covers sensitive topics and there is no obligation to answer these or any other questions, and by providing support organisation links. Results will be disseminated with reports to Government and papers submitted to pre-print servers and peer reviewed journals.

Registration details.

Trial ID: ISRCTN11811602

STRENGTHS AND LIMITATIONS OF THIS STUDY

- Sampling frame includes a variety of healthcare worker job roles including ancillary workers in healthcare settings will improve the generalisability of results across diverse healthcare job roles.
- Longitudinal study including three waves of questionnaire data collection, and linkage to administrative data over 25 years, with consent, will enable researchers to infer causal relationships.
- Unique support from all major UK healthcare worker regulators, relevant healthcare worker organisations, and a Professional Expert Panel to increase participant uptake and the validity of findings.
- Potential for self-selection bias and low response rates.
- The use of electronic invitations and online data collection makes it harder to reach ancillary workers without regular access to work email addresses.



INTRODUCTION

COVID-19 has spread rapidly across the world, causing significant morbidity and mortality, and devastating health economies in many countries. Healthcare workers (HCWs) have been identified as being at increased risk of SARS-CoV-2 infection and adverse outcomes,(1-3) as have individuals from ethnic minority groups.(2, 4-13) Emerging evidence suggests that ethnic minority groups may also be at greater risk of long-term COVID-19 sequelae.(4) HCWs and individuals from ethnic minority groups may also be at increased risk of COVID-19-related poor mental health outcomes, including anxiety, depression and post-traumatic stress.(14-19)

There are concerns that HCWs from ethnic minority groups are at particular risk of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection and adverse COVID-19 outcomes compared to white HCWs (3, 20, 21) However, the quality of data relating to COVID-19 outcomes in HCWs remains poor, with no large representative studies of the risk of COVID-19 infection or adverse outcomes in healthcare workers or ancillary workers in healthcare settings (hereafter "HCWs") stratified by ethnicity or occupation type, controlling for potential confounders.

To address this, UK-REACH (United Kingdom Research study into COVID-19 outcomes in Healthcare workers) will rapidly examine differences in COVID-19 diagnosis, clinical outcomes (diagnosis, hospitalisation, ICU admission), professional roles, and well-being among ethnic minority and white HCWs through a unique large database analysis (rapid linkage and analysis of anonymised professional registration and National Health Service (NHS) datasets), longitudinal cohort study, legal/ethical analysis, and qualitative work packages. This work will provide information on very short-term outcomes and produce rapid actionable outputs, as well as enabling investigations of the medium/long-term effects of COVID-19 on HCWs in future studies through the linkage and cohort study. This protocol describes the UK-REACH longitudinal cohort study.

Research Question

What is the impact of COVID-19 on the physical and mental health of ethnic minority HCWs compared to white HCWs in the short term and the longer term?

Aims

To examine the relationship between ethnicity and COVID-19-related mental and physical health outcomes through the establishment of a novel longitudinal cohort study of HCWs, including recruitment from the membership bodies and professional registers for different healthcare roles, providers of facilities management, and directly from UK healthcare settings.

To study changes in health outcomes, social circumstances and professional roles of HCWs of different ethnicities, over the course of the COVID-19 pandemic and to characterise longer-term outcomes and consequences.

To measure differences in the impact of COVID-19 infection and working during the pandemic on physical and mental health in a multi-ethnic group of HCWs in the UK.

Objectives

To survey HCWs at baseline to collect data on demographics, job role, attitudes to work and work climate, social and living circumstances, values and personality, and physical and mental health.

To collect baseline biological samples for future analysis in a subsample of consenting participants.

To conduct follow-up surveys and samples over 12 months in order to capture changes over subsequent COVID-19 pandemic waves.

To link survey data to participant healthcare records, with consent.

METHODS AND ANALYSIS

Study design

National prospective longitudinal cohort study in all four nations of the United Kingdom.

Setting

Healthcare workers and ancillary workers in healthcare settings within the UK.

Participants

Inclusion criteria

Age ≥ 16 years;

Living in the UK;

Healthcare worker or ancillary worker in a UK healthcare setting OR Registered with the following UK healthcare professional regulatory bodies: the General Medical Council (GMC), Nursing and Midwifery Council (NMC), General Dental Council (GDC), Health and Care Professions Council (HCPC), General Optical Council (GOC), General Pharmaceutical Council (GPC) or the Pharmaceutical Society of Northern Ireland (PSNI);

Willing and able to give informed consent.

Exclusion criteria

Age <16 years;

Living outside the UK;

Not a healthcare worker or ancillary worker in a healthcare setting AND not regulated by one of the professional regulatory bodies listed above;

Unwilling and/or unable to give informed consent.

Sample size

We aim to recruit at least 32,000 HCWs (66% from ethnic minority groups). See Figure 1 for the study flow chart. The proposed sample will approximately comprise:

- 10,000 doctors
- 10,000 nurses, midwives and nursing associates
- 4,000 ancillary workers
- 2,000 allied health professionals
- 2,000 ambulance workers
- 2,000 pharmacists and pharmacy technicians
- 1,000 dentists and dental care professionals
- 1,000 optometrists and dispensing opticians

Whilst the above numbers represent our target numbers for recruitment, we will welcome participants working in other roles within healthcare settings. We may adapt sampling frame for subgroups following initial response, to ensure we have appropriate representation of ethnic minority participants in each job role.

This sample size has been pragmatically chosen to allow for adequate representation of all ethnic groups within all job-role categories. Based on general population prevalence estimates (11) producing conservative power estimates, we anticipate at least 80% (statistical) power to detect modest effects of ethnicity (RR \geq 1.5) for more prevalent outcomes (e.g. COVID-19 diagnosis) and larger effects (RR \geq 2) for rarer outcomes (e.g. mortality). Power calculations will be reviewed to reflect changing rates of infection.

Recruitment

Recruitment will be via several routes, and will be incentivised by the inclusion of a prize draw for those who complete the questionnaire:

- i) Email, letter, and/or text message invitations from healthcare professional regulators. The records and registrations with the GMC, NMC, GDC, HCPC, GOC, GPC, PSNI will be used as a sampling frame. Where possible, we will utilise demographic data routinely collected by regulators to oversample for people identifying as being from ethnic minority backgrounds. We will endeavour to sample representatively across age groups, sex/gender, job roles, and other characteristics, in order to maximise the generalisability of our findings. Regulators will send invitations and reminders on behalf of the principal investigator. Alongside these invites regulators will also promote the study through their social media channels as the invites go out.
- ii) Targeted advertisement to key staff groups through healthcare organisations. We will advertise the study through the general communication channels of regulators, professional bodies (e.g. Royal College of Midwives, Royal College of General Practitioners), Health Education bodies, and other relevant organisations (e.g. the British Medical Association, the British Association of Physicians of Indian Origin (BAPIO), The Filipino Nurses Association United Kingdom). This will include promotion through newsletters, web pages, email communications and banners on self-service portals (for example, on the NHS Electronic Staff Record portal used for accessing payslips).
- iii) General publicity of the study via print and broadcast media, social media for the study and other relevant organisations, and posters or flyers in workplaces, as relevant to participant staff groups.
- Direct invitation and recruitment via UK healthcare providers.

 UK healthcare providers, including at least 30 NHS Hospital Trusts, will advertise to potential participants by email, text, mail, verbally, or through posters/flyers. Trusts will be selected to represent a range of geographical areas (to include England, Scotland, Wales, and Northern Ireland). We will aim to recruit from both large teaching hospitals and smaller community healthcare trusts, and will take into consideration regional ethnic diversity when selecting trusts. We will also utilise a study infographic to promote recruitment through NHS trusts. Recruitment of ancillary staff has been facilitated by Serco at specific trusts, through utilisation of content handouts and posters which have been cascaded by contractors on site.

Invitations and advertisements will direct staff via a weblink and/or QR code to the study recruitment site. In the case of direct recruitment through UK healthcare settings, potential participants will be supported to join with the help of suitably trained members of the local research team where appropriate. Reminders will also be sent to improve recruitment to the study.

Data collection

See Figure 2 for the study timeline.

To gain informed consent, potentially interested participants will have the opportunity to read the UK-REACH participant information sheet (PIS) online via a web application, or in person with a member of the local research team, before deciding if they would like to take part. Potential participants will be asked to register for a UK-REACH account (https://uk-reach.org/) by entering an email address and password, then will be asked to sign an online consent form. To complete registration, participants will be asked to provide personal details including name, date of birth, and address. Participants will be considered enrolled into the study after completing the registration process, and giving their electronic consent on a secure web page. They will be assigned a unique identifier at this point. This will be securely retained in an electronic database at the University of Leicester, which will also function as an enrolment log.

Once translation has been undertaken and checked, we will make study materials (PIS and consent form) available in alternative languages commonly used by workers in healthcare settings as required. These will be made available on the UK-REACH website.

After consenting to participation in the study, participants will be asked to complete a baseline online questionnaire on demographics, job role and other work circumstances, location of work/residence, interaction with COVID-19 patients (including access to personal protective equipment, social and living circumstances, discrimination and harassment, values and personality, and physical and mental health (see Measures, below). This questionnaire will be accessible via the study website, and support to complete the questionnaire will also be available from the study team. Some identifiable data (e.g. name, DOB, address) will be collected during registration and/or the questionnaire to facilitate secure data linkage (see Data linkage, below).

Participants will be invited to complete the baseline questionnaire between December 2020 and January 2021. Participants will have the option of completing two further questionnaires, one at approximately 4 months from baseline and one at approximately 8 months from baseline. Consent will be requested to follow up participants for up to 25 years (subject to funding), and during this time serial questionnaire data will be collected, and periodic linkage with healthcare records will take place (see Data linkage, below).

Data linkage

Participants will be asked to provide consent for the study to follow their health by extracting information from their past and future NHS health care records (including NHS number), any COVID-19 related records, and from "COVID-19 symptom study" websites or apps (22) if they use them.

Initially, questionnaire and personal data, for which consent has been given, will be electronically transferred to University of Leicester, and stored separately on secure servers. A study ID for each participant together with identifiable data will be sent to NHS Wales Informatics Service in order to acquire the list of NHS numbers/Community Health Index (CHI) number (for Scotland)/Health and

Care number (for Northern Ireland) in partnership with the relevant UK NHS data providers. Study ID and NHS/CHI/H&C number will then be used to link to healthcare records by the relevant data provider across the UK. De-identified records will be sent directly to the Secure Anonymised Information Linkage databank (SAIL, https://saildatabank.com), retaining Study ID. Separately, study ID and corresponding questionnaire data will be sent from the University of Leicester to SAIL. These datasets will be linked within SAIL to provide the complete dataset. Interim analysis of unlinked questionnaire data will be performed at the University of Leicester using pseudonymised datasets. All linked data analysis will take place within SAIL.

Questionnaire design

The questionnaires will be designed by the study team with input from the Professional Expert Panel (PEP) - see Patient and Public Involvement, below. Where possible, previously used and/or validated measures are being used. The study team will devise measures where none are available.

The baseline questionnaire will ask about participants' current experiences and attitudes, as well as collecting some retrospective data about participants' experiences and attitudes at the start of the pandemic and/or pre-pandemic. Follow-up questionnaires will repeat outcome measures, and may include new items relevant to the progression of the pandemic. The data dictionary (https://www.uk-reach.org/data-dictionary) contains the source(s) for each question. The baseline questionnaire is included as an Appendix.

Patient and public involvement

The UK-REACH team have worked closely with national and local organisations representing ethnic minority HCWs, who have been closely involved in identifying the research questions, deciding the study methodology, and are included either as members of the study delivery team or collaborators. They are also part of the Stakeholder group (see Supplementary Information for list of organisations) that will meet monthly to monitor study progress and research outputs, and provide advice to the research team on study delivery and progress. This group will also be central in disseminating the research findings. Alongside the high-level national organisation input into this stakeholder group, we will have representation from ethnic minority HCWs, including those who have contracted COVID-19 (mild to severe), to provide feedback on our work and how it should be disseminated. Members of our stakeholder/public engagement group will also sit on the Scientific Committee to ensure there is a seamless flow of information from the research team and the public engagement/stakeholder group. In addition we are working closely with the Centre for BME Health (Leicester, UK) to ensure that we are working to engage staff from a range of ethnic groups.

A Professional Expert Panel (PEP) will provide feedback on UK-REACH study materials and sampling methodology such as surveys, questionnaires, and interview and focus group topic guides. The PEP is made up of individuals who work within a healthcare setting from a range of ethnic backgrounds, occupational backgrounds, and genders. Staff have unique insight related to their professions or ethnic groups and are, therefore, in a position to provide advice and lived experience related to certain aspects of the project. The aim is for the PEP to draw on their experiences when providing their comments to ensure research instruments are at optimum suitability for study participants. The PEP meets virtually on a bi-monthly basis via Microsoft Teams. Study items/documents for discussion are circulated a week in advance of the PEP meeting and the group's Chair and Co-chair (PEP members who both volunteered to take on the role) moderate the meeting. UK-REACH team members are present in order to answer study-specific queries, and so only enter the discussions to

do so. The PEP also interacts with the study team between meetings via email with any additional feedback.

Primary outcome measures

Clinical COVID-19 outcomes

Participants will be asked to self-report COVID-19 infection, defined as either a positive SARS-CoV-2 polymerase chain reaction (PCR) or antibody test, or as self-reported suspected infection; the latter will be particularly relevant for those reporting historic illness early in the pandemic before widespread availability of testing. In our analyses we will consider all those with a PCR assay for SARS-CoV-2 or a positive anti-SARS-CoV-2 serology assay as being infected. To ensure those that acquired infection prior to widespread testing availability are not excluded, in those who have never been tested by PCR or serology, we will determine infection status based on whether they, or another healthcare professional, suspected them of having had COVID-19. To investigate how the inclusion of those that report suspected (but not confirmed) COVID-19 impacts upon our results, we will conduct sensitivity analyses examining only those who have undergone laboratory testing for current/previous infection.

Those reporting COVID-19 illness will be asked about: date of onset, the nature of symptoms experienced and their duration, and hospitalisation (including any time spent in intensive care). Corroboration of the details of these outcomes will be possible using linked electronic healthcare records (see "Measures obtained via data linkage", below).

General health

This will be measured using the EQ-5D-5L instrument(23) (https://euroqol.org/), which contains five dimensions on mobility, self-care, usual activities, pain and discomfort, and anxiety and depression, plus an overall self-report of health.

Mental health

This will be measured using the Patient Health Questionnaire-2 (PHQ-2)(24) for depression, the Generalised Anxiety Disorder-2 (GAD-2)(25) scale for anxiety, a three-item abbreviated version of the PCL-6 scale for post-traumatic stress disorder,(26) a three-item abbreviated version of the UCLA Loneliness scale, (27) and an Office for National Statistics question about overall life satisfaction.(28) Participants will also be asked key questions from the Utrecht Work Engagement Scale (29) and the GMC National Training Survey questions on burnout(30) (from the Copenhagen Burnout Inventory (31)).

Questionnaire measures

Ethnicity

In this study we will ask participants to self-identify the ethnic group with which they most identify using the 18 UK Census 2011 Categories.(32) The questionnaire also asks the ethnic group of any partner and of parents.

We will then collapse these 18 categories into five main ethnic categories also defined within the Census (Black, Asian, Mixed, Other, White). We will further collapse them into two groups which we will refer to as "white" (White British, White Irish, White Gypsy or Traveller, White Other) and "ethnic minority" (all other ethnic groups). There is currently considerable debate about the categorisation of people using ethnic groups, and in particular, the grouping of people who do not

identify as white into a single category. There is also considerable debate and controversy about the words used to describe such a broad and heterogeneous grouping, with terms such as "people of colour", "Black Asian and Minority Ethnic" or "BAME" used. In our choice of terms we have followed the BMJ who in their special edition on Racism in Medicine use the term "ethnic minority" as one that is most likely to be understood by our study population.(33) We fully acknowledge that broad ethnic groupings can mask important ethnic and cultural differences, and where possible we will use more refined ethnic groupings, while also acknowledging the heterogeneity within them.

Nationality, religion, and languages

Country of birth, nationality, parents' country of birth, grandparents' country of birth (born in UK / not born in UK), age learned English (if second language), language(s) spoken at home (currently and as a child), religion, religiosity, ethnic identity.

Other demographics and education

Age, gender, sex, marital status, highest level of education completed, year and country of primary professional qualification (if applicable), highest level of education achieved by parents.

Work

Job role(s), sector(s), grade and specialty (for doctors), NHS band (for other HCWs), registered field of practice (nurses); work location(s); whether currently working, reasons for not working (if applicable); hours worked in a typical week; frequency of night shifts; contact with patients (with and without COVID-19), colleagues and others (remotely, face-to-face with social distancing, with physical contact); time spent travelling to and from work, modes of transport; access to, use of, and training to use personal protective equipment (PPE); exposure to aerosol-generating procedures; NHS COVID-19 risk assessment experiences; feelings about raising a clinical concern at work, perceptions of fairness of organisation with regards career progression; redeployment as a result of the pandemic, patient exposure, training and supervision in redeployed role (if applicable); proportion of colleagues of same ethnicity to self, proportion of colleagues who are white; work engagement.

Home and social life

Household composition (numbers, ages, relationship to participant) and sharing of accommodation; number of household members travelling using public transport or in jobs that bring them into close contact with others; childcare and support "bubbles"; length of time at current address; type and size of accommodation including amount of shared space and access to safe outdoor space; numbers of social contacts (remotely, face to face with social distancing, with physical contact), proportion of friends of the same ethnic group to self.

Harassment and discrimination

Experiences of discrimination in day-to-day life; discrimination at work and whether made a complaint (if applicable).

Physical health, mental health, and wellbeing

Height, weight, smoking and alcohol use, physical activity at work, general physical activity, change in lifestyle since start of pandemic, healthcare experience in 2019 (GP consultations and hospital admittance), flu vaccine uptake, medication, health conditions and pregnancy, quality of life, general anxiety, depression, post-traumatic stress disorder (PTSD), loneliness, and general life satisfaction.

COVID-19 experiences and beliefs

COVID-19 exposure, testing and test positivity; symptoms experienced, plus their severity and longevity, including diagnosis of long-COVID (if applicable); behaviour changes due to COVID-19; concern, knowledge and beliefs about COVID-19; COVID-19 information sources; enjoyment of first national lockdown (Spring 2020), COVID-19 vaccine trial participation; COVID-19 vaccination intention including offers, uptake (including vaccine brand), or reasons for refusal, and vaccine beliefs.

Trait and state psychological measures

'Big five' personality traits, locus of control, health locus of control, risk taking, burnout, personal need for structure.

Open-ended questions

The baseline questionnaire will include three open-ended free-text questions: "What are your thoughts on why people from ethnic minorities working in health and care have been more severely affected by COVID-19?", "How do you see society changing as a result of COVID-19?", "How do you see your own future changing as a result of COVID-19?".

Evaluation questions

Views on the length of the questionnaire and on its usefulness for understanding ethnicity and COVID-19.

Measures obtained via data linkage

Data linkage will be used to corroborate COVID-19 clinical outcomes (acute infection, antibody positivity), major comorbidities and patterns of healthcare use.

Biological sampling

At baseline we will also seek consent to re-contact participants in the future for DNA sampling and sampling related to immune profiling although we will submit an amendment to implement this sampling and detail the specifics relating to this at the time of submitting the amendment.

Statistical analysis

Descriptive statistics will be calculated for the primary outcome measures, and for ethnicity and key confounder/explanatory variables.

Univariate associations between ethnicity and primary outcome measures, and between ethnicity and key confounders/explanatory variables calculated using chi-squared tests for categorical variables, and t-tests and analyses of variance for continuous measures, with non-parametric equivalents used as appropriate for ordinal variables. This will enable the examination of the behavioural, social, and clinical phenotypes of the cohort in relation to the patterns of demographics, job role, attitudes to work and work climate, social and living circumstances, values and personality, and physical and mental health by ethnicity.

Using baseline data, multivariable analyses will test for associations between ethnicity and key outcomes, adjusted for the confounder/explanatory variables found to have a statistically significant univariate association with either ethnicity or the primary outcome variable(s), with interactions

included as appropriate. Using follow-up data, mixed models will be used to model changes over time by ethnic group.

Models will fit ethnicity as both a binary indicator (ethnic minority versus white) and as a categorical variable based on ONS categorisation of ethnicity, with the white group used as the reference group.

ETHICS AND DISSEMINATION

Ethical approval

The study has been approved by the Health Research Authority (Brighton and Sussex Research Ethics Committee; ethics reference: 20/HRA/4718).

Ethical considerations

Whilst this study is low risk, the questionnaire covers sensitive topics around COVID-19, ethnicity (including issues of discrimination and harassment), and mental health, and these could be distressing to participants. We aim to manage this risk by clearly indicating on the PIS that the questionnaire covers sensitive topics and that participants are under no obligation to answer these, or indeed any other, questions, and provide links to support organisations.

Participant confidentiality

The participants will be identified only by a unique identifier in the main research database. Identifiable information (name, date of birth, address etc) will be stored in a separate secure database, and will be accessed only by a small number of authorised staff at the University of Leicester who require access to administer the study. All documents will be stored securely, and only be accessible by study staff and authorised personnel. The study will comply with the Data Protection Act, which requires data to be anonymised as soon as it is practical to do so. Any dissemination of study findings will follow best-practice guidelines for deductive disclosure. Only aggregate data will included in publications.

Discontinuation/withdrawal of participants from study

Participants who wish to withdraw from the cohort study will be asked to determine the desired level of withdrawal from the study as described by the two options below. We will keep a record of consent for all participants to manage re-contact and for future audit. We will accept signed withdrawal forms from participants or, if they are unable to complete a withdrawal form themselves, from someone acting on the participant's behalf. At the present time, withdrawal forms will be completed electronically, but signed written forms will also be accepted when it is feasible to securely receive and store these. The options that participants will be given if they wish to withdraw:

Option 1 - No further contact: we would no longer contact the participant, but would have the participant's permission to continue to obtain information by accessing their health records in the future.

Option 2 – No further contact or access: we would no longer contact the participant or obtain information from the participant's health records in the future.

If participants withdraw from UK-REACH, then any data and samples already collected will remain and be used in the study. Information and data will continue to be collected about participants'

health from central NHS records, hospital records, and participants' GPs, unless participants state otherwise on the withdrawal form.

Description of data flow

See Figure 3 for a description of the data flow.

Dissemination plan

Quarterly reports in months 3, 6, 9, and 12 summarising recruitment progress and initial findings on relationship between ethnicity, COVID-19 diagnosis and outcomes, physical/mental well-being, and professional and social factors. Brief reports will be produced and submitted for review by the stakeholder group (see Supplementary material for details), PEP, Study Steering Committee and the UK Government's Scientific Advisory Group for Emergencies (SAGE). Papers submitted to peer reviewed journals and pre-print servers.

DATA SHARING STATEMENT

To access data or samples produced by the UK-REACH study, the working group representative must first submit a data and material request form to the **Data Access Committee** (DAC) providing details for all manuscript proposals. The DAC will establish priorities for core and ancillary projects. For ancillary studies outside of the core deliverables, the **Steering Committee** will make final decisions once they have been approved by the **Core Management Group** and the DAC. Decisions on granting the access to data/materials will be made within eight weeks. Third party requests from outside the Project will require explicit approval of the Steering Committee once approved by the Core Management Group and the DAC.

AUTHORS CONTRIBUTIONS

MP conceived of the idea and led the application for funding with input from MT, KK, ICM, KW, RF, LN, SC, KRA, LG, AG, LVW and CJ. The survey was designed by KW, MP, ICM, CMel, CJ, ALG, AG, LN, CAM and RF. Online consent and survey tools were developed by LB with support from CG and VM. KW wrote the first draft of the manuscript with input from MP and all co-authors. All authors approved the submitted manuscript.

ACKNOWLEDGEMENTS

We wish to acknowledge the PEP group and the STAG group (see Supplementary material), and SERCO, as well as the following people for their support in organising the email invites from the regulatory bodies: Kerrin Clapton and Andrew Ledgard (General Medical Council), Caroline Kenny (Nursing and Midwifery Council), David Teeman and Lisa Bainbridge (General Dental Council), My Phan and John Tse (General Pharmaceutical Council), Angharad Jones (General Optical Council), Katherine Timms and Charlotte Rogers (The Health and Care Professions Council) and Mark Neale (Pharmaceutical Society of Northern Ireland).

FUNDING STATEMENT

UK-REACH is supported by a grant from the MRC-UK Research and Innovation (MR/V027549/1) and the Department of Health and Social Care through the National Institute for Health Research (NIHR) rapid response panel to tackle COVID-19. Core funding was also provided by NIHR Biomedical

Research Centres. This work is carried out with the support of BREATHE -The Health Data Research Hub for Respiratory Health [UKRI MC_PC_19004] in partnership with SAIL Databank. BREATHE is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK.

ALG was funded by internal fellowships at the University of Leicester from the Wellcome Trust Institutional Strategic Support Fund (204801/Z/16/Z) and the BHF Accelerator Award (AA/18/3/34220). CJ holds a Medical Research Council Clinical Research Training Fellowship (MR/P00167X/1). KA is supported by Health Data Research (HDR) UK and as a NIHR Senior Investigator Emeritus (NF-SI-0512-10159). KK and LJG are supported by the National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands (ARC EM). KK, MP, and RCF are supported by the NIHR Leicester Biomedical Research Centre (BRC). CAM is an NIHR Academic Clinical Fellow (ACF-2018-11-004). LBN is supported by an Academy of Medical Sciences Springboard Award (SBF005\1047). MP is supported by a NIHR Development and Skills Enhancement Award. MDT holds a Wellcome Trust Investigator Award (WT 202849/Z/16/Z) and an NIHR Senior Investigator Award. KW holds an NIHR Career Development Fellowship (CDF: CDF-2017-10-008). LVW holds a GSK/British Lung Foundation Chair in Respiratory Research (C17-1).

The views expressed in the publication are those of the author(s) and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health and Social Care.

This research was funded in whole, or in part, by the Wellcome Trust [WT204801/Z/16/Z and WT 202849/Z/16/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

COMPETING INTERESTS STATEMENT

SC is Deputy Medical Director of the General Medical Council, UK Honorary Professor, University of Leicester. KK is Director of the University of Leicester Centre for Black Minority Ethnic Health, Trustee of the South Asian Health Foundation, Chair of the Ethnicity Subgroup of SAGE and Member of Independent SAGE. LVW receives grant funding from GSK and Orion, outside of the submitted work. KA has served as a paid consultant, providing unrelated methodological and strategic advice, to the pharmaceutical and life sciences industry generally and has received unrelated research funding from Association of the British Pharmaceutical Industry, European Federation of Pharmaceutical Industries & Associations, Pfizer, Sanofi and Swiss Precision Diagnostics. He is a Partner and Director of Visible Analytics Limited, a healthcare consultancy company.

WORD COUNT

REFERENCES

1. Office for National Statistics. Coronavirus (COVID-19) related deaths by occupation, England and Wales: deaths registered between 9 March and 28 December 2020 2021 [Available from: <a href="https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/causesofdeath/bulletins/coronaviruscovid19relateddeathsbyoccupationenglandandwales/deathsregisteredbetween9marchand28december2020#deaths-involving-covid-19-among-men-and-women-health-and-socialcare-workers."

- 2. Mutambudzi M, Niedwiedz C, Macdonald EB, Leyland A, Mair F, Anderson J, et al. Occupation and risk of severe COVID-19: prospective cohort study of 120 075 UK Biobank participants. Occupational and Environmental Medicine. 2020:oemed-2020-106731.
- 3. Levene LS, Coles B, Davies MJ, Hanif W, Zaccardi F, Khunti K. COVID-19 cumulative mortality rates for frontline healthcare staff in England. British Journal of General Practice. 2020;70(696):327-8.
- 4. Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond SI, et al. Epidemiology of post-COVID syndrome following hospitalisation with coronavirus: a retrospective cohort study. medRxiv. 2021:2021.01.15.21249885.
- 5. Khanijahani A. Racial, ethnic, and socioeconomic disparities in confirmed COVID-19 cases and deaths in the United States: a county-level analysis as of November 2020. Ethnicity & Health. 2020:1-14.
- 6. Khunti K, Singh AK, Pareek M, Hanif W. Is ethnicity linked to incidence or outcomes of covid-19? BMJ. 2020;369:m1548.
- 7. Kirby T. Evidence mounts on the disproportionate effect of COVID-19 on ethnic minorities. The Lancet Respiratory Medicine. 2020;8(6):547-8.
- 8. Platt L, Warwick R. COVID-19 and Ethnic Inequalities in England and Wales*. Fiscal Studies. 2020;41(2):259-89.
- 9. Webb Hooper M, Nápoles AM, Pérez-Stable EJ. COVID-19 and Racial/Ethnic Disparities. JAMA. 2020;323(24):2466-7.
- 10. Nazroo J, Murray K, Taylor H, Bécares L, Field Y, Kapadia D, et al. Rapid Evidence Review: Inequalities in relation to COVID-19 and their effects on London. University of Manchester, The Ubele Initiative, University of Sussex; 2020.
- 11. Sze S, Pan D, Nevill CR, Gray LJ, Martin CA, Nazareth J, et al. Ethnicity and clinical outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine. 2020;29-30:100630.
- 12. Pan D, Sze S, Minhas JS, Bangash MN, Pareek N, Divall P, et al. The impact of ethnicity on clinical outcomes in COVID-19: A systematic review. EClinicalMedicine. 2020;23.
- 13. Clift AK, Coupland CAC, Keogh RH, Diaz-Ordaz K, Williamson E, Harrison EM, et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ. 2020;371:m3731.
- 14. Sahebi A, Nejati B, Moayedi S, Yousefi K, Torres M, Golitaleb M. The prevalence of anxiety and depression among healthcare workers during the COVID-19 pandemic: An umbrella review of meta-analyses. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2021:110247.

- 15. Galli F, Pozzi G, Ruggiero F, Mameli F, Cavicchioli M, Barbieri S, et al. A Systematic Review and Provisional Metanalysis on Psychopathologic Burden on Health Care Workers of Coronavirus Outbreaks. Frontiers in Psychiatry. 2020;11(1001).
- 16. Greene T, Harju-Seppänen J, Adeniji M, Steel C, Grey N, Brewin CR, et al. Predictors and rates of PTSD, depression and anxiety in UK frontline health and social care workers during COVID-19. medRxiv. 2020:2020.10.21.20216804.
- 17. Iob E, Frank P, Steptoe A, Fancourt D. Levels of Severity of Depressive Symptoms Among At-Risk Groups in the UK During the COVID-19 Pandemic. JAMA Network Open. 2020;3(10):e2026064-e.
- 18. Iob E, Steptoe A, Fancourt D. Abuse, self-harm and suicidal ideation in the UK during the COVID-19 pandemic. The British Journal of Psychiatry. 2020;217(4):543-6.
- 19. Wanigasooriya K, Palimar P, Naumann DN, Ismail K, Fellows JL, Logan P, et al. Mental health symptoms in a cohort of hospital healthcare workers following the first peak of the COVID-19 pandemic in the UK. BJPsych Open. 2020;7(1):e24.
- 20. Trivedy C, Mills I, Dhanoya O. The impact of the risk of COVID-19 on Black, Asian and Minority Ethnic (BAME) members of the UK dental profession. British Dental Journal. 2020;228(12):919-22.
- 21. Martin CA, Patel P, Goss C, Jenkins DR, Price A, Barton L, et al. Demographic and occupational determinants of anti-SARS-CoV-2 IgG seropositivity in hospital staff. Journal of Public Health. 2020.
- 22. Drew DA, Nguyen LH, Steves CJ, Menni C, Freydin M, Varsavsky T, et al. Rapid implementation of mobile technology for real-time epidemiology of COVID-19. Science. 2020;368(6497):1362-7.
- 23. Herdman M, Gudex C, Lloyd A, Janssen MF, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research. 2011;20(10):1727-36.
- 24. Löwe B, Kroenke K, Gräfe K. Detecting and monitoring depression with a two-item questionnaire (PHQ-2). Journal of Psychosomatic Research. 2005;58(2):163-71.
- 25. Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. General Hospital Psychiatry. 2016;39:24-31.
- 26. Lang AJ, Wilkins K, Roy-Byrne PP, Golinelli D, Chavira D, Sherbourne C, et al. Abbreviated PTSD Checklist (PCL) as a guide to clinical response. General hospital psychiatry. 2012;34(4):332-8.
- 27. Hughes ME, Waite LJ, Hawkley LC, Cacioppo JT. A Short Scale for Measuring Loneliness in Large Surveys:Results From Two Population-Based Studies. Research on Aging. 2004;26(6):655-72.

- 28. Surveys using our four personal well-being questions: A guide to what surveys include the four ONS personal well-being questions: Office for National Statistics; 2018 [Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/wellbeing/methodologies/surveysusingthe40fficefornationalstatisticspersonalwellbeingquestions.
- 29. Schaufeli WB, Bakker AB, Salanova M. The Measurement of Work Engagement With a Short Questionnaire: A Cross-National Study. Educational and Psychological Measurement. 2006;66(4):701-16.
- 30. General Medical Council National training surveys 2019: Initial findings report. General Medical Council, 2019.
- 31. Kristensen TS, Borritz M, Villadsen E, Christensen KB. The Copenhagen Burnout Inventory: A new tool for the assessment of burnout. Work & Stress. 2005;19(3):192-207.

- 32. Harmonised Concepts and Questions for Social Data Sources, Primary Principles: Ethnic Group. Government Statistical Service; 2016.
- 33. Ladher N. Let's talk about race: BMJ; 2020 [Available from: https://blogs.bmj.com/bmj/2020/02/13/navjoyt-ladher-lets-talk-about-race/.

Figure captions

Figure 1: Study flowchart

Figure 2: UK-REACH Work package 2 timeline as of 4th February 2021. Dates are shown across the bottom from October 2019 to July 2021. The COVID-19 outbreak began in the UK in January 2020 with numbers of daily hospital admissions due to COVID-19 shown by the lower orange line for Wave one and Wave two. Vaccinations began in December 2020 and are shown by the green line for daily vaccinations. Lockdowns are shown by horizontal red bars, the first national lockdown beginning on March 23^{rd} 2020, the second on November 5^{th} , and the third of January 5^{th} 2021. Lockdowns differed somewhat in timing between England, Wales, Scotland and Northern Ireland. Tiered local restrictions were in place in various regions of the UK between lockdowns, shown in yellow. Questionnaire 1 of Work package 2 began to be distributed on December 4th onwards and is being distributed until the end of March 2021. Questionnaire 1 asks about current events and working conditions, as well as retrospectively about events and working conditions pre-Covid in 2019, about early Covid responses in the first months of 2021, and about events during the first national lockdown. Questionnaire 2 will be distributed four months after registration for questionnaire 1 and therefore will be distributed between April and June 2021. Questionnaire 2 asks primarily about current working conditions, and changes to other aspects of participants' lives captured in Questionnaire 1, including key measures of physical and mental health. With consent, the questionnaire data will be linked to electronic healthcare record data.

Figure 3: Data flow diagram. Solid lines with a circle indicate identifiable data flows for linkage purposes only. Solid lines with an arrow indicate anonymous outputs. Dashed lines indicate deidentified data. After consenting to join UK-REACH, participants provide limited personal identifiable information (PII) which are stored in a secure location at the University of Leicester, alongside study ID. Questionnaire data (including study ID but not alongside the aforementioned PII) are stored in a different secure location at the University of Leicester. Participants provide consent for the study to follow their health by extracting information from electronic health records. Relevant PII for each participant will be securely transferred to NHS Wales Informatics Service (alongside the UK-REACH study ID) in order to acquire NHS number/Community Health Index (CHI) number (for Scotland)/Health and Care number (for Northern Ireland). NHS/CHI/H&C number will then be used to link to healthcare records by the relevant data provider across the UK. De-identified health records will be sent directly to the Secure Anonymised Information Linkage databank (SAIL, https://saildatabank.com), retaining Study ID but excluding PII. Questionnaire data (including study ID) will be sent from the University of Leicester to SAIL. These datasets will be linked within SAIL to provide the complete dataset. Interim analysis of unlinked questionnaire data will be performed at the University of Leicester using pseudonymised datasets. All linked data analysis will take place within SAIL. The above diagram and style was interpreted by Anna Guyatt and Chris Orton from an initial data flow diagram created and provided by Andy Boyd at the University of Bristol. It has been repurposed and amended to illustrate data flows specific to the UK-REACH project.




Figure 1: Study flowchart 116x65mm (300 x 300 DPI)




Figure 2: UK-REACH Work package 2 timeline as of 4th February 2021. Dates are shown across the bottom from October 2019 to July 2021. The COVID-19 outbreak began in the UK in January 2020 with numbers of daily hospital admissions due to COVID-19 shown by the lower orange line for Wave one and Wave two. Vaccinations began in December 2020 and are shown by the green line for daily vaccinations. Lockdowns are shown by horizontal red bars, the first national lockdown beginning on March 23rd 2020, the second on November 5th, and the third of January 5th 2021. Lockdowns differed somewhat in timing between England, Wales, Scotland and Northern Ireland. Tiered local restrictions were in place in various regions of the UK between lockdowns, shown in yellow. Questionnaire 1 of Work package 2 began to be distributed on December 4th onwards and is being distributed until the end of March 2021. Questionnaire 1 asks about current events and working conditions, as well as retrospectively about events and working conditions pre-Covid in 2019, about early Covid responses in the first months of 2021, and about events during the first national lockdown. Questionnaire 2 will be distributed four months after registration for questionnaire 1 and therefore will be distributed between April and June 2021. Questionnaire 2 asks primarily about current working conditions, and changes to other aspects of participants' lives captured in Questionnaire 1, including key measures of physical and mental health. With consent, the questionnaire data will be linked to electronic healthcare record data.

108x60mm (300 x 300 DPI)




Figure 3: Data flow diagram. Solid lines with a circle indicate identifiable data flows for linkage purposes only. Solid lines with an arrow indicate anonymous outputs. Dashed lines indicate de-identified data. After consenting to join UK-REACH, participants provide limited personal identifiable information (PII) which are stored in a secure location at the University of Leicester, alongside study ID. Questionnaire data (including study ID but not alongside the aforementioned PII) are stored in a different secure location at the University of Leicester. Participants provide consent for the study to follow their health by extracting information from electronic health records. Relevant PII for each participant will be securely transferred to NHS Wales Informatics Service (alongside the UK-REACH study ID) in order to acquire NHS number/Community Health Index (CHI) number (for Scotland)/Health and Care number (for Northern Ireland). NHS/CHI/H&C number will then be used to link to healthcare records by the relevant data provider across the UK. De-identified health records will be sent directly to the Secure Anonymised Information Linkage databank (SAIL, https://saildatabank.com), retaining Study ID but excluding PII. Questionnaire data (including study ID) will be sent from the University of Leicester to SAIL. These datasets will be linked within SAIL to provide the complete dataset. Interim analysis of unlinked questionnaire data will be performed at the University of Leicester using pseudonymised datasets. All linked data analysis will take place within SAIL. The above diagram and style was interpreted by Anna Guyatt and Chris Orton from an initial data flow diagram created and provided by Andy Boyd at the University of Bristol. It has been repurposed and amended to illustrate data flows specific to the UK-REACH project.

108x60mm (300 x 300 DPI)

SUPPLEMENTARY INFORMATION

List of Members of UK-REACH Stakeholder Group (STAG) as at January 2021

- 1. General Medical Council (GMC)
- 2. Nursing and Midwifery Council (NMC)
- 3. General Dental Council (GDC)
- 4. General Pharmaceutical Council (GPC)
- 5. Royal College of Psychiatrists (RCPsych)
- 6. Royal College of Obstetricians and Gynaecologists (RCOG)
- 7. Royal College of Midwives (RCM)
- 8. NHS Confederation
- 9. British Association of Physicians of Indian Origin (BAPIO)
- 10. Sudan Doctors' Union -UK Branch
- 11. Association of Pakistani Physicians of Northern Europe (APPNE)
- 12. South Asian Health Foundation (SAHF)
- 13. Health Education England (HEE)
- 14. General Optical Council (GOC)
- 15. Filipino Nurses Association UK (FNAUK)
- 16. Pharmaceutical Society of Northern Ireland (PSNI)
- 17. Health and Care Professions Council (HCPC)
- 18. NHS England & Improvement
- 19. British Medical Association (BMA)
- 20. Medical Association of Nigerians Across Great Britain (MANSAG)

List of Members of UK-REACH Professional Expert Panel (PEP) as at January 2021

Susie Lagrata (co-Chair), Nurse.

Padmasayee Papineni (co-Chair), Doctor.

Sandra Kazembe, Nurse.

Tatiana Monteiro, Domestic worker.

Juliette Mutumiyana, Doctor.

Satheesh Mathew, Doctor.

Amir Burney, Doctor.

Ahmed Hashim, Doctor.

Tiffanie Harrison, Nurse.

UK-REACH Questionnaire

Introduction	
token	

Thank you for taking part in the UK-REACH study on understanding Covid-19 outcomes for ethnic minority healthcare workers (https://uk-reach.org/).

The study is interested in healthcare workers from all backgrounds, and particularly in healthcare workers from ethnic minorities.

This questionnaire asks about your work and about your ethnic and cultural background. It also asks questions that will help the research team understand how work fits into your life more broadly, and how work affects your life. These include questions about:

- your age and other background information;
- your work in healthcare;
- your ethnicity, culture, religion, languages and education;
- your home environment and living circumstances;
- your health, both physical and mental;
- your attitudes and values in life and at work;
- your occupation and working life;
- your possible exposure to COVID-19;
- your experience of events before and during the UK national lockdown

Some questions may seem unusual and it will not always seem obvious why they are being asked. They are however important, and it would be helpful if you could answer as many as possible.

Some of the questions ask about sensitive topics, and if you cannot or do not wish to answer them then simply click on "Prefer not to answer". Please be reassured that answers will be treated in accordance with strict research governance procedures, and the study has been reviewed by the Brighton and Sussex Research Ethics Committee.

Most people should be able to answer this questionnaire in about 30 minutes or so. Your answers will be stored as you go along, so you can pause the questionnaire and resume it later if you want. To do this, please select Save & Return Later. You can then continue the questionnaire from where you left off by selecting the Resume button in your UK REACH profile. You can return to your profile using the Return to Profile button provided.

If you need any further information about the study, or you have problems with any part of it, then the study team can be reached via email at uk-reach@leicester.ac.uk or by telephone on 07425611865.

If you are affected by any of the issues raised in this questionnaire or are looking for information on COVID-19 (coronavirus) please visit:

- · Government guidelines: www.gov.uk/coronavirus
- NHS advice: https://www.nhs.uk/conditions/coronavirus-covid-19/symptoms/
- NHS Where to get urgent help for mental health:

https://www.nhs.uk/using-the-nhs/nhs-services/mental-health-services/where-to-get-urgent-help-for-mental-health/

- Covid-19 Workforce Wellbeing: https://www.practitionerhealth.nhs.uk/covid-19-workforce-wellbeing
- Victim Support support for people affected by crime or traumatic events, including hate crime: https://www.victimsupport.org.uk/

ittps://www.victimsuppoit.org.uk/

- Samaritans Emotional support for everyone: www.samaritans.org
- Mind Advice and support for anyone with a mental health problem: www.mind.org.uk

	ACI	

This has been autocompleted. This ID is used for research purposes only.

Your UK-REACH ID is Empty!

Please return to your user profile and use the link provided there to access the questionnaire.

Return to User Profile

o.org REDCap

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Introduction

If you wish to go back to an earlier question, please use the Previous Page button at the bottom of each page. Please do not use the back button on your browser as that will mean that you leave the questionnaire.



REDCap[®]

Section 1/10: Background information

0% complete

.

These questions ask for some simple information about you.

There will be a separate section on your ethnic and cultural background later in the questionnaire.





Section 1/10: Background information	
0% complete	
•	
Which of the following best describes you?	ManWomanI use another term to describe my genderPrefer not to answer
Please enter the term you use to describe your gender, or enter "Prefer not to answer".	
What was your sex assigned at birth?	○ Male○ Female○ Other○ Prefer not to answer
Which of the following best describes your marital status? You will be asked more about who you live with later in the questionnaire.	 Single (never married or in civil partnership) Cohabiting with a partner Married (including those in civil partnerships) Divorced (including formerly in a civil partnership which is now legally dissolved) Separated (but still legally married or in a civil partnership) Widowed (including surviving partner from a civil partnership) Prefer not to answer

Section 2/10: Your Job

1% complete

There are many different types of healthcare jobs, and the study needs to know some things about your job.

Some people have more than one job or several roles within their job. These questions are principally about your main role/job. This is usually the role/job you spend most time in per week. If you have roles/jobs in both clinical and non-clinical settings, please think about the main role/job you have in a clinical setting, even if it is not the job you spend most time in each week.

You will also be asked about personal protective equipment (PPE).





Section 2/10: Your job 1% complete

1
3
4 5
6 7
8
9 10
11 12
13
14 15
16 17
18
19 20
21 22
23
24 25
26 27
28
29 30
31 32
33
34 35
36 37
38
39 40
41 42
43
44 45
46 47
48
49 50
51 52
53
54 55
56 57
58
59 60

What is your main job/role? Please choose the best fit and specify further if you wish.	 Allied Health Professional - Arts therapist Allied Health Professional - Biomedical scientist
The dried specify further if you wish.	
If you are not assumently would be also a consular about	Allied Health Professional - Chiropodist/Podiatrist
If you are not currently working, please answer about	Allied Health Professional - Clinical scientist
your most recent role.	Allied Health Professional - Dietician
	Allied Health Professional - Hearing aid dispenser
	 Allied Health Professional - Occupational therapist
	 Allied Health Professional - Operating department
	practicioner
	Allied Health Professional - Orthoptist
	Allied Health Professional - Physiotherapist
	Allied Health Professional - Practitioner
	psychologist
	Allied Health Professional - Prosthetist /
	Orthotist
	Allied Health Professional - Radiographer
	 Allied Health Professional - Speech and language
	therapist
	 Allied Health Professional - Other Allied Health
	Professional role (please specify)
	Ambulance - Emergency medical technician
	Ambulance - Paramedic
	Ambulance - Other ambulance role (please specify)
	Clinical support staff - OT Support Worker
	Clinical support staff - Phlebotomist
	Clinical support staff - Physiotherapy Assistant
	Clinical support staff - Radiography Assistant
	Clinical support staff - Other clinical support
	role (please specify)
	Dental - Clinical dental technician
	•
	O Dental - Dental Hygienist
	O Dental - Dental nurse
	O Dental - Dental technician
	O Dental - Dentist
	Opental - Other dental role (please specify)
	O Doctors - Doctor
	Medical associates - Advanced Critical Care
	Practitioner
	Medical associates - Anaesthesia associate
	Medical associates - Physician Associate
	 Medical associates - Surgical Care Practitioner
	 Medical associates - Other medical associate
	(please specify)
	 Nursing and midwifery - Advanced Nurse Practitioner
	 Nursing and midwifery - Healthcare assistant
	 Nursing and midwifery - Maternity support worker
	Nursing and midwifery - Midwife
	Nursing and midwifery - Nurse
	Nursing and midwifery - Nursing Associate
	Nursing and midwifery - Other nursing and
	midwifery role (please specify)
	Pharmacy - Pharmacist
	O Pharmacy - Pharmacy technician
	O Pharmacy - Other pharmacy role (please specify)
	Optical - Dispensing optician
	Optical - Dispensing optician Optical - Optometrist
	Other Optical role (please specify)
	Wider healthcare role - Administration
	Wider healthcare role - Catering services
	Wider healthcare role - Domestic services
	○ Wider healthcare role - Estates services
	Wider healthcare role - Porter
	Wider healthcare role - Other (Please specify)
	Any other role (please specify)
	Prefer not to answer



1
2
3 4 5 6 7 8 9
5
6
7
8
9
10
11 12
13
14
15
16
13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
10 10
20
21
22
23
24
25 26
27
28
29
30
31
32 33
34
34 35
36
37
38
39 40
41
42
43
44
45
46 47
48
49
50
51
52
53 54
55
56
57
58
59

Please specify your wider healthcare r	ole:		
Please specify your Allied Health Profe	ssional role:		
Please specify your ambulance role:			
Please specify your clinical support sta	aff role:		
Please specify your dental role:			
Please specify your medical associates	s role:		
Please specify your nursing and midwi	fery role:		
Please specify your pharmacy role:	0		
Please specify your optical role:			
Please specify your job role:)	
Please tell us about your working statu 23rd March 2020:	us now, and in the firs	at month after the start of the	e UK national lockdown on
	Not working	Working	Prefer not to answer
Now In the first month after the start of the UK national lockdown on 23rd March 2020	0	0	0
Please indicate the reason(s) you are re (Select all that apply): By 'shielding' we mean taking extra st yourself, by minimising interactions be yourself and others because you are a severe illness from coronavirus (COVIE By 'On furlough', we mean paid by you through the Job Support Scheme or Job Scheme and not allowed to work.	eps to protect etween t high risk of D-19). ur employer	Shielding due to ow Shielding due to hou Shielding due to hou On furlough On sick leave On carer's leave Unemployed Retired Other (please specif Prefer not to answer	usehold member's health
Please specify why you are not current	tly working:		

Please indicate the reason(s) you were not working at the start of the UK national lockdown on 23rd March 2020 (select all that apply): By 'shielding' we mean taking extra steps to protect yourself, by minimising interactions between yourself and others because you are at high risk of severe illness from coronavirus (COVID-19).	☐ Shielding due to own health ☐ Shielding due to household member's health ☐ On furlough ☐ On sick leave ☐ On carer's leave ☐ Unemployed ☐ Retired ☐ Other (please specify)
By 'On furlough', we mean paid by your employer through the Job Support Scheme or Job Retention Scheme and not allowed to work.	☐ Prefer not to answer
Please specify why you were not working at the start of the UK national lockdown on 23rd March 2020:	
In which of the following sectors is your current main job/ role?	NHSOther public sector (e.g. local or national government)
If not currently working, please answer for your most recent main job/role.	☐ Private sector☐ Private facility temporarily used by the NHS☐ University / higher education
Select all that apply.	☐ Prefer not to answer
It would be helpful to us to know where in the UK your main job/role is located. Please type the first part of the postcode (e.g. W1G, CF24, BT12 or EH16). If you can't remember the number at the end, just type the first letters (e.g. CF, BT or EH).	·
f not currently working, please answer for your most recent main job/role.	
Please note: We cannot directly identify your place of work from the first part of the postcode, but it does give a good indication of geographical location, such that place of work may be inferred.	
You may enter "Prefer not to answer" if you do not wish to provide this information.	
In which of the following sectors was your main job/role in the first month after the start of the UK national lockdown on 23rd March 2020?	NHSOther public sector (e.g. local or national government)Private sector
Select all that apply.	☐ Private facility temporarily used by the NHS ☐ University / higher education ☐ Prefer not to answer

1	
2 3	
3	
1	
-	
5	
6	
7	
Q	
0	
9	
3 4 5 6 7 8 9	
11	
12	
12	
13	
14	
15	
16	٠
17	
1/	
18	
11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31	
20	
21	
21	
22	
23	
24	
27	
25	
26	
27	
28	
20	
29	
30	
31	
32	
22	
33	
31 32 33 34 35 36	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
J /	

What is your current or most recent grade?	 Doctor in training post - Foundation level Doctor in training post - Core level Doctor in training post - Specialty level Locally employed / trust doctor - Foundation level Locally employed / trust doctor - Core level Locally employed / trust doctor - Specialty level GP Consultant SAS Other (please specify) Prefer not to answer
Please specify your current or most recent grade:	
What was your grade at the start of the UK national lockdown on 23rd March 2020?	 Doctor in training post - Foundation level Doctor in training post - Core level Doctor in training post - Specialty level Locally employed / trust doctor - Foundation level Locally employed / trust doctor - Core level Locally employed / trust doctor - Specialty level GP Consultant SAS Other (please specify) Prefer not to answer
Please specify your grade:	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml



1 Acute internal medicine What is your current or most recent specialty? 2 ○ Allergy 3 ○ Anaesthetics 4 O Audio vestibular medicine 5 O Aviation and space medicine 6 Cardio-thoracic surgery 7 Cardiology 8 Chemical pathology Child and adolescent psychiatry 9 Child mental health 10 Clinical genetics 11 Clinical neurophysiology 12 Clinical oncology 13 Clinical pharmacology and therapeutics 14 Clinical radiology 15 Community child health 16 Community sexual and reproductive health 17 Congenital cardiac surgery 18 Cytopathology 19 Dermatology 20 Diagnostic neuropathology 21 Emergency medicine 22 Endocrinology and diabetes mellitus 23 Forensic histopathology 24 Forensic psychiatry 25 Gastroenterology 26 General (internal) medicine 27 General practice General psychiatry 28 General surgery 29 Genitourinary medicine 30 Geriatric medicine 31 Gynaecological oncology 32 Haematology 33 Hepatology 34 Histopathology 35 Immunology 36 Infectious diseases 37 Intensive care medicine 38 Interventional radiology 39 Liaison psychiatry 40 Maternal and fetal medicine 41 Medical microbiology Medical oncology 42 Medical ophthalmology 43 Medical psychotherapy 44 Medical virology 45 Metabolic medicine 46 Neonatal medicine 47 Neurology 48 Neurosurgery 49 Nuclear medicine 50 Obstetrics and gynaecology 51 Occupational medicine 52 Old age psychiatry 53 Ophthalmology 54 Oral and maxillofacial surgery 55 Otolaryngology 56 O Paediatric allergy, immunology and infectious 57 diseases 58 Paediatric clinical pharmacology and therapeutics 59 Paediatric diabetes and endocrinology 60 O Paediatric emergency medicine O Paediatric gastroenterology, hepatology and nutrition Paediatric inherited metabolic medicine For peer review only - http://bmjopen.bmj.com/speediatric intensive care medicine Paediatric nephrology Paediatric neuroglisability ap.org

Paediatric neurology Paediatric oncology Paediatric palliative medicine Paediatric respiratory medicine Paediatric rheumatology Paediatric and perinatal pathology Paediatric surgery Paediatrics Palliative medicine Pharmaceutical medicine Plastic surgery Pre-hospital emergency medicine Psychiatry of learning disability Public health medicine Rehabilitation medicine Rehabilitation psychiatry Renal medicine Reproductive medicine Respiratory medicine Respiratory medicine Stroke medicine Stroke medicine Substance misuse psychiatry Trauma and orthopaedic surgery Tropical medicine Urogynaecology Urology Vascular surgery Prefer not to answer

1 What was your specialty in the first month after the Acute internal medicine 2 start of the UK national lockdown on 23rd March 2020? ○ Allergy 3 ○ Anaesthetics 4 O Audio vestibular medicine 5 O Aviation and space medicine 6 Cardio-thoracic surgery 7 Cardiology 8 Chemical pathology Child and adolescent psychiatry 9 Child mental health 10 Clinical genetics 11 Clinical neurophysiology 12 Clinical oncology 13 Clinical pharmacology and therapeutics 14 Clinical radiology 15 Community child health 16 Community sexual and reproductive health 17 Congenital cardiac surgery 18 Cytopathology 19 Dermatology 20 Diagnostic neuropathology 21 Emergency medicine 22 Endocrinology and diabetes mellitus 23 Forensic histopathology 24 Forensic psychiatry 25 Gastroenterology 26 General (internal) medicine 27 General practice General psychiatry 28 General surgery 29 Genitourinary medicine 30 Geriatric medicine 31 Gynaecological oncology 32 Haematology 33 Hepatology 34 Histopathology 35 Immunology 36 Infectious diseases 37 Intensive care medicine 38 Interventional radiology 39 Liaison psychiatry 40 Maternal and fetal medicine 41 Medical microbiology Medical oncology 42 Medical ophthalmology 43 Medical psychotherapy 44 Medical virology 45 Metabolic medicine 46 Neonatal medicine 47 Neurology 48 Neurosurgery 49 Nuclear medicine 50 Obstetrics and gynaecology 51 Occupational medicine 52 Old age psychiatry 53 Ophthalmology 54 Oral and maxillofacial surgery 55 Otolaryngology 56 O Paediatric allergy, immunology and infectious 57 diseases 58 Paediatric clinical pharmacology and therapeutics 59 Paediatric diabetes and endocrinology 60 O Paediatric emergency medicine O Paediatric gastroenterology, hepatology and nutrition Paediatric inherited metabolic medicine For peer review only - http://bmjopen.bmj.co@/saediatricintensive.care, medicine Paediatric nephrology Paediatric neuroglisability ap.org

	Paediatric neurology Paediatric oncology Paediatric palliative medicine Paediatric respiratory medicine Paediatric rheumatology Paediatric and perinatal pathology Paediatric cardiology Paediatric surgery Paediatrics Palliative medicine Pharmaceutical medicine Pharmaceutical medicine Plastic surgery Pre-hospital emergency medicine Psychiatry of learning disability Public health medicine Rehabilitation medicine Rehabilitation psychiatry Renal medicine Reproductive medicine Respiratory medicine Respiratory medicine Stroke medicine Stroke medicine Substance misuse psychiatry Trauma and orthopaedic surgery Tropical medicine Urogynaecology Urology Vascular surgery Prefer not to answer
What is your current or most recent NHS band?	 ○ Band 1 ○ Band 2 ○ Band 3 ○ Band 4 ○ Band 5 ○ Band 6 ○ Band 7 ○ Band 8a ○ Band 8b ○ Band 8c ○ Band 8d ○ Band 9 ○ Prefer not to answer
What was your NHS band at the start of the UK national lockdown on 23rd March 2020?	Band 1 Band 2 Band 3 Band 4 Band 5 Band 6 Band 7 Band 8a Band 8b Band 8c Band 8d Band 9 Prefer not to answer

BMJ Open

Page 38 of 143

1	
2	
3	
4	
5	
6	
7	
8	
9	
1	0
1	1
1	2
1	3
1	4
1	5
1	6
1	7
1	8
1	9
	0
2	
2	
2	3
2	
2	5
2	6
2	
2	8
	9
_	0
3	
3	
3	_
2	ر 4
2	- 5
	5 6
3	_
_	, 8
	o 9
4	
	1
4	
4	
	6
4	
4	
4	
ر	0
ر	
5	
	3
	4
	5
	6
	7
	8
	9
6	n

What is your registered field of nursing?	 Adult Children's Learning disability Mental health Dual registration (please specify) Prefer not to answer 	
Please specify the two fields in which you practice:		

Section 2/10: Your job

7% complete

r you work in the same area(s) now as ick the "now" and "UK national lockdo	you were working i wn" boxes.	n the first month after the UK na	ational lockdown, please
Please leave blank any areas you have	not worked in since	e the UK national lockdown.	
on bodon or Consultation of	Now	UK national lockdown	Prefer not to answer
Ambulance (inc air ambulance)			
Armed forces Community clinical / primary are setting			
Community non-clinical settings			
Hospitals - Emergency Department			
lospital - Intensive Care Unit			
lospital - other inpatient setting			
lospital - outpatients			
lospital - other clinical setting			
lospital - other non-clinical etting			
lospital - public / communal reas			
aboratory			
l aternity			
Nobile across areas			
lursing or care home			
Prison			
sychiatric hospital or inpatient init			
Iniversity			
our home			
Other (Please specify)			
Please specify the workplace for which Other":	you selected		

1	
1	
2	
3	
4	
5	
6	
6	
7	
8	
9	
1	0
1	1
1	2
1	3
1	4
1	
1	0
1	7
1	
1	9
	0
_	-
2	
2	2
2	3
2	
2	
2	
2	7
2	
2	
3	0
3	1
3	2
3	3
3	_
_	-
3	_
3	6
3	7
	8
_	_
	9
	0
4	1
4	2
4	
+	ر.
4	
4	_
4	6
4	
	8
	9
	0
5	1
5	
5	
5	
5	5
5	6
5	
5	
5	9

In the first month after the start of the UK national lockdown on 23rd March 2020, how many hours did you	
work in a typical week?	

How often do you work night shifts now, and did you typically work in the early months after the start of the UK national lockdown on 23rd March 2020?

If these are on call shifts, please answer based on how often you are actually required to work. If you were not working during the specified time frame please select "Not applicable". If you are answering this questionnaire on a smartphone, you may find it easier to view by rotating the screen.

	Not applicable	Never	Less than once a month	Once a month or more, but not every week	Once a week or more, but not every shift	l always work nights	Prefer not to answer
Now In the early months following the start of the UK national lockdown on 23rd March 2020	0	0 0	0	0	0	0	0

Prefer not to answer

Prefer not to answer

 \bigcirc

Prefer not to answer

How many people did you talk with at work last week from each of the following groups: If you are answering this questionnaire on a smartphone, you may find it easier to view by rotating the solution of th	If you are answering this questionnaire on a smartphone, you may find it easier to view by rotating the so Remotely (e.g. over the phone or via video media) 0	8% complete .						
Remotely (e.g. over the phone or via video media)	Remotely (e.g. over the phone or via video media)	How many people did you talk with	n at work last	week from eac	ch of the follow	ving groups:		
Number of patients	Number of patients	If you are answering this questionr	naire on a sm	artphone, you	may find it eas	sier to view by	rotating the	SC
Number of patients Number of colleagues Number of others (not patients or colleagues) Pace to face with social distancing O 1-5 6-20 21-50 51+ Number of patients with O O O O O O O O O O O O O O O O O O O	Number of patients Number of colleagues Number of others (not patients or colleagues) Pace to face with social distancing O 1-5 6-20 21-50 51+ Number of patients with O O O O O O O O O O O O O O O O O O O	Remotely (e.g. over the phone or v	via video med	lia)				
Number of colleagues Face to face with social distancing O 1-5 6-20 21-50 51+ Number of patients with confirmed or suspected COVID-19 Number of colleagues Number of patients O 1-5 6-20 21-50 51+ Number of patients O O O O O O O O O O O O O O O O O O O	Number of colleagues Number of others (not patients or colleagues) Face to face with social distancing 0 1-5 6-20 21-50 51+ Number of patients with confirmed or suspected COVID-19 Number of others (not patients or colleagues) With physical contact 0 1-5 6-20 21-50 51+ Number of colleagues 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		0	1-5	6-20	21-50	51+	
Number of colleagues Number of others (not patients or colleagues) Face to face with social distancing 0 1-5 6-20 21-50 51+ Number of patients with confirmed or suspected COVID-19 Number of others (not patients or colleagues) With physical contact 0 1-5 6-20 21-50 51+ Number of colleagues 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Number of colleagues Number of others (not patients or colleagues) Face to face with social distancing 0 1-5 6-20 21-50 51+ Number of patients with confirmed or suspected COVID-19 Number of others (not patients or colleagues) With physical contact 0 1-5 6-20 21-50 51+ Number of colleagues 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Number of patients	\circ	\circ	\circ	\circ	\circ	
Number of others (not patients or colleagues) Face to face with social distancing 0 1-5 6-20 21-50 51+ Number of patients with	Number of others (not patients or colleagues) Face to face with social distancing 0 1-5 6-20 21-50 51+ Number of patients with		\circ	\circ	\circ	\circ	\circ	
Number of patients with	Number of patients with	Number of others (not patients	0	0	0	0	0	
Number of patients with confirmed or suspected COVID-19 Number of other patients	Number of patients with confirmed or suspected COVID-19 Number of other patients	Face to face with social distancing						
confirmed or suspected COVID-19 Number of other patients Number of colleagues Number of others (not patients or colleagues) With physical contact 0 1-5 6-20 21-50 51+ Number of patients with confirmed or suspected COVID-19 Number of other patients Number of colleagues Number of colleagues Number of others (not patients O O O O O O O O O O O O O O O O O O O	confirmed or suspected COVID-19 Number of other patients Number of colleagues Number of others (not patients or colleagues) With physical contact 0 1-5 6-20 21-50 51+ Number of patients with confirmed or suspected COVID-19 Number of other patients Number of colleagues Number of colleagues Number of others (not patients O O O O O O O O O O O O O O O O O O O		0	1-5	6-20	21-50	51+	
Number of other patients Number of colleagues Number of others (not patients or colleagues) With physical contact 0 1-5 6-20 21-50 51+ Number of patients with confirmed or suspected COVID-19 Number of other patients Number of colleagues Number of colleagues Number of others (not patients O O O O O O O O O O O O O O O O O O O	Number of other patients Number of colleagues Number of others (not patients or colleagues) With physical contact 0 1-5 6-20 21-50 51+ Number of patients with confirmed or suspected COVID-19 Number of other patients Number of colleagues Number of colleagues Number of others (not patients O O O O O O O O O O O O O O O O O O O	confirmed or suspected	0	0	0	0	0	
Number of others (not patients or colleagues) With physical contact 0 1-5 6-20 21-50 51+ Number of patients with confirmed or suspected COVID-19 Number of other patients O O O O O O O O O O O O O O O O O O O	Number of others (not patients or colleagues) With physical contact 0 1-5 6-20 21-50 51+ Number of patients with confirmed or suspected COVID-19 Number of other patients O O O O O O O O O O O O O O O O O O O	Number of other patients	\bigcirc	0	\circ	\circ	\circ	
With physical contact 0 1-5 6-20 21-50 51+ Number of patients with	With physical contact 0 1-5 6-20 21-50 51+ Number of patients with	Number of colleagues	\bigcirc	0	\circ	\circ	\circ	
Number of patients with OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO	Number of patients with OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO	Number of others (not patients or colleagues)	0	0	0	0	0	
Number of patients with confirmed or suspected COVID-19 Number of other patients OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO	Number of patients with confirmed or suspected COVID-19 Number of other patients OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO	With physical contact		•	(0)			
confirmed or suspected COVID-19 Number of other patients Number of colleagues Number of others (not patients	confirmed or suspected COVID-19 Number of other patients Number of colleagues Number of others (not patients		0	1-5	6-20	21-50	51+	
Number of other patients O O O O O O O O O O O O O O O O O O	Number of other patients O O O O O O O O O O O O O O O O O O	confirmed or suspected	0	0	0	0	0	
Number of others (not patients O O O O	Number of others (not patients O O O O	Number of other patients	\circ	\bigcirc	0	0	\bigcirc	
		Number of colleagues	\circ	\bigcirc	\bigcirc	0	\circ	
			0	0	0	0	0	

1	
2	
3	
4	
5	
0	
/	
8	
5 6 7 8 9 10 11	
10	
11	
12	
14	
15	
16	
17	
15 16 17 18 19	
19	
20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
41	
42	
43 44	
44	
45 46	
46 47	
4 <i>/</i>	
48 49	
49 50	
50 51	
52 53	
54 55	
56	
57	
58	
59	
60	

Setion 2/10: Your job						
8% complete						
How many people did you talk with lockdown on 23rd March 2020 from If you are answering this questionn	each of the	following group	s:			
Remotely (e.g. over the phone, or v	via video med	dia)				
	0	1-5	6-20	21-50	51+	Prefer not to answer
Number of patients	\circ	\circ	\circ	\circ	\circ	\circ
Number of colleagues	0	\bigcirc	\circ	\bigcirc	\circ	\circ
Number of others (not patients or colleagues)	0	0	0	0	0	0
Face to face with social distancing						
	0	1-5	6-20	21-50	51+	Prefer not to answer
Number of patients with confirmed or suspected COVID-19	0	0	0	0	0	0
Number of other patients	\circ	0	\circ	\circ	\circ	\circ
Number of colleagues	\bigcirc	O	\circ	\circ	\circ	\circ
Number of others (not patients or colleagues)	\circ	0	0	0	0	0
With physical contact			(0),			
	0	1-5	6-20	21-50	51+	Prefer not to answer
Number of patients with confirmed or suspected	0	0	0	0	0	0
COVID-19 Number of other patients	\bigcirc	\bigcirc	0	0	\circ	\circ
Number of colleagues	\circ	\circ	\bigcirc	0	\circ	\circ
Number of others (not patients or colleagues)	0	0	0	0	0	0

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 30 30 30 30 30 30 30 30 30 30 30 30	
33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 60 60 60 60 60 60 60 60 60 60 60 60	

Section 2/10: Your job						
9% complete						
When working in your main role/jo	b, how long o	do you spend tr	avelling to and	from work pe	r day?	
You may select 'Not at all' if you w	ork exclusive	ely from home.				
If you are answering this questionr	naire on a sm	artphone, you	may find it easi	ier to view by	rotating the sc	reen.
	Not at all	Less than 10 minutes	10 minutes to 1 hour	1 to 2 hours	Over 2 hours	Prefer not to answer
Typical working day over the past month	0	\bigcirc	0	0	0	0
Typical working day during the first month after the UK national lockdown on 23rd March 2020	0	0	0	0	0	0
Which of the following modes of transport do you use to commute on a typical working day over the past month? Please select all that apply.		Car share househol Taxi or p Public tra undergro	e, with a smal d rivate hire vel ansport (e.g. b	us, train, tram,	e outside of	
Please enter the mode of transport for which you selected 'Other':			0			
Which of the following modes of transport did you use to commute on a typical working day, during the first month after the start of the UK national lockdown on 23 March 2020? Please select all that apply.			 □ Car, alone or with member of household □ Car share, with a small pool of people outside of household □ Taxi or private hire vehicle □ Public transport (e.g. bus, train, tram, underground) □ Motorcycle, scooter or moped □ Bicycle □ On foot □ Other 			
Please enter the mode of transport for which you selected 'Other':						

11% complete							
This question is about your acces	s to appropria	ate personal	protective	equipment	(PPE) at wor	·k.	
If you have more than one role or across all of your jobs.		·					E) in ger
	Not applicable	Not at all	Rarely	Some of the time	Yes, most of the time	Yes, all of the time	Prefer to ans
At present, do you have access to appropriate personal protective equipment (PPE) at work?	0	0	0	0	0	0	C
In the first month after the start of the UK national lockdown on 23rd March 2020, did you have access to appropriate personal protective equipment (PPE) at work?	00	0	0	0	0	0	С
main job/role.	g you may ha	ive received	in the use	of personal	l protective e	quipment (F	PPE) in y
main job/role.	g you may ha		For	mal	I protective e	quipment (F	Prefe
main job/role. Select all that apply. Have you received training in the use of personal protective equipment (PPE) for your current		e Formal training i	For	mal	Informal		Prefe
This question is about any training main job/role. Select all that apply. Have you received training in the use of personal protective equipment (PPE) for your current work? In the first month after the start of the UK national lockdown on 23rd March 2020, did you receive training in the use of personal protective equipment (PPE) for your work?		e Formal training i	For	mal	Informal		PPE) in y

₹EDCap°

		Not
		applicable
<u>2</u> 3	At present, how often are you in	\circ
ļ 5	a room where	
))	aerosol-generating procedures are performed?	
7	are performed.	
} }	In the first month after the start	\bigcirc
0	of the UK national lockdown on	
1	23rd March 2020, how often were you in a room where	
2	aerosol-generating procedures	
3	are performed?	
4		
5 6		
7		
8		
9		
)		
1 2		
3		
4		
5		
5		
7 3		
,		
)		
'		
,		
;		
)		
)		
l 2		
, ļ		

-		J
1		
2		
3		
4		
5		
6		
7		
8		
9		
	0	
	1	
1		
	3	
	4	
	5	
1	6 7	
1	7	
1	8	
1	9	
	_	
2	1	
2	2	
	3	
	4	
	5	
	6	
2	7	
2	8	
2	9	
	_	
	1	
	2	
	3	
	၁ 4	
	5	
	6	
3	7	
3	8	
3	9	
	0	
4		
4		
4	_	
	4	
4		
4		
4		
	8	
	9	
5	0	
5		
5		
5		
	4	
	4 5	
5		
5		
5	8	
5	9	
6	n	

Section 2/10: Your job							
13% complete							
Have you been offered an NHS COVID-19 risk assessment at work?			○ No ○ No as ○ Ye as ○ Ye as	 Not applicable No, I have not heard of COVID-19 risk assessments No, I have not been offered a COVID-19 risk assessment Yes, I have been offered a COVID-19 risk assessment but I chose not to complete it Yes, I have been offered a COVID-19 risk assessment and I completed it Prefer not to answer 			
Did your work change as a result of the NHS COVID-19 risk assessment result? (Select the best answer)			○ No ○ No ○ Ye ae ○ Ye ○ Ye ○ Ye	o, because o, but I did es, differen erosol-gene es, reducec es, remove es, advised	t duties (e.gerating proced patient cord patient cord to shield blease specifications)	nt it to . advised no edures) ntact ntact	t to conduct
Please specify how your work changed as a result of the NHS COVID-19 risk assessment result:							
Thinking about where you work in statements? If you are answering this question				_	_		-
	Strongly disagree	Disagree	Neither agree or disagree	Agree	Strongly agree	Not applicable	Prefer not to answer
I would feel secure raising concerns about unsafe clinical practice	0	0	0	0	0	0	0
I am confident that my organisation would address my concern		0	0	0	0		0

1 2
3 4
5 6
7 8
9 10
11 12
13 14
15
16 17
18 19
20 21
22 23
24 25
26 27
28 29
30 31
32 33
34 35
36 37
38
39 40
41 42
43 44
45 46
47 48
49 50
51 52
53 54
55 56
57 58
59 60

o es, I was redeployed but continued to work in my le prior to the UK national lockdown more than alf the time es, I was redeployed but continued to work in my le prior to the UK national lockdown for less an half the time es, I was redeployed all of the time
es, I was redeployed but continued to work in my le prior to the UK national lockdown more than alf the time es, I was redeployed but continued to work in my le prior to the UK national lockdown for less an half the time es, I was redeployed all of the time
es, I was redeployed but continued to work in my le prior to the UK national lockdown more than alf the time es, I was redeployed but continued to work in my le prior to the UK national lockdown for less an half the time es, I was redeployed all of the time
efer not to answer
uch less omewhat less oout the same omewhat more uch more efer not to answer
ormal training face to face ormal training online formal training o training refer not to answer
ormal supervision formal supervision o supervision refer not to answer



Section 3/10: Your ethnic, cultural and national identity and background

17% complete

Ethnicity relates to a range of different factors. Most studies of ethnicity in healthcare workers use the standard UK Census question on ethnicity with its broad but limited ethnic groupings.

We will start with the UK Census ethnicity question but we recognise its limitations in describing the subtleties of how people vary in relation to migration, social identity, and experiences of them and their families. We hope this more detailed information will help in understanding how COVID-19 affects different groups.

This section asks about:

- Ethnic group and place of birth of you and your parents
- English and other languages spoken
- The role of religion in your life
- Your sense of identity
- The ethnicity of those you work with

Please remember that if you prefer not to answer any question then simply click on Prefer not to answer, but remember that there are good reasons for asking these questions



1	
2	
3	
4	
5	
6	
7	
8	
9	
	0
1	
1	
1	
	4
1	5
1	
	7 8
	9
	0
2	1
2	2
2	
	4
	5
	6
2	
	8
2	9
3	0
3	1
	2
3	
	4
	5
	6
	7
	8
	9
	_
	1
4	
4	
4	
4	
4	
4	
	8
	9
	0
5	1
5	
5	3
5	4
5	5
5	6
	7
	8
5	
6	0

Section 3/10: Your ethnic, cultural and national ide	ntity and background
17% complete	
•	
What is your ethnic group? Select the one that best describes your ethnic group or background. The categories are the ethnic groups used in the UK National Census.	Asian/Asian British - Indian Asian/Asian British - Pakistani Asian/Asian British - Bangladeshi Asian/Asian British - Chinese Asian/Asian British - Any other Asian background Black/African/Caribbean/Black British - African Black/African/Caribbean/Black British - Caribbean Black/African/Caribbean/Black British - Any other Black/African/Caribbean/Black British - Any other Black/African/Caribbean background Mixed/Multiple ethnic groups - White and Black Caribbean Mixed/Multiple ethnic groups - White and Black African Mixed/Multiple ethnic groups - White and Asian Mixed/Multiple ethnic groups - Any other Mixed/Multiple ethnic background White - English/Welsh/Scottish/Northern Irish/British White - Irish
Please specify your ethnic group:	 White - Gypsy or Irish Traveller White - Any other white background Other ethnic group - Arab Other ethnic group - Any other ethnic background Prefer not to say
Were you born in the UK?	○ No○ Yes○ Prefer not to answer

1	In which country were	vou horn?		$\overline{\bigcirc}$	Afghanistan
2	in winch country were	you boill:		\sim	Albania
3					Algeria
4					Andorra
5					Angola
6					Antigua and Barbuda
7					Argentina
8					Armenia
9					Australia
					Austria
10					Azerbaijan
11					Bahamas, The
12					Bahrain
13					Bangladesh
14					Barbados
15				=	
16				\sim	Belgium
17				\sim	Belize
18				\sim	Renin
19				\sim	Bhutan
20				\sim	Bolivia
21				\sim	Bosnia and Herzegovina
22				\sim	Botswana
23				\sim	Brazil
24				\sim	Brunei
25				\sim	Bulgaria
26				\tilde{a}	Burkina Faso
27				\sim	Burundi
28				\sim	Cambodia
29				\sim	Cameroon
				\sim	Canada
30				\sim	Cane Verde
31				\tilde{a}	Central African Republic
32				\tilde{a}	Chad
33				ŏ	Belarus Belgium Belize Benin Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Central African Republic Chad Chile China Colombia Comoros Congo Congo (Democratic Republic) Costa Rica Croatia
34				Ŏ	China
35				Ŏ	Colombia
36				Ŏ	Comoros
37				Ŏ	Congo
38				Ŏ	Congo (Democratic Republic)
39				Ŏ	Costa Rica
40				Ŏ	Croatia
41				Ŏ	Cuba
42				Ŏ	Cyprus
43				Ō	Czechia
44				Ŏ	Denmark
45				\bigcirc	Djibouti
46					Dominica
47				\bigcirc	Dominican Republic
48				\bigcirc	East Timor
49					Ecuador
50				\bigcirc	Egypt
50 51				\bigcirc	El Salvador
				\bigcirc	Equatorial Guinea
52					Eritrea
53					Estonia
54					Eswatini
55					Ethiopia
56					Fiji
57					Finland
58					France
59					Gabon
60					Gambia, The
					Georgia
					Germany
					Ghana
		For peer review only -	http://bmjopen.bmj.co	om)	/∰@966 ut/guidelines.xhtml
				()	Grenada



O Guinea Republic of Guinea ◯ Guinea-Bissau Guyana ○ Haiti ○ Honduras Hungary ○ Iceland \bigcirc India ○ Indonesia ○ Iran ○ Iraq Ireland ○ Israel ○ Italy Ivory Coast Jamaica Japan Jordan Kazakhstan Kenya Kiribati ○ Korea (North) ○ Korea (South) Kuwait Kyrgyzstan Catvia ○ Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Madagascar Malawi Malaysia Maldives O Mali O Malta Marshall Islands Mauritania Mauritius Mexico Micronesia Moldova ○ Monaco Mongolia ○ Montenegro ○ Morocco Mozambique ○ Myanmar (Burma) ○ Namibia ○ Nauru ○ Nepal ○ Netherlands O New Zealand ○ Nicaragua ○ Niger ○ Nigeria North Macedonia ○ Norway Oman Pakistan O Palau Panama Papua New Guinea For peer review only - http://bmjopen.bmj.com/slet/auto/guidelines.xhtml Peru O Philippines

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

	Portugal Qatar Romania Russia Rwanda St Kitts and Nevis St Lucia St Vincent Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Sudan Spain Sri Lanka Sudan Suriname Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Togo Tonga Trinidad and Tobago Turkey Turkmenistan Tuvalu Uganda Ukraine United Arab Emirates Ulruguay Uzbekistan Vanuatu Vatican City Venezuela Vietnam Yemen Zambia Zimbabwe Other (Please specify)
Diago specify the country in which you were have	Prefer not to answer
Please specify the country in which you were born:	
In which year did you move to the UK?	
If you are unsure, please give your best estimate.	((Please enter in format YYYY, e.g. 1967))

Page 53 of 143

For which countries do you hold a passport?

We have provided boxes to select up to three nationalities. Please leave the boxes for nationality 2 and nationality 3 blank if they do not apply to you.



NI - 41 114 1	O Haitad Kingdon O Afabanistan
Nationality 1:	○ United Kingdom ○ Afghanistan
	🔾 Albania 🔾 Algeria 🔾 Andorra
	O Angola O Antigua and Barbuda
	○ Argentina ○ Armenia
	○ Australia ○ Austria
	○ Azerbaijan ○ Bahamas, The
	O Bahrain O Bangladesh
	○ Barbados ○ Belarus
	Dalabaus Delia O Bartin
	O Belgium O Belize O Benin
	O Bhutan O Bolivia O Bosnia and
	Herzegovina O Botswana
	O Brazil O Brunei O Bulgaria
	O Burkina Faso O Burundi
	○ Cambodia ○ Cameroon
	◯ Canada ⊃ Cape Verde
	Central African Republic
	○ Chad ○ Chile ○ China
	○ Congo ○ Congo (Democratic Republic)
	Congo Congo (Democratic Republic)
	○ Costa Rica ○ Croatia
	○ Cuba ○ Cyprus ○ Czechia
	Openmark Dijibouti
	Deminio Dipouti
	O Dominica O Dominican Republic
	Colombia Comoros Congo Congo (Democratic Republic) Costa Rica Croatia Cuba Cyprus Czechia Denmark Djibouti Dominica Dominican Republic East Timor Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Eswatini Ethiopia Fiji Finland France Gabon Gambia, The Georgia Germany Ghana Greece Grenada Guatemala Guinea Republic of Guinea Guinea-Bissau Guyana
	◯ Egypt ⊃ El Salvador
	○ Equatorial Guinea ○ Eritrea
	C Equational Guillea C Efficient
	○ Estonia ○ Eswatini
	○ Ethiopia ○ Fiji ○ Finland
	◯ France ◯ Gabon ◯ Gambia, The
	Coording Cormany
	○ Georgia ○ Germany
	◯ Guatemala ◯ Guinea Republic of Guinea
	Guinea-Bissau Guyana
	☐ Haiti ☐ Honduras ☐ Hungary
	◯ Iceland ◯ India ◯ Indonesia
	◯ Iran ◯ Iraq ◯ Ireland
	Israel Italy Ivory Coast
	◯ Jamaica ◯ Japan ◯ Jordan
	○ Kazakhstan ○ Kenya
	◯ Kiribati ◯ Korea (North)
	○ Korea (North) ○ Kosovo
	○ Kuwait ○ Kyrgyzstan
	○ Laos ○ Latvia ○ Lebanon
	C Lesotho C Liberia
	○ Libya ○ Liechtenstein
	Lithuania Luxembourg
	Madagascar
	○ Malaysia ○ Maldives
	○ Mali ○ Malta ○ Marshall Islands
	○ Mauritania ○ Mauritius
	○ Mexico ○ Micronesia
	○ Myanmar (Burma) ○ Namibia
	○ Nauru ○ Nepal ○ Netherlands
	New Zealand Nicaragua
	○ Niger ○ Nigeria ○ North Macedonia
	○ Norway ○ Oman ○ Pakistan
	○ Palau ○ Panama ○ Papua New Guinea
	O Paraguay O Peru O Philippines
	O Poland O Portugal
	○ Qatar ○ Romania ○ Russia
	Rwanda St Kitts and Nevis
	○ St Lucia ○ St Vincent
	○ Samoa ○ San Marino
	For peer review only - http://bmjopen.bmj.com/ssaantomejande/hipsipeml
	Saudi Arabia Senegal
02/09/2021 15:46	் Serbia ் Seyshellesedcap.org ₹EDCap



	 Sierra Leone
Please specify nationality 1:	

Page 56 of 143

Nationality 2:	◯ United Kingdom ◯ Afghanistan
Nucloriality 2.	○ Albania ○ Algeria ○ Andorra
	○ Angola ○ Antigua and Barbuda
	○ Argentina ○ Armenia
	O Australia O Austria
	○ Azerbaijan ○ Bahamas, The
	○ Bahrain ○ Bangladesh
	○ Barbados ○ Belarus
	○ Belgium ○ Belize ○ Benin
	O Bhutan O Bolivia O Bosnia and
	Herzegovina Botswana
	○ Brazil ○ Brunei ○ Bulgaria
	○ Burkina Faso ○ Burundi
	Cambodia Cameroon
	○ Canada ○ Cape Verde○ Central African Republic
	○ Chad ○ Chile ○ China
	Colombia Comoros
	Congo Congo (Democratic Republic)
	Cuba Cyprus Czechia
	○ Denmark ○ Djibouti
	 Costa Rica
	○ East Timor ○ Ecuador
	○ Egypt ○ El Salvador
	○ Equatorial Guinea ○ Eritrea
	◯ Estonia ◯ Eswatini
	C Ethiopia C Fiji C Finland
	France Gabon Gambia, The
	Georgia Germany
	☐ Guatemala ☐ Guinea Republic of Guinea
	○ Guinea-Bissau ○ Guyana
	○ Haiti ○ Honduras ○ Hungary
	○ Iceland ○ India ○ Indonesia
	○ Iran ○ Iraq ○ Ireland
	○ Israel ○ Italy ○ Ivory Coast
	○ Jamaica ○ Japan ○ Jordan
	○ Kazakhstan ○ Kenya
	○ Kiribati○ Korea (North)○ Korea (South)○ Kosovo
	○ Kuwait ○ Kyrgyzstan
	○ Laos ○ Latvia ○ Lebanon
	Lesotho Liberia
	Libya Liechtenstein
	○ Lithuania ○ Luxembourg
	○ Madagascar ○ Malawi
	○ Malaysia ○ Maldives
	○ Mali ○ Malta ○ Marshall Islands
	○ Mauritania ○ Mauritius
	○ Mexico ○ Micronesia
	○ Moldova ○ Monaco
	Mongolia Montenegro
	◯ Morocco ⊃ Mozambique
	O Myanmar (Burma) O Namibia
	Nauru Nepal Netherlands
	New Zealand Nicaragua
	◯ Niger ◯ Nigeria ◯ North Macedonia
	○ Norway ○ Oman ○ Pakistan
	○ Palau ○ Panama ○ Papua New Guinea
	O Paraguay O Peru O Philippines
	○ Poland ○ Portugal
	○ Qatar ○ Romania ○ Russia
	Rwanda St Kitts and Nevis
	○ St Lucia ○ St Vincent
	○ Samoa ○ San Marino
	For peer review only - http://bmjopen.bmj.compsharentempende Principemi
	◯ Saudi Arabia 🤾 Senegai
02/09/2021 15:46	○ Serbia ○ Seyshellesedcap.org REDCap



	 Sierra Leone
Please specify nationality 2:	

Page 58 of 143

Nationality 2	O United Kingdom O Afglesnisten
Nationality 3:	○ United Kingdom ○ Afghanistan
	○ Albania ○ Algeria ○ Andorra
	Angola Antigua and Barbuda
	○ Argentina ○ Armenia
	○ Australia
	○ Azerbaijan ○ Bahamas, The
	○ Bahrain ○ Bangladesh
	O Barbados O Belarus
	○ Belgium ○ Belize ○ Benin
	o beigium o beilze o beilin
	O Bhutan O Bolivia O Bosnia and
	Herzegovina 🔘 Botswana
	○ Brazil ○ Brunei ○ Bulgaria
	O Burkina Faso O Burundi
	○ Cambodia ○ Cameroon
	○ Canada ○ Cape Verde
	Central African Republic
	○ Chad ○ Chile ○ China
	○ Colombia ○ Comoros
	○ Congo ○ Congo (Democratic Republic)
	Costa Rica Croatia
	Cuba Curria Crackia
	○ Cuba ○ Cyprus ○ Czechia
	○ Denmark ○ Djibouti
	O Dominica O Dominican Republic
	○ East Timor ○ Ecuador
	○ Egypt ○ El Salvador
	○ Equatorial Guinea ○ Eritrea
	Colombia Comoros Congo Congo (Democratic Republic) Costa Rica Croatia Cuba Cyprus Czechia Denmark Djibouti Dominica Dominican Republic East Timor Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Eswatini Ethiopia Fiji Finland France Gabon Gambia, The Georgia Germany Ghana Greece Grenada Guatemala Guinea Republic of Guinea Guinea-Bissau Guyana
	○ Ethiopia ○ Fiji ○ Finland
	Change Cohen Combin The
	○ France ○ Gabon ○ Gambia, The
	○ Ghana ○ Greece ○ Grenada
	○ Guatemala ○ Guinea Republic of Guinea
	Guinea Bissay Guyana
	○ Haiti ○ Honduras ○ Hungary
	◯ Iceland ◯ India ◯ Indonesia
	○ Iran ○ Iraq ○ Ireland
	Olerand Oltaber Change
	○ Israel ○ Italy ○ Ivory Coast
	◯ Jamaica ◯ Japan ◯ Jordan
	○ Kazakhstan ○ Kenya
	◯ Kiribati ◯ Korea (North)
	○ Korea (South) ○ Kosovo
	○ Kuwait ○ Kyrgyzstan
	○ Latvia ○ Lebanon
	C Lesotho C Liberia
	○ Libya ○ Liechtenstein
	○ Lithuania ○ Luxembourg
	Madagascar Malawi
	○ Malaysia ○ Maldives
	○ Mali : ○ Malta ○ Marshall Islands
	MauritaniaMauritius
	○ Mexico ○ Micronesia
	○ Moldova ○ Monaco
	○ Mongolia ○ Montenegro
	○ Morocco ○ Mozambique
	○ Myanmar (Burma) ○ Namibia
	○ Nauru ○ Nepal ○ Netherlands
	○ New Zealand ○ Nicaragua
	○ Niger ○ Nigeria ○ North Macedonia
	○ Norway ○ Oman ○ Pakistan
	○ Palau ○ Panama ○ Papua New Guinea
	○ Paraguay ○ Peru ○ Philippines
	O Poland O Portugal
	○ Qatar ○ Romania ○ Russia
	RwandaSt Kitts and Nevis
	St Lucia St Vincent
	○ Samoa ○ San Marino
	— Con Town and Drive in a
	For peer review only - http://bmjopen.bmj.coiossantemegandenscinemi
	Saudi Arabia (Senegai
02/09/2021 15:46	○ Serbia ○ Seyshellesedcap.org REDCas
J_, JJ, LULI IJ, TU	Sprojecticacap.org REDCa



	Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Sudan Spain Sri Lanka Sudan Suriname Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Tuvalu Uganda Ukraine United Arab Emirates United States Uruguay Uzbekistan Vanuatu Vatican City Venezuela Vietnam Yemen Zambia Zimbabwe Other (Please specify) Prefer not to answer
Please specify nationality 3:	
What is or was your partner's ethnic group? The following categories are the ethnic groups used in the UK National Census.	Asian/Asian British - Indian Asian/Asian British - Pakistani Asian/Asian British - Bangladeshi Asian/Asian British - Chinese Asian/Asian British - Any other Asian background Black/African/Caribbean/Black British - African Black/African/Caribbean/Black British - Caribbean Black/African/Caribbean/Black British - Any other Black/African/Caribbean background Mixed/Multiple ethnic groups - White and Black Caribbean Mixed/Multiple ethnic groups - White and Black African Mixed/Multiple ethnic groups - White and Asian Mixed/Multiple ethnic groups - Any other Mixed/multiple ethnic background White - English/Welsh/Scottish/Northern Irish/British White - Irish White - Gypsy or Irish Traveller White - Any other white background Other ethnic group - Arab Other ethnic group - Any other ethnic background (please specify) Prefer not to say
Please specify your partner's ethnic group:	

Page 60 of 143

1	
2	
2	
4	
4	
2	
0	
/	
8	
9	
	0
1	1
1	2
1	
1	4
1	5
1	6
1	7
1	
1	9
2	0
2	1 2
2	2
	3
2	4
2	
2	5 6
2	, δ
2	o o
2	0
3	1
3	_
3	3
3	4
3	5
3	6
3	7
_	8
3	9
4	0
4	1
4	2
4	3
4	4
4	5
4	_
4	
4	
4	
	0
5	1
5	
5	
5	
5	-
	6
ر	
	8
	9
6	0

What is or was your mother's ethnic group?	Asian/Asian British - Indian
The following categories are the ethnic groups used	Asian/Asian British - PakistaniAsian/Asian British - Bangladeshi
in the UK National Census.	Asian/Asian British - Chinese
	Asian/Asian British - Any other Asian backgroundBlack/African/Caribbean/Black British - African
	 Black/African/Caribbean/Black British - Caribbean
	Black/African/Caribbean/Black British - Any other Black/African/Caribbean background
	Black/African/Caribbean background Mixed/Multiple ethnic groups - White and Black
	Caribbean
	 Mixed/Multiple ethnic groups - White and Black African
	 Mixed/Multiple ethnic groups - White and Asian
	 Mixed/Multiple ethnic groups - Any other Mixed/multiple ethnic background
	White - English/Welsh/Scottish/Northern
	Irish/British ○ White - Irish
	White - Gypsy or Irish Traveller
	White - Any other white backgroundOther ethnic group - Arab
	Other ethnic group - Any other ethnic background
	(please specify) ○ Prefer not to say
	O Freier Hot to suy
Please specify your mother's ethnic group:	
Was your mother born in the UK?	No
	Yes○ Do not know
	Prefer not to answer

1	In which country was	your mother born?) Afghanistan		
2	•	•	Ċ) Albania		
4) Algeria		
5) Andorra) Angola		
6) Antigua and B	arbuda	
7			Č) Argentina		
8) Armenia		
9			\subseteq	Australia		
10) Austria		
11) Azerbaijan) Bahamas, The	1	
12 13) Bahrain	•	
14) Bangladesh		
15			Č) Barbados		
16) Belarus		
17) Belgium		
18) Belize) Benin		
19) Bhutan		
20) Bolivia		
21) Bosnia and He	erzegovina	
22			Č) Botswana		
23			\subseteq) Brazil		
24 25) Brunei		
25 26) Bulgaria) Burkina Faso		
27) Burundi		
28) Cambodia		
29			Č) Cameroon		
30) Canada		
31				Cape Verde	n Danishlia	
32) Central Africar) Chad	n Republic	
33) Chile		
34				China		
35				Colombia		
36 37			C	Comoros		
38			C	Congo	B	
39) Congo (Demod) Costa Rica	cratic Republic)	
40) Croatia		
41) Cuba		
42) Cyprus		
43) Czechia		
44) Denmark		
45) Djibouti		
46) Dominica) Dominican Re	nublic	
47) East Timor	public	
48) Ecuador		
49 50			Č) Egypt		
51			\subset) El Salvador		
52				Equatorial Gui	inea	
53) Eritrea		
54) Estonia) Eswatini		
55) Ethiopia		
56) Fiji		
57			Č) Finland		
58				France		
59) Gabon		
60) Gambia, The) Georgia		
) Georgia) Germany		
) Ghana		
		For peer review only - http://	bmjopen.bmj.com)/ \$469 66 ut/quid	lelines.xhtml	
		, , , , , , ,) Grenada		A
	02/09/2021 15:46) Guatemala	projectredcap org	₹FDCan°

projectredcap.org

O Philippines

Page 64 of 143

1	
2	
2	
4	
4	
5	
6	
7	
8	
9	
1	0
1	1
1	2
1	3
1	4
1	5
1	6
1	_
1	
	9
	0
2	-
2	
2	
2	
2	-
2	
2	
2	
2	
	0
3	-
3	
3	
3	4
3	5
	6
3	7
3	8
3	9
4	0
	1
4	
4	
	4
	5
4	
4	
	8
	9
	0
	1
5	
5	
5	
	5
5	
5	
	8
	9
6	0

What is or was your father's ethnic group?	Asian/Asian British - Indian
The following categories are the ethnic groups used	Asian/Asian British - PakistaniAsian/Asian British - Bangladeshi
in the UK National Census.	Asian/Asian British - Chinese
	Asian/Asian British - Any other Asian background
	Black/African/Caribbean/Black British - AfricanBlack/African/Caribbean/Black British - Caribbean
	Black/African/Caribbean/Black British - Any other
	Black/African/Caribbean background
	Mixed/Multiple ethnic groups - White and Black Caribbe and Black
	Caribbean Mixed/Multiple ethnic groups - White and Black
	African
	Mixed/Multiple ethnic groups - White and Asian
	 Mixed/Multiple ethnic groups - Any other Mixed/multiple ethnic background
	White - English/Welsh/Scottish/Northern
	Irish/British
	White - IrishWhite - Gypsy or Irish Traveller
	White - dypsy of mish Havelier White - Any other white background
	Other ethnic group - Arab
	 Other ethnic group - Any other ethnic background (please specify)
	Prefer not to say
Please specify your father's ethnic group:	
Was your father born in the UK?	○ No
	Yes
	Do not know Prefer not to answer
	O Trefer flor to distres

)			fghanistan
<u>′</u>			lbania
1			lgeria
+			ndorra
-			ngola
,			ntigua and Barbuda
,			rgentina
3			rmenia
)			ustralia
10			ustria
1			zerbaijan
12			ahamas, The
13			ahrain
14			angladesh
15			arbados
16			elarus
17			elgium
18			elize
19	\bigcirc		enin butan
20	\bigcirc		hutan
21			olivia
22			osnia and Herzegovina
23			otswana
			razil _.
24			runei .
25			ulgaria_
26	Q		urkina Faso
27	Q		urundi
28	Ŏ		ambodia
29	Q		ameroon
30	Q Q		anada
31	Q Q		ape Verde
32		C	entral African Republic
33		C	had
34		C	hile
35			hina
36			olombia
37			omoros
38	\bigcirc	C	ongo (D
39			ongo (Democratic Republic)
			osta Rica
10			roatia
11			uba
12	\bigcirc		yprus
13			zechia
14			enmark
15			jibouti
16			ominica
17			ominican Republic
18			ast Timor
19			cuador
50	\bigcirc) E(gypt
51			l Salvador
52			quatorial Guinea
53			ritrea
54			stonia .
55			swatini
56			thiopia
57			inland
8			rance
59			abon
50			ambia, The
			eorgia
			sermany
			hana
	For peer review only - http://bmjopen.bmj.co@/	/ Ģ ∣	ଏକ୍ଟିକ୍ଲେut/guidelines.xhtml
		G	irenada

O Philippines

Were your grandparents born in the UK?	
Please specify the country in which your father was born:	
	Romania Russia Russia St Kitts and Nevis St Lucia St Vincent Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands South Africa South Syain Spain Sri Lanka Sudan Suriname Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Togo Tonga Trinidad and Tobago Tunisia Tuvalu Uganda Ukraine United Arab Emirates Uruguay Uzbekistan Vanuatu Vatican City Venezuela Vietnam Yemen Zambia Zimbabwe Other (Please specify) Prefer not to answer
	○ Poland○ Portugal○ Qatar

Page 68 of 143

Confidential Page 69 of 143	
Page 09 01 143	

BMJ Open

,	_	op		Page 45
	NOT born in the UK	Born in the UK	Do not know	Prefer not to answer
Your mother's mother	\circ	\circ	\circ	\circ
Your mother's father	\circ	\circ	\circ	\circ
Your father's mother	\bigcirc	\circ	\bigcirc	\circ
Your father's father	\circ	\circ	\circ	\circ
	· ·	· ·	· ·	· ·

Section 3/10: Your ethnic, cultural and national identity and background		
24% complete		
How old were you when you first learned English?	 Always spoken it 2-5 years 6-10 years 11-17 years 18+ Prefer not to answer 	

What language or languages do you speak most often at home?

If you only speak one language at home, please leave the box for "Language 2" blank.



Language 1	○ English
	Afrikaans
	Ŏ Akan
	○ Arabic
	○ Bengali
	○ Bulgarian
	O Burmese
	O Cebuano
	○ Chinese
	O Czech
	O Dutch
) French
	German
	○ Greek
	○ Gujarati
	O 11 '
) Hindi
	○ Hungarian
	○ Igbo
	○ Irish
	() Italian
	Kurdish
	O Latvian
	Lithuanian
	O Malay
	○ Malayalam
	O Maltese
	O Maori
	O Ndebele
	○ Nepali
	O Persian/Farsi
	OPolish
	OPortuguese
	O Punjabi
	Romanian
	Russian
	0 31.31.3
	Sinhala
	Slovakian
	○ Somali
	○ Spanish
	Swahili
	Swedish
	<u>Tagalog</u>
	<u>Tamil</u>
	O Turkish
	O Twi
	Ukrainian
	○ Urdu
	○ Welsh
	○ Xhosa
	○ Yoruba
	Other (Places are sife)
	Other (Please specify)
	Prefer not to answer
Please specify language 1:	

1 2 3	Language 2	EnglishAfrikaans
5 4		○ Akan
5		○ Arabic○ Bengali
6		○ Bulgarian
7		○ Burmese
8		○ Cebuano
9		Chinese
10		© Czech
11		○ Dutch○ French
12		German
13 14		○ Greek
15		Ogjarati
16		○ Hausa
17		○ Hindi
18		○ Hungarian
19		○ Igbo ○ Irish
20		○ Italian
21		○ Kurdish
22		○ Latvian
23		Lithuanian
24		○ Malay
25		○ Malayalam
26 27		○ Maltese ○ Maori
27 28		Ndebele
20 29		○ Nepali
29 30		O Persian/Farsi
31		Polish
32		O Portuguese
33		O Punjabi
34		RomanianRussian
35		Shona
36		Sinhala
37		Slovakian
38		 Somali
39 40		○ Spanish
40 41		○ Swahili
41 42		○ Swedish○ Tagalog
43		○ Tagalog ○ Tamil
44		○ Turkish
45		Ō Twi
46		O Ukrainian
47		○ Urdu
48		○ Welsh○ Xhosa
49		○ Xnosa ○ Yoruba
50		O Zulu
51		Other (Please specify)
52		Prefer not to answer
53 54		
5 4 55	Please specify language 2:	
56		
57		
58		
59		
50		

What language was spoken in your home when you were a	☐ English
child?	☐ Afrikaans
If more than one language was spoken, please give	☐ Akan
them all.	☐ Arabic
	☐ Bengali
	☐ Bulgarian
	☐ Burmese
	☐ Cebuano
	☐ Chinese
	☐ Czech
	□ Dutch
	☐ French
	☐ German
	☐ Greek
	☐ Gujarati
	□ Hausa
	☐ Hindi
	Hungarian
	☐ Igbo
	☐ Irish
	☐ Italian
	☐ Kurdish
	Latvian
	Lithuanian
	☐ Malay
	☐ Malayalam
	☐ Maltese
	☐ Maori
	☐ Ndebele
	☐ Nepali
	☐ Persian/Farsi
	Polish
	Portuguese
	Punjabi
	Romanian
	Shona
	Sinhala
	Slovakian
	☐ Somali
	☐ Spanish
	☐ Swahili
	☐ Swedish
	☐ Tagalog
	☐ Tamil
	☐ Turkish
	□ Twi
	☐ Ukrainian
	Urdu
	☐ Welsh
	☐ Xhosa
	☐ Yoruba
	☐ Zulu
	Other (Please specify)
	Prefer not to answer
	- Freier not to answer
Please specify the language spoken in your home when	
you were a child for which you selected "Other":	
-	

REDCap[®]

26% complete	
•	
What is your religion?	No religion Christian (including Church of England, Catholic
This is the question that was asked in the 2011 UK Census.	 Christian (including Church of England, Catholic, Protestant and all other Christian denominations) Buddhist Hindu Jewish Muslim Sikh Any other religion (please specify) Prefer not to answer
Please specify your religion:	
How important is religion to you in your everyday life?	 ○ Not at all important ○ Fairly important ○ Very important ○ Extremely important ○ Prefer not to answer
How important was religion in your upbringing?	 ○ Not at all important ○ Fairly important ○ Very important ○ Extremely important ○ Prefer not to answer
How often would you usually attend a holy place or a place of worship outside your home?	 Never On festive occasions only Once every few months About once a month Most weeks More than once a week Prefer not to answer

1
2
3
4
5
6
7
8
9
10
11
12
12 13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
43 44
45
46
47
48
49
50
51
52
53
54
55
56
56 57
5 <i>/</i>
59
60

Section 3/10: Your ethnic, cultural and national identity and background		
28% complete		
•		
How important is your ethnic and cultural background to your identity?	○ 0 Not at all important○ 1○ 2	
Use the scale of 0 to 10, where 0 means 'not at all important', and 10 means 'extremely important'.	3 4 5 6 7 8 9 10 Extremely important Prefer not to answer	
How important is/was your mother's ethnic and cultural background to your identity?	0 Not at all important12	
Use the scale of 0 to 10, where 0 means 'not at all important', and 10 means 'extremely important'.	3 4 5 6 7 8 9 10 Extremely important Prefer not to answer	
How important is/was your father's ethnic and cultural background to your identity?	○ 0 Not at all important○ 1○ 2	
Use the scale of 0 to 10, where 0 means 'not at all important', and 10 means 'extremely important'.	3 4 5 6 7 8 9 10 Extremely important Prefer not to answer	
How important is/was your partner's ethnic and cultural background to your identity?	○ 0 Not at all important○ 1○ 2	
Use the scale of 0 to 10, where 0 means 'not at all important', and 10 means 'extremely important'.	3 4 5 6 7 8 9 10 Extremely important Prefer not to answer	

Section 3/10: Your ethnic, cultural and national identity and background

30% complete

₹EDCap°

	which country did you gain your primary offessional qualification?	 Not applicable - I do not hold a professional qualification
		○ ÚK
(Th	ne qualification used for registration with your	○ Australia
	ofessional regulator, such as the GDC, GMC, GOC,	Bangladesh
	hC, PSNI, HCPC, NMC)	O Bulgaria
	-, - ,,	○ Canada
		○ China
		Czech Republic
		Egypt
		○ France
		Germany
		○ Ghana
		○ Greece
		○ Hungary
		○ India
		○ Iran
		○ Iraq
		○ Ireland
		○ Italy
		○ Jamaica
		○ Kenya
		○ Latvia
		○ Libya
		○ Lithuania
		O Malta
		Mauritius
		Myanmar
		○ Népal
		○ Netherlands
		New Zealand
		○ Nigeria
		Pakistan
		O Philippines
		Poland
		Portugal
		Romania
		Russia
		○ Slovakia
		Somalia
		○ South Africa
		○ Spain
		○ Sri Lanka
		○ Sudan
		○ Sweden
		○ Syria
		Trinidad and Tobago
		○ Uganda
		○ Ukraine
		○ USA
		○ Zimbabwe
		Other country (please specify)
		Prefer not to answer
		O Freier flot to diswer
DI.	age an ediffy the country in which you as in advour	
	ase specify the country in which you gained your mary professional qualification:	
۱۰۰۰	2 N. F. 2. 222. 200. Manuscon.	
	which year did you obtain your primary ofessional qualification?	
•	•	((Please enter in format YYYY, e.g. 1990))
		· · · · · · · · · · · · · · · · · · ·

1	
2	
2	
3 4 5 6 7 8 9	
4	
5	
6	
7	
e R	
0	
9	
10	
11	
12	
13	
14	
15	
10	
10	
17	
18	
19	
20	
21	
12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36	
22	
23	
24	
25	
26	
27	
28	
20	
29	
30	
31	
32	
33	
34	
35	
22	
37	
38	
39	
40	
41	
42	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

What is the highest level of education you have completed?	 Primary (up to 11 years) Secondary (11 to 16 years) Post-secondary (16-18 years) Other qualifications below degree level (e.g. nursing diploma) Undergraduate degree or equivalent (e.g. BA, BSc medical or nursing degree) Masters degree or equivalent (e.g. MSc, Ma) Doctorate level (e.g. PhD, MD) Prefer not to answer
What is the highest level of education your mother has completed?	 Primary (up to 11 years) Secondary (11 to 16 years) Post-secondary (16-18 years) Other qualifications below degree level (e.g. nursing diploma) Undergraduate degree or equivalent (e.g. BA, BSc medical or nursing degree) Masters degree or equivalent (e.g. MSc, Ma) Doctorate level (e.g. PhD, MD) Prefer not to answer
What is the highest level of education your father has completed?	 Primary (up to 11 years) Secondary (11 to 16 years) Post-secondary (16-18 years) Other qualifications below degree level (e.g. nursing diploma) Undergraduate degree or equivalent (e.g. BA, BSc medical or nursing degree) Masters degree or equivalent (e.g. MSc, Ma) Doctorate level (e.g. PhD, MD) Prefer not to answer

1	
2	
3	
4	
•	
5	
6	
7	
8	
9	
1	0
1	1
	2
•	_
•	
1	4
1	5
1	6
1	7
1	
1	
	0
2	1
2	2
2	3
2	4
2	5
2	6
2	7
2	8
2	
	0
3	
3	2
3	3
3	
	5
2	6
2	0
ر	′
3	
	9
4	0
4	1
4	
4	3
4	ر ⊿
4	
4	
4	
4	
4	9
5	0
	1
5	
5	
	4
5	
	6
5	7
5	
	9
6	-

33% complete		
In your current main job/role, what proportion of colleagues who are senior to you are of the same ethnic group as yourself?	 ○ None ○ Hardly any ○ Some ○ About a half ○ Most ○ Almost all ○ All ○ Prefer not to answer 	
In your current main job/role, what proportion of your colleagues who are senior to you are White?	 ○ None ○ Hardly any ○ Some ○ About a half ○ Most ○ Almost all ○ All ○ Prefer not to answer 	
Thinking about where you work in your current main job/role, does your organisation act fairly with regard to career progression / promotion, regardless of ethnic background, gender, religion, sexual orientation, disability or age?	 ○ Not at all ○ Rarely ○ Sometimes ○ Mostly ○ Definitely ○ Prefer not to answer 	

Section 4/10: Your home and family life

35% complete

.

This section asks about your home and the people who live with you, to help us to understand more about how things outside work may affect COVID-19 risk.



Section 4/10: Your home and family life	
35% complete .	
The following questions may refer to your household.	
A household is one person living alone, or a group of people (no share cooking facilities and share a living room, sitting room or	
A household can consist of a single family, more than one family	y or no families in the case of a group of unrelated
people. Your household does not include anyone you may be in a suppo address to you.	rt or childcare bubble with who live at a different
Do you have a "support bubble" (in England or Northern Ireland) or "extended household" (in	○ No ○ Yes
Wales or Scotland) which includes people who usually live at a different address?	O Do not know
live at a different address?	Prefer not to answer
How many people are in this "support bubble"?	
Only count those who usually live at a different address.	
Do you have a "childcare bubble" which includes people who usually live at a different address?	○ No ○ Yes
Do not include anyone already counted in the support bubble in the previous question.	Do not knowPrefer not to answer
How many people are in this "childcare bubble"?	
Only count those who usually live at a different address.	1
Apart from you, how many other people are in your household?	$\bigcirc 0$ $\bigcirc 1$
	○ 2 ○ 3
	○ 4○ 5
	○ 6○ 7
	○ 8 ○ 9
	○ 10 ○ 11
	○ 12○ 13 or more people
	O Prefer not to answer

Section 4/10: Your home and family life

40% complete

.

These questions are about each person living with you in your current household. We will ask you about each person in turn. It is your choice as to which order you put them in, but it might help to order them by age, from oldest to youngest.

Reminder: A household is one person living alone, or a group of people (not necessarily related) living at the same address who share cooking facilities and share a living room, sitting room or dining area.

A household can consist of a single family, more than one family, or no families in the case of a group of unrelated people.

Your household does not include anyone you may be in a support or childcare bubble with who live at a different address to you.





1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26 27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
58 59	
29	

40% complete .	
Person 1 - What best describes this person's relationship to you? Please select from the list provided.	Spouse/Partner Child Grandchild Parent Mother-in-law/Father-in-law/Your partner's parent Twin Sibling (not including your twin) Sister-in-law/Brother-in-law/Your partner's sibling Friend/Housemate Grandparent Aunt/Uncle/Your parent's sibling Great-Aunt/Great-Uncle/Your grandparent's sibling Cousin/Other familial relation Colleague Other
Person 1 - How old is this person?	0-1 2-4 5-10 11-16 17-18 19-24 25-34 35-44 45-54 55-64 65-74 75-84 85-94 95+ Prefer not to answer

1 2 3	
3 4 5 6 7	
9 10	
11 12 13 14 15	
16 17 18	
19	
20 21 22 23 24 25 26 27 28 29	
27 28 29 30	
31 32 33	
34 35 36 37	
38 39 40 41	
42 43 44 45	
46 47 48 49	
50 51 52 53	
54 55 56 57	
58 59 60	

Section 4/10: Your home and family life	
42% complete	
Person 2 - What best describes this person's relationship to you?	Spouse/Partner Child Grandchild Parent Mother-in-law/Father-in-law/Your partner's parent Twin Sibling (not including your twin) Sister-in-law/Brother-in-law/Your partner's sibling Friend/Housemate Grandparent Aunt/Uncle/Your parent's sibling Great-Aunt/Great-Uncle/Your grandparent's sibling Cousin/Other familial relation Colleague Other Prefer not to answer
Person 2 - How old is this person?	○ 0-1 ○ 2-4 ○ 5-10 ○ 11-16 ○ 17-18 ○ 19-24 ○ 25-34 ○ 35-44 ○ 45-54 ○ 55-64 ○ 65-74 ○ 75-84 ○ 85-94 ○ 95+ ○ Prefer not to answer

1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
59 60	

44% complete .	
Person 3 - What best describes this person's relationship to you? Please select from the list provided.	 Spouse/Partner Child Grandchild Parent Mother-in-law/Father-in-law/Your partner's parent Twin Sibling (not including your twin) Sister-in-law/Brother-in-law/Your partner's sibling Friend/Housemate Grandparent Aunt/Uncle/Your parent's sibling Great-Aunt/Great-Uncle/Your grandparent's sibling Cousin/Other familial relation Colleague Other Prefer not to answer
Person 3 - How old is this person?	○ 0-1 ○ 2-4 ○ 5-10 ○ 11-16 ○ 17-18 ○ 19-24 ○ 25-34 ○ 35-44 ○ 45-54 ○ 55-64 ○ 65-74 ○ 75-84 ○ 85-94 ○ 95+ ○ Prefer not to answer

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	
17 18 19 20 21 22 23 24 25 26 27 28 29	
30 31 32 33 34 35 36 37 38 39 40 41	
41 42 43 44 45 46 47 48 49 50 51 52 53	
54 55 56 57 58 59 60	

Section 4/10: Your home and family life	
46% complete	
•	
Person 4 - What best describes this person's relationship to you? Please select from the list provided.	 Spouse/Partner Child Grandchild Parent Mother-in-law/Father-in-law/Your partner's parent Twin Sibling (not including your twin) Sister-in-law/Brother-in-law/Your partner's sibling Friend/Housemate Grandparent Aunt/Uncle/Your parent's sibling Great-Aunt/Great-Uncle/Your grandparent's sibling Cousin/Other familial relation Colleague Other Prefer not to answer
Person 4 - How old is this person?	○ 0-1 ○ 2-4 ○ 5-10 ○ 11-16 ○ 17-18 ○ 19-24 ○ 25-34 ○ 35-44 ○ 45-54 ○ 55-64 ○ 65-74 ○ 75-84 ○ 85-94 ○ 95+ ○ Prefer not to answer

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
50
57
58
59
60

Section 4/10: Your home and family life	
47% complete .	
Person 5 - What best describes this person's relationship to you? Please select from the list provided.	 Spouse/Partner Child Grandchild Parent Mother-in-law/Father-in-law/Your partner's parent Twin Sibling (not including your twin) Sister-in-law/Brother-in-law/Your partner's sibling Friend/Housemate Grandparent Aunt/Uncle/Your parent's sibling Great-Aunt/Great-Uncle/Your grandparent's sibling Cousin/Other familial relation Colleague Other Prefer not to answer
Person 5 - How old is this person?	○ 0-1 ○ 2-4 ○ 5-10 ○ 11-16 ○ 17-18 ○ 19-24 ○ 25-34 ○ 35-44 ○ 45-54 ○ 55-64 ○ 65-74 ○ 75-84 ○ 85-94 ○ 95+ ○ Prefer not to answer

1 2 3	
3 4 5 6 7 8 9	
13 14 15	
17 18 19 20	
21 22 23 24	
12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36	
30 31 32 33	
34 35 36 37	
38 39 40 41	
42 43 44 45	
46 47 48 49 50	
51 52 53 54	
55 56 57 58	
59 60	

Section 4/10: Your home and family life	
49% complete	
Person 6 - What best describes this person's relationship to you? Please select from the list provided.	 Spouse/Partner Child Grandchild Parent Mother-in-law/Father-in-law/Your partner's parent Twin Sibling (not including your twin) Sister-in-law/Brother-in-law/Your partner's sibling Friend/Housemate Grandparent Aunt/Uncle/Your parent's sibling Great-Aunt/Great-Uncle/Your grandparent's sibling Cousin/Other familial relation Colleague Other Prefer not to answer
Person 6 - How old is this person?	0-1 2-4 5-10 11-16 17-18 19-24 25-34 35-44 45-54 55-64 65-74 75-84 85-94 95+ Prefer not to answer

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
51 52
32
55
54
55
56
57
58
59
60
UU

Section 4/10: Your home and family life	
51% complete .	
Person 7 - What best describes this person's relationship to you? Please select from the list provided.	Spouse/Partner Child Grandchild Parent Mother-in-law/Father-in-law/Your partner's parent Twin Sibling (not including your twin) Sister-in-law/Brother-in-law/Your partner's sibling Friend/Housemate Grandparent Aunt/Uncle/Your parent's sibling Great-Aunt/Great-Uncle/Your grandparent's sibling Cousin/Other familial relation Colleague Other Prefer not to answer
Person 7 - How old is this person?	○ 0-1 ○ 2-4 ○ 5-10 ○ 11-16 ○ 17-18 ○ 19-24 ○ 25-34 ○ 35-44 ○ 45-54 ○ 55-64 ○ 65-74 ○ 75-84 ○ 85-94 ○ 95+ ○ Prefer not to answer

1 2 3 4 5	
7 8 9 10 11 12	
13 14 15 16 17 18 19	
20 21 22 23 24 25 26	
27 28 29 30 31 32 33	
34 35 36 37 38 39	
40 41 42 43 44 45 46	
47 48 49 50 51 52	
53 54 55 56 57 58 59	
60	

Section 4/10: Your home and family life	
53% complete	
Person 8 - What best describes this person's relationship to you? Please select from the list provided.	Spouse/Partner Child Grandchild Parent Mother-in-law/Father-in-law/Your partner's parent Twin Sibling (not including your twin) Sister-in-law/Brother-in-law/Your partner's sibling Friend/Housemate Grandparent Aunt/Uncle/Your parent's sibling Great-Aunt/Great-Uncle/Your grandparent's sibling Cousin/Other familial relation Colleague Other Prefer not to answer
Person 8 - How old is this person?	0-1 2-4 5-10 11-16 17-18 19-24 25-34 35-44 45-54 55-64 65-74 75-84 85-94 95+ Prefer not to answer

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
40 41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
57 58
58 59
60

54% complete	
•	
Person 9 - What best describes this person's relationship to you? Please select from the list provided.	 Spouse/Partner Child Grandchild Parent Mother-in-law/Father-in-law/Your partner's parent Twin Sibling (not including your twin) Sister-in-law/Brother-in-law/Your partner's sibling Friend/Housemate Grandparent Aunt/Uncle/Your parent's sibling Great-Aunt/Great-Uncle/Your grandparent's sibling Cousin/Other familial relation Colleague Other Prefer not to answer
Person 9 - How old is this person?	○ 0-1 ○ 2-4 ○ 5-10 ○ 11-16 ○ 17-18 ○ 19-24 ○ 25-34 ○ 35-44 ○ 45-54 ○ 55-64 ○ 65-74 ○ 75-84 ○ 85-94 ○ 95+ ○ Prefer not to answer

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	
17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32	
33 34 35 36 37 38 39 40 41 42 43 44 45 46 47	
48 49 50 51 52 53 54 55 56 57 58 59 60	

Section 4/10: Your home and family life	
56% complete	
Person 10 - What best describes this person's relationship to you? Please select from the list provided.	 Spouse/Partner Child Grandchild Parent Mother-in-law/Father-in-law/Your partner's parent Twin Sibling (not including your twin) Sister-in-law/Brother-in-law/Your partner's sibling Friend/Housemate Grandparent Aunt/Uncle/Your parent's sibling Great-Aunt/Great-Uncle/Your grandparent's sibling Cousin/Other familial relation Colleague Other Prefer not to answer
Person 10 - How old is this person?	○ 0-1 ○ 2-4 ○ 5-10 ○ 11-16 ○ 17-18 ○ 19-24 ○ 25-34 ○ 35-44 ○ 45-54 ○ 55-64 ○ 65-74 ○ 75-84 ○ 85-94 ○ 95+ ○ Prefer not to answer

1	
2	
_	
3	
4	
5	
Э	
6	
7	
,	
7 8	
9	
10	
11	
12	
13 14	
14	
15	
16	
17	
16 17 18	
10	
19	
20	
21	
21	
21 22	
23 24	
23	
24	
25	
26	
26 27	
27	
28	
29	
30 31 32 33 34	
21	
31	
32	
33	
2.4	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

Section 4/10: Your home and family life	
58% complete	
Person 11 - What best describes this person's relationship to you? Please select from the list provided.	Spouse/Partner Child Grandchild Parent Mother-in-law/Father-in-law/Your partner's parent Twin Sibling (not including your twin) Sister-in-law/Brother-in-law/Your partner's sibling Friend/Housemate Grandparent Aunt/Uncle/Your parent's sibling Great-Aunt/Great-Uncle/Your grandparent's sibling Cousin/Other familial relation Colleague Other Prefer not to answer
Person 11 - How old is this person?	○ 0-1 ○ 2-4 ○ 5-10 ○ 11-16 ○ 17-18 ○ 19-24 ○ 25-34 ○ 35-44 ○ 45-54 ○ 55-64 ○ 65-74 ○ 75-84 ○ 85-94 ○ 95+ ○ Prefer not to answer

1 2 3	
3 4 5 6 7	
9 10	
11 12 13 14 15	
16 17 18	
19	
20 21 22 23 24 25 26 27 28 29	
27 28 29 30	
31 32 33	
34 35 36 37	
38 39 40 41	
42 43 44 45	
46 47 48 49	
50 51 52 53	
54 55 56 57	
58 59 60	

 Spouse/Partner Child Grandchild Parent Mother-in-law/Father-in-law/Your partner's parent Twin Sibling (not including your twin) Sister-in-law/Brother-in-law/Your partner's sibling Friend/Housemate Grandparent Aunt/Uncle/Your parent's sibling Great-Aunt/Great-Uncle/Your grandparent's sibling Cousin/Other familial relation Colleague Other Prefer not to answer
0-1 2-4 5-10 11-16 17-18 19-24 25-34 35-44 45-54 55-64 65-74 75-84 85-94 95+ Prefer not to answer

Section 4/10: Your home and family life	
62% complete	
If you live with more than 12 people, please state the relationship to you and ages for the others in this box separated by a comma, e.g.:	

Aunt 56, Colleague 25





Section 4/10: Your home and family life	
62% complete	
Apart from yourself, how many people in your household travel to work using public transport?	(Enter the number of people)
Apart from yourself, how many people in your household work in jobs that often bring them into close physical contact (within 2 metres) with others?	(Enter the number of people)

Some examples include: bus driver, carer, cleaner,

doctor, supermarket checkout worker, teacher.

2

3

4

5

6

7

8 9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29 30 31

32

33

34

35

36

37 38 39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

BMJ Open

 \bigcirc 1953

	○ 1952○ 1951○ 1950
	○ 1949 ○ 1948
	○ 1947
	<u> </u>
	○ 1945 ○ 1944
	○ 1944 ○ 1943
	○ 1942
	<u></u> 1941
	○ 1940 ○ 1930
	○ 1939 ○ 1938
	○ 1937
	<u>0</u> 1936
	○ 1935 ○ 1934
	○ 1934 ○ 1933
	○ 1932
	○ 1931
	○ 1930 ○ 1929
	○ 1929 ○ 1928
	○ 1926 ○ 1925
	○ 1924 ○ 1923
	○ 1922
	○ 1921 ○ 1922
	○ 1920○ Prefer not to answer
In which month did you move to your current address?	◯ Jan ◯ Feb
	Mar
	Apr
	May
	○ Jun ○ Jul
	O Aug
	○ Sep
	O Oct
	○ Nov ○ Dec
	Prefer not to answer
What type of accommodation are you currently living	O Detached house
in?	Semi-detached house
	Terraced houseFlat or apartment
	○ Hostel
	Mobile home or caravan
	Mobile home or caravanSheltered house
	Mobile home or caravanSheltered houseHomeless
	Mobile home or caravanSheltered house
Please specify what type of accommodation you live in:	Mobile home or caravanSheltered houseHomelessOther (please specify)

BMJ Open

Page 98 of 143

Is your current accommodation provided by or linked to your employer, e.g. hospital staff accommodation?	○ No○ Yes○ Prefer not to answer
How many rooms are in your accommodation (not including the kitchen and bathroom(s))?	
Do you share any of the following rooms with people you do not consider to be a part of your household? You may select more than one answer. If you do not share any of the rooms listed, please select 'None'.	 None Kitchen Bathroom Living room, sitting room or dining area Prefer not to answer
Does your accommodation include shared communal areas such as hallways, stairwells or lifts?	○ No○ Yes○ Prefer not to answer
Does your accommodation have a safe outdoor space (e.g., a garden or yard) where you can exercise or relax?	○ No○ Yes○ Prefer not to answer
Is your garden/yard shared with other households or private?	○ Shared ○ Private ○ Prefer not to answer

Section 5/10: Your friends and social network

63% complete

This section asks questions about your friends, social relationships and social networks.

REDCap[®]

_	
1	
3	
3 4	
4	
6	
7	
8	
9	
1	0
1	1
1	2
1	3
1	4
1	
1	
1	
1	8
	9
	0
2	
2	
2	
2	
	5
	6
2	8 9
	9 0
2	1
3	
3	
3	
	5
3	
3	
3	
3	
4	0
4	1
4	2
4	3
	4
4	5
4	6
4	7
4	8
	9
	0
5	1
5	
5	3
	4
	5
5	6
5	/ 8
2	8 9
_	
О	U

53% complete						
How many people outside those in f you are answering this questionn	your househo	old did you tal artphone, you	k with in the la may find it eas	st week (but no sier to view by r	ot as a part of	of your work) screen.
	0	1-5	6-20	21-50	51+	Prefer not to answer
Remotely (e.g. over the phone, social media or via video media)	\circ	0	0	0	0	0
ace-to-face with social	\bigcirc	\bigcirc	\circ	\bigcirc	\bigcirc	\bigcirc
distancing With physical contact (e.g. nandshake/hug/kiss, etc)	0	0	0	0	0	0
What proportion of your friends are ethnic group as yourself?	of the same		○ None○ Hardly a○ Some○ About a○ Most○ Almost a○ All○ Prefer no	half		

Section 6/10: Harassment and discrimination

64% complete

People from any background can be harassed or discriminated against for many reasons.

This section asks about your experiences of discrimination and harassment. Depending on your experiences, you may find some of the questions upsetting or difficult. You can stop at any time and return later if you wish, or you can choose not to answer a question.

You can find information about sources of support on our website and from the organisations below:

- Victim Support support for people affected by crime or traumatic events, including hate crime: https://www.victimsupport.org.uk/
- Samaritans Emotional support for everyone: www.samaritans.org
- Mind Advice and support for anyone with a mental health problem: www.mind.org.uk



1	
2	
3	
4	
5	
6	
7	
8	
9	
	0
1	
1	1
1	2 3
1	3
1	4
1	5
1	6
1	7
1	8
	9
2	0
2	1
2	2
2	3
2	ر ا
2	4
	5
2	6
2	7
2	8
2	9
3	0
3	1
3	2
3	3
	4
2	5
	6
3	
	8
3	
4	
4	1
4	2
4	3
4	4
4	
	6
4	7
	8
4	
5	
5	
5	
5	3
5	4
5	5
5	6
5	
	8
	9
	9
O	U

Section 6/10: Harassment and discrimination							
64% complete							
In your day-to-day life, how often	do any of th	e following	things happe	en to you?			
If you are answering this question	naire on a s	martphone	, you may fin	d it easier to	o view by rota	ating the s	creen.
	Almost everyday	At least once a week	A few times a month	A few times a year	Less than once a year	Never	Prefer not to answer
You are treated with less courtesy than other people are.	0	\circ	0	\circ	0	0	0
You are treated with less respect than other people are.	0	0	0	0	0	0	\circ
You receive poorer service than other people at restaurants or shops.	0	0	0	0	0	0	0
People act as if they think you are not smart.	0	0	0	0	0	0	0
People act as if they are afraid of you.	0		\circ	0	0	0	0
People act as if they think you are dishonest.	0	0	0	0	\circ	0	0
People act as if they're better than you are.	0	0	0	0	0	0	0
You are called names or	\bigcirc	\circ		\bigcirc	\bigcirc	\bigcirc	\bigcirc
insulted You are threatened or harassed.	0	0	0	\circ	0	0	0
What do you think are the reasons for these experiences? Please select all that apply. Your gender Your ethnicity Your age Your religion Your height Your height Your health or disability Your dress Some other aspect of your physical appearance Your sexual orientation Your education or income level Your social class Other (please specify) Prefer not to answer							
Please specify what you think is these experiences:	ne main reas	son for					

In the last 12 months have you personally expediscrimination at work from any of the following Select all that apply.
On what grounds have you experienced discrimat work?
Please specify the grounds on which you have experienced discrimination at work:
Did you make a complaint about the discrimina work?

n the last 12 months have you personally experienced discrimination at work from any of the following? Select all that apply.	 □ Patients / service users, their relatives or other members of the public □ Manager / team leader or other colleagues □ I have not experienced discrimination at work in the last 12 months □ I have not worked in the last 12 months □ Prefer not to answer
On what grounds have you experienced discrimination at work?	 Your national origins Your gender Your ethnicity Your age Your religion Your height Your weight Your health or disability Your dress Some other aspect of your physical appearance Your sexual orientation Your education or income level Your language or accent Your social class Other (please specify) Prefer not to answer
Please specify the grounds on which you have experienced discrimination at work:	
Did you make a complaint about the discrimination at work?	 ○ No ○ No - but I did consider it ○ Yes - informally ○ Yes, I made a formal complaint ○ Prefer not to answer

Section 7/10: Your health

67% complete

.

This section asks about your overall physical and mental health. It will ask about:

- Height and weight
- · Cigarette, vaping and alcohol usage
- Exercise and physical activity
- · Overall health and specific health problems
- Mental health issues





1
2
3
4
5
6
0
7
8
9
2
10
11
12
13
14
15
16
17
18
19
19 20
20
21
22
21 22 23
2.4
24 25 26
25
26
27
27 28
28
29
29 30
31
32
32
33
34
35
33
36
37
38
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
56
57
58
59
60

Section 7/10: Your health	
67% complete	
What is your current height?	 Enter height in centimetres Enter height in feet and inches Do not know Prefer not to answer
Please enter your current height to the nearest centimetre:	
Feet	
Inches	
What is your current weight?	Enter weight in kilogramsEnter weight in stones and poundsDo not knowPrefer not to answer
Please enter your current weight in kilograms:	
Stones	
Pounds	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Section 7/10: Your health	
68% complete	
Do you or have you ever smoked tobacco?	NeverEx-smokerCurrent smokerPrefer not to answer
Do you currently use an e-cigarette or vape?	YesNoPrefer not to answer
How often do you have a drink containing alcohol?	 Never Monthly or less 2-4 times per month 2-3 times per week 4+ times per week Prefer not to answer
How many units of alcohol do you drink in a typical week? If you are unsure, see the guide below. Pint of standard strength (3.6%) lager/beer/cider 2 units Pint of higher strength (5.2%) lager/beer/cider 3 units Medium (175ml) glass of wine 2 units Large (250ml) glass of wine 3 units Bottle (275ml) of alcopop1 1.5 units Single shot (25ml) of spirits (e.g. vodka, whisky, gin, rum) 1 unit	0 1-7 8-14 15-21 22-28 29-35 36-50 51+ Prefer not to answer (Select the number of units)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
43 44
45
43 46
47
48
40 49
50
51
51 52
52 53
53 54
54 57
55
56 57
5/
58
59 60
60

Section 7/10: Your health					
71% complete					
•					
Think about a typical week at work month. Please consider the type an physical activity involved in your w	d amount of	Ŏ	I spend most of		
Please select one option only.			My work involve including handli tools	s definite physic ng of heavy obje s vigorous physi	cts and use of
				ng of very heavy loyment	
During the last week, about how many hours did you spend on each of the following activities? If you are answering this questionnaire on a smartphone, you may find it easier to view by rotating the screen.					
	None	Less than 1 hour	1 - 3 hours	3 hours +	Prefer not to answer
Physical exercise such as swimming, jogging, aerobics, football, tennis, gym workout etc.	0	0	0	0	0
Cycling, including cycling to work and during leisure time	0	0	0	0	0
Walking, including walking to work, shopping, for pleasure etc.	0	0	0	0	0
Housework/Childcare	\circ		\circ	\bigcirc	\bigcirc
Gardening/DIY	0	0	0	0	0
How would you describe your usual Please select one option only.	walking pace	0	Slow pace Steady average Brisk pace Fast pace Prefer not to ans		

1	
1	
3	
4	
5	
6	
7	
8	
9	
1	1
1	
1	
1	
	5
1	
1	
1	8 9
	9 0
2	
2	
2	3
2	
_	5
	6
2	/ 8
2	_
	0
3	
3	2
3	3
3	4
_	5
3	
	, 8
	9
	ó
4	1
	2
4	3
	4
	5 6
4	7
4	8
	9
	0
5	1
5 5	1 2
5 5 5	1 2 3
5 5 5 5	1 2 3 4
5 5 5 5	1 2 3 4 5
5 5 5 5 5	1 2 3 4 5 6
5 5 5 5 5 5	1 2 3 4 5 6 7
5 5 5 5 5 5	1 2 3 4 5 6 7 8
5 5 5 5 5 5 5 5	1 2 3 4 5 6 7
5 5 5 5 5 5 5 5	1 2 3 4 5 6 7 8 9

Section 7/10: Your healt	h				
72% complete					
•					
Has your lifestyle changed sin	ice the beginning of the C	COVID-19 pandemic?			
Select 'This has not changed' if an option does not apply, e.g. you still do not smoke. If you are answering this questionnaire on a smartphone, you may find it easier to view by rotating the screen.					
	I do this more often	This has not changed	I do this less often	Prefer not to answer	
Smoking	\circ	\circ	\circ	\circ	
Drinking alcohol	\circ	\circ	\bigcirc	\circ	
Eating healthy food	\bigcirc	\circ	\circ	\circ	
Physical activity (including walking and cycling)	0	0	0	0	

1	
3	
4 5	
6	
8	
9	0
1	1
1 1	
1	4
	5 6
1	7
1	8 9
	0 1
2	2
2	3 4
2	5
	6 7
2	8 9
3	0
3	1 2
3	3
	4 5
3	6 7
3	8
3 4	9
4	1
4	
4	
4	6
4 4	
4	9
5	0 1
5 5	2
5	4
5 5	
5	7
5 5	
_	_

Section 7/10: Your health	
73% complete	
Last year, in 2019, how many times did you have a consultation with your GP about your own health?	○ 0 ○ 1 ○ 2 ○ 3-5 ○ 6-10 ○ 11-20 ○ 21+ ○ Prefer not to answer
Last year, in 2019, how many days did you spend as a hospital inpatient?	○ 0 ○ 1 ○ 2 ○ 3-5 ○ 6-10 ○ 11-20 ○ 21+ ○ Prefer not to answer
Did you have a flu vaccine last winter (2019-2020)?	○ No○ Yes○ Do not know○ Prefer not to answer
Have you had a flu vaccine for this winter (2020-2021)?	○ No○ Yes○ Do not know○ Prefer not to answer
Have you been contacted by letter or text message to say you are at severe risk from COVID-19 due to an underlying health condition and should be shielding?	○ No○ Yes○ Do not know○ Prefer not to answer
Do you currently take any of these medications/supplements?	☐ Ibuprofen / Nurofen, any other type of non-steroidal anti-inflammatory ☐ Vitamin D
Please select all that apply. If you do not take any of these, please select "None of these".	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
50 51
51 52
<i>J</i> 2
55
J-T
55
56
57
58
59

Are you, or do you, currently have any of the following?	☐ Pregnant ☐ Organ transplant ☐ Diabetes (Type Ler II)
Please select all that apply. If none apply to you, please select "None of the above".	 □ Diabetes (Type I or II) □ Heart disease or heart problems □ Hypertension □ Overweight □ Stroke □ Kidney disease □ Liver disease □ Anaemia □ Asthma □ Other lung condition such as COPD, bronchitis or emphysema □ Cancer □ Condition affecting the brain and nerves (e.g. Dementia, Parkinson's, Multiple Sclerosis) □ A weakened immune system or reduced ability to deal with infections (as a result of a disease or treatment)
	□ Depression □ Anxiety □ Psychiatric disorder □ None of the above □ Prefer not to answer

Section 7/10: Your health

74% complete

Some of the following questions ask about your mental health. We would like to reassure you that your answers will be treated in accordance with strict research governance procedures, and the study has been reviewed by the Brighton and Sussex Research Ethics Committee.

If do not wish to answer a question, then please click on 'Prefer not to answer', or leave it blank.

For help during a mental health crisis or emergency:

Call 999 or go to A&E now if your life is at risk, or if you do not feel you can keep yourself safe.

For free confidential advice or to talk about anything that's troubling you, no matter how difficult: Call 116 123 to talk to Samaritans at any time of day or night, or email: jo@samaritans.org for a reply within 24 hours Text "SHOUT" to 85258 to contact the Shout Crisis Text Line, or text "YM" if you're under 19 You can find a local NHS urgent mental health helpline here Urgent sources of support are also summarised at this NHS webpage. Other sources of support include: the Covid-19 Workforce Wellbeing pages, the mental health charity Mind, and Victim Support for victims of crime.



74% complete	
•	
Please select the ONE option that best describes your health TODAY.	
	 ○ I have no problems in walking about ○ I have slight problems in walking about ○ I have moderate problems in walking about ○ I have severe problems in walking about ○ I am unable to walk about
MOBILITY	
© EuroQol Research Foundation. EQ-5D™ is a trade mark of the	e EuroQol Research Foundation. UK (English) v2.1



74% complete	
Please select the ONE option that best describes your health 7	TODAY.
	 ○ I have no problems washing or dressing myself ○ I have slight problems washing or dressing myself ○ I have moderate problems washing or dressing myself ○ I have severe problems washing or dressing myself ○ I am unable to wash or dress myself
SELF-CARE	
© EuroQol Research Foundation. EQ-5D™ is a trade mark of the search Foundation.	



74% complete	
Please select the ONE option that best describes your health	n TODAY.
	 ○ I have no problems doing my usual activities ○ I have slight problems doing my usual activities ○ I have moderate problems doing my usual activities ○ I have severe problems doing my usual activities ○ I am unable to do my usual activities
USUAL ACTIVITIES (e.g. work, study, housework, family or leisure activities)	
© EuroOol Research Foundation, FO-5D™ is a trade mark of	f the EuroOol Research Foundation, UK (English) v2.1



74% complete	
•	
Please select the ONE option that best describes	your health TODAY.
PAIN / DISCOMFORT	 ○ I have no pain or discomfort ○ I have slight pain or discomfort ○ I have moderate pain or discomfort ○ I have severe pain or discomfort ○ I have extreme pain or discomfort
© FuroOol Research Foundation FO-5D™ is a tra	de mark of the EuroOol Research Foundation, LIK (English) v2.1



74% complete	
•	
Please select the ONE option that best describes your he	alth TODAY.
ANXIETY / DEPRESSION	 ○ I am not anxious or depressed ○ I am slightly anxious or depressed ○ I am moderately anxious or depressed ○ I am severely anxious or depressed ○ I am extremely anxious or depressed
© EuroQol Research Foundation. EQ-5D™ is a trade mark	k of the EuroQol Research Foundation. UK (English) v2.1



74% complete			
We would like to know how good or bad your health is TODAY.			
This scale is numbered from 0 to 100. 100 means the best health you can imagine. 0 means the worst health you can imagine.			
Using the slider, please indicate how your health is TODAY.	0 The worst health you can imagine	50	100 The best health you can imagine

(Place a mark on the scale above)

© EuroQol Research Foundation. EQ-5D™ is a trade mark of the EuroQol Research Foundation. UK (English) v2.1

REDCap[®]

1	
2	
3	
4	
5	
6	
7	
8 9	
	0
	1
1	2
1	3
1	4
	5
1	6
1	7
	8 9
	0
2	1
2	2
2	3
2	4
2	5
	6
2	7
	8
	9
2	0 1
3	
3	
	4
3	5
3	6
3	
	8
	9
4	0
4	
4	
4	_
4	5
4	
4	7
4	8
4	9
5	0
5	1 2
5	3
5	4
5	5
5	6
5	
	8
	9
6	0

Section 7/10: Your health						
78% complete						
Over the last 2 weeks, how often h	ave you been	bothered by any	of the follow	wing problem	s?	
If you are answering this questionr	aire on a sma	artphone, you ma	y find it easi	er to view by	rotating the	screen.
	Not at all	Several days	More that		y every day	Prefer not to answer
Feeling nervous, anxious or on edge?	0	0	0		0	0
Not being able to stop or control worrying?	0	0	0		\circ	0
Little interest or pleasure in doing things	0	\circ	0		0	0
Feeling down, depressed, or hopeless?	0	0	0		0	0
How worried are you about your fu situation? These questions are about problem		aints that neonle		t ely it y t to answer	nse to stresst	ful life
experiences. Please indicate how n If you are answering this questionn	nuch you have	e been bothered artphone, you ma	by each prol	olem in the pa er to view by	ast month.	screen.
	Not at all	A little bit	Moderately	Quite a bit	Extremely	Prefer not to answer
Repeated, disturbing memories, thoughts, or images of a stressful experience from the past?	0	0	0	0	0	0
Feeling very upset when something reminded you of a stressful experience from the past?	0	0	0	0	0	0
Avoided activities or situations because they reminded you of a stressful experience from the past?			0		0	0

1
2
3
4 5
6
7
8
9
10 11
12
13
14
15
16
17 18
19
20
21
22 23
23 24
25
26
27
28
29 30
31
32
33
34
35 36
30 37
38
39
40
41 42
42 43
44
45
46
47 48
49
50
51
52
53 54
54 55
56
57
58
59 60
OU

Section 7/10: Your health				
80% complete				
The following statements describ feel this way. If you are answering this questio				
	Hardly ever or never	Some of the time	Often	Prefer not to answer
How often do you feel you lack companionship?	, 0	0	\circ	0
How often do you feel left out?	\bigcirc	\bigcirc	\circ	\circ
How often do you feel isolated from others?	0	0	0	0
Overall, how satisfied are you wi nowadays? Please give an answer on a scale is 'not at all' and 10 is 'complete	of 0 to 10, where 0	0 Not at al 1 2 3 4 5 6 7 8 9 10 Comple Prefer not	etely satisfied	

Section 7/10: Your health

This is the end of the questions about your mental health. We have repeated the information about sources of support from the beginning of this section here. For help during a mental health crisis or emergency:

Call 999 or go to A&E now if your life is at risk, or if you do not feel you can keep yourself safe.

For free confidential advice or to talk about anything that's troubling you, no matter how difficult: Call 116 123 to talk to Samaritans at any time of day or night, or email: jo@samaritans.org for a reply within 24 hours Text "SHOUT" to 85258 to contact the Shout Crisis Text Line, or text "YM" if you're under 19 You can find a local NHS urgent mental health helpline here Urgent sources of support are also summarised at this NHS webpage. Other sources of support include: the Covid-19 Workforce Wellbeing pages, the mental health charity Mind, and Victim Support for victims of crime.





Section 8/10: Your health and COVID-19

81% complete

01/0 00111

This next section asks questions about COVID-19 and your health and your feelings about the pandemic. It will ask about:

What changes you made during the UK national lockdown COVID-19 tests and whether you have had COVID-19 The chances of catching COVID-19 The possible effects of COVID-19 on society Possible vaccines for COVID-19 Attitudes towards the COVID-19 pandemic





81% complete				
Have you been in close contact with anyone with COVID-19 outside of your work in the last two weeks?		 Yes, someone in my household had/has confirmed/tested COVID-19 Yes, someone in my household had/has suspect COVID-19 Yes, contact with a confirmed/tested COVID-19 outside of my household Yes, contact with a suspected COVID-19 case outside of my household No, not to my knowledge Prefer not to answer 		
Thinking back to when COVID-19 w 23rd March 2020, which of the follo few weeks? Please select all that apply.				
	Between January 2020and March 2020	Past few weeks	Prefer not to answer	
Cancelling my usual social activities				
Not going to work				
Only going shopping for essential things				
Not going to a grocery store or pharmacy				
Not leaving the house				
Wearing a face mask outside my home				
Trying to avoid physical contact with people		70		
Following handwashing recommendations				
Using hand sanitiser more than usual				
Following coughing and sneezing recommendations				
Using tissues more than usual				
Wearing gloves while going out of my home				
Avoiding public transport				
Avoiding going to restaurants/bars/pubs				

dential	ВМЈ О	pen	Page 124 of 143 Page 100
Avoiding going for walks or exercise outside			
Avoiding taking my children out of my home (if applicable)			
Prefer not to answer			
Thinking back to the months of UK nawhich began on 23rd March, which of so your view?		 ○ I enjoyed a few aspect ○ I enjoyed some aspect ○ I enjoyed most aspects ○ I enjoyed almost all of ○ Prefer not to answer 	ut the UK national lockdown is of the UK national lockdown is of the UK national lockdown the UK national lockdown the UK national lockdown.

1 2	
3	
4 5	
6 7	
8	
9 10	
11 12	
13	
14 15	
16 17	
18	
19 20	
21 22	
23	
24 25	
26 27	
28	
29 30	
31 32	
33	
34 35	
36 37	
38	
39 40	
41 42	
43 44	
45	
46 47	
48 49	
50	
51 52	
53 54	
55	
56 57	
58 59	
60	

Section 8/10: Your health and COVID-19	
83% complete	
Have you ever had a test to see if you have or have had COVID-19? Select all that apply.	 No Yes, A swab test (swab of your throat and/or nose) which tests for active infection Yes, An antibody test for COVID-19 (a blood test, or a drop of blood from your finger) which tests for past infection Do not know Prefer not to answer
What was the reason that you had the swab test? Please select all that apply.	 □ Because I had symptoms □ Because I have been in contact with someone who had COVID-19 □ Because of my job □ Before going into hospital as a patient (e.g. for surgery) □ It was offered by my local council (e.g. posted through my door) □ For another reason (please specify) □ Prefer not to answer
Please specify the reason you had the swab test:	
Have you ever had a positive result from a swab test (i.e. showing that you had coronavirus when the swab was taken)?	○ No○ Yes○ Do not know○ Prefer not to answer
When was the sample taken for the test that came back positive?	
Give the latest date if you have had more than one	
Have you had a positive result from an antibody test (i.e. showing that you had coronavirus at some time previously)?	○ No○ Yes○ Do not know○ Prefer not to answer
When was the sample taken for the test that came back positive?	
Give the latest date if you have had more than one	

☐ Fever ☐ Cough - dry ☐ Cough - mucus or phlegm ☐ Sore throat ☐ Chest tightness ☐ Shortness of breath ☐ Runny nose ☐ Nasal congestion
☐ Cough - mucus or phlegm ☐ Sore throat ☐ Chest tightness ☐ Shortness of breath ☐ Runny nose ☐ Nasal congestion
☐ Sore throat ☐ Chest tightness ☐ Shortness of breath ☐ Runny nose ☐ Nasal congestion
☐ Chest tightness ☐ Shortness of breath ☐ Runny nose ☐ Nasal congestion
☐ Shortness of breath ☐ Runny nose ☐ Nasal congestion
☐ Nasal congestion
☐ Sneezing☐ Muscle or body aches
☐ Fatigue
Unusual loose motions or diarrhoea
☐ Vomiting ☐ Loss of smell
Loss of taste
☐ Skin rash
☐ None of these
☐ Prefer not to answer
○ No
Unsure
Yes, my own suspicions
Yes, suspected by a doctor but not testedYes, confirmed by a positive test
Prefer not to answer
○ Jan
○ Feb
○ Mar○ Apr
May
○ Jun
◯ Jul ◯ Aug
Sep
Oct
○ Nov
O Dec Prefer not to answer
Trefer flot to allswer
○ 2021
○ 2020 ○ 2019
Prefer not to answer
○ No ○ Yes
Prefer not to answer
○ No ○ Yos
○ Yes○ Prefer not to answer
C

1	
2	
3	
_	
4	
5	
6	
7	
8	
9	
-	0
1	1
1	2
1	3
1	
1	
1	6
1	7
1	8
1	
	0
2	
2	
2	_
2	-
	5
2	
2	
2	8
2	9
3	0
3	
3	
3	_
3	_
3	
3	2
3	6
3	′
3	
3	
1	Λ
4	1
4	2
4	3
4	4
4	
4	
4	
4	
4	
	0
5	1
5	
5	3
5	
5	
	6
5	
ر 5	
	o 9
	()

How long have you been unwell since having COVID-19?	 Less than 3 weeks 3 - 5 weeks More than 5 weeks but less than 3 months More than 3 months but less than 6 months More than 6 months Prefer not to answer
Has any health professional told you that your symptoms are likely to be the ongoing effect of COVID-19?	YesNoPrefer not to answer



1	
2	
3	
4	
5	
6	
0	
/	
8	
9	
10	
11	
12	
12	
13	
14	
15	
16	
17	
18	
10	
19	
20	
21	
22	
23	
24	
25	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

Section 8/10: Your health and COVID-19	
89% complete	
•	
How concerned are you that you will get COVID-19 and require hospitalisation?	 Not at all concerned A little concerned Quite concerned Very concerned Prefer not to answer
How concerned are you that you might unknowingly spread COVID-19 to others?	 Not at all concerned A little concerned Quite concerned Very concerned Prefer not to answer
Do you personally know anyone who has died from COVID-19 (not including patients you have cared for as part of your work)? Select all that apply.	 Yes, family member(s) Yes, friend(s) Yes, colleague(s) Yes, someone else No Prefer not to answer
Where do you get information about COVID-19? Select all that apply.	☐ Friends, family, neighbours ☐ Colleagues ☐ Employer or manager ☐ Television ☐ Radio ☐ Newspapers or magazines ☐ Government or NHS posters, adverts or leaflets ☐ Twitter ☐ Other social media (e.g. Facebook, Instagram) ☐ UK Government website ☐ Welsh, Scottish or NI government website ☐ NHS website ☐ WHO website ☐ Other websites ☐ Local council ☐ My own GP or other healthcare workers ☐ Scientific journals ☐ Not applicable ☐ Prefer not to answer

		,
1		
2		
3		
4		
_		
•		٠
5		
7		
5 7 3		
a		
, 1	0	
	1	
1	2	
1	3	
1	4	
1	_	
	6	
1	7	
1	8	
1	9	
•	012345678901234-	
_	1	
2	1	
2	2	
2	3	
2	4	
)	5	
<u>-</u>	ر د	
_	0	
2	/	
2	8	
2	9	
3	0	
2	1	
ر د	י ר	
3	_	
3	3	
3	4	
3	5	
2	6	
3	7	
	, ^	
3	_	
3		
	0	
4	1	
4		
4		
	4	
4		
4	_	
4	7	
	8	
4		
	0	
5		
5	2	
5	3	
	4	
5		
	6	
5	7	
5	8	
5		

Section 8/10: Your health and COVID-19	
92% complete	
·	
What do you think is your personal chance of catching the coronavirus in the next month?	
Please enter a value on a scale from 0 to 100, where 0 means there is no possibility that you will and 100 means that you definitely will.	
What do you think is your personal chance of catching the coronavirus in the next six months?	
Please enter a value on a scale from 0 to 100, where 0 means there is no possibility that you will and 100 means that you definitely will.	
If you do catch coronavirus, what do you think are your chances of needing hospital treatment? Please enter a value on a scale from 0 to 100, where 0 means there is no possibility that you will and 100 means that you definitely will.	
What percentage of people in the UK who are hospitalised with coronavirus do you think will end up dying as a result of the disease? Please enter a value on a scale from 0 to 100, where 0 means nobody hospitalised will die and 100 means everybody hospitalised will die.	



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Section 8/10: Your health and COVID-19	
93% complete	
Have you taken part in a trial of a COVID-19 vaccine?	YesNo, but I would if askedNo, but I would not if askedPrefer not to answer
If yes, which one?	
The following question refers to any vaccine you have been COVID-19 vaccine trial.	offered or may be offered that is not as part of a
Have you had, or are you going to have, a vaccination against COVID-19?	 ○ I have already had at least one COVID-19 vaccination ○ I have not had a vaccination but have been told that I will be offered a vaccination in the near future ○ I have been offered a vaccination but have decided not to have the vaccine ○ I have not yet been offered a vaccination but intend to have the vaccine when offered ○ I have not yet been offered a vaccination but have decided not to have a vaccine when offered ○ Prefer not to answer
How many doses have you had?	○ 1 ○ 2 ○ Unsure ○ Prefer not to answer
Was the vaccination:	○ In a hospital○ In a care home○ From a GP○ Other○ Prefer not to answer
Please specify:	
What was the date when you had your first vaccination? (if you are unsure please give your best estimate)	
Which vaccine did you receive?	 ○ Pfizer-Biontech ○ Oxford-AstraZeneca ○ Moderna ○ Other ○ Unsure ○ Prefer not to answer
Please specify:	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Did you consider not having the vaccination?	○ No○ Yes, I did consider not having the vaccination○ Prefer not to answer
What would have been your reason(s) for not having the vaccination? Please select all that apply.	☐ I have allergies, needle-phobia, am immuno-compromised, or have other clinical reasons not to be vaccinated ☐ I am concerned about the safety or potential side-effects of a COVID-19 vaccine ☐ I am not convinced that COVID-19 vaccines will be effective ☐ Vaccines may not have been tested thoroughly in all ethnic groups ☐ I have had COVID-19 and therefore do not feel I need the vaccine ☐ I am taking part in a clinical trial of a COVID-19 vaccine ☐ I would prefer one of the other COVID-19 vaccines that are being developed ☐ I would prefer to wait until many other people have received a COVID-19 vaccine ☐ I do not feel that I personally am at risk from COVID-19 ☐ I would rather the vaccine were used for other people who need it more than I do ☐ I do not believe in vaccinations in general ☐ Other reason ☐ Prefer not to answer
Please specify:	
When is the vaccination likely to be?	 ○ In a few days ○ In the next week ○ In the next two weeks ○ In the next month ○ Other ○ Prefer not to answer
Please specify:	
Will this vaccination be:	 ○ In a hospital ○ In a care home ○ From a GP ○ Other ○ Prefer not to answer
Please specify:	
Are you considering not having the vaccination?	 ○ No ○ Yes, I am considering not having the vaccination ○ Prefer not to answer

1	
י ר	
2	
3	
4	
5	
6	
7	
/	
8	
9	
10	
11	
12	
13	
14	
15	
15 16	
17	
10	
18	
18 19 20	
20	
21	
22	
22	
23	
24	
25	
22 23 24 25 26 27 28 29	
27	
20	
28	
28 29 30	
30	
31	
32	
33	
33	
34 35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
JU	

What might be your reason(s) for not having the vaccination? Please select all that apply.	☐ I have allergies, needle-phobia, am immuno-compromised, or have other clinical reasons not to be vaccinated ☐ I am concerned about the safety or potential side-effects of a COVID-19 vaccine ☐ I am not convinced that COVID-19 vaccines will be effective ☐ Vaccines may not have been tested thoroughly in all ethnic groups ☐ I have had COVID-19 and therefore do not feel I need the vaccine ☐ I am taking part in a clinical trial of a COVID-19 vaccine ☐ I would prefer one of the other COVID-19 vaccines that are being developed ☐ I would prefer to wait until many other people have received a COVID-19 vaccine ☐ I do not feel that I personally am at risk from COVID-19 ☐ I would rather the vaccine were used for other people who need it more than I do ☐ I do not believe in vaccinations in general ☐ Other reason ☐ Prefer not to answer
Please specify:	
Was the vaccination offered by:	○ A hospital○ A care home○ A GP○ Other○ Prefer not to answer.
Please specify:	

₹EDCap°

What were your reason(s) for not having the vaccination? Please select all that apply.	 I have allergies, needle-phobia, am immuno-compromised, or have other clinical reason
vaccination? Please select all that apply.	not to be vaccinated
	☐ I am concerned about the safety or potential
	side-effects of a COVID-19 vaccine
	☐ I am not convinced that COVID-19 vaccines will be effective
	□ Vaccines may not have been tested thoroughly in all ethnic groups
	☐ I have had COVID-19 and therefore do not feel I
	need the vaccine
	☐ I am taking part in a clinical trial of a COVID-19 vaccine
	\square I would prefer one of the other COVID-19 vaccines
	that are being developed I would prefer to wait until many other people
	have received a COVID-19 vaccine ☐ I do not feel that I personally am at risk from
	COVID-19
	I would rather the vaccine were used for other people who need it more than I do
	☐ I do not believe in vaccinations in general
	Other reason
	☐ Prefer not to answer
Please specify:	
Alban and the control of the control	O No.
When you are offered the vaccine, is there anything that might make you consider not having it?	NoYes, I would consider not having the vaccine
	Prefer not to answer
What are your reason(s) for considering not having	☐ I have allergies, needle-phobia, am
the vaccine? Please select all that apply.	immuno-compromised, or have other clinical reasons
	not to be vaccinated
	☐ I am concerned about the safety or potential side-effects of a COVID-19 vaccine
	☐ I am not convinced that COVID-19 vaccines will be
	effective
	 Vaccines may not have been tested thoroughly in all ethnic groups
	☐ I have had COVID-19 and therefore do not feel I
	need the vaccine
	□ I am taking part in a clinical trial of a COVID-19 vaccine
	☐ I would prefer one of the other COVID-19 vaccines
	that are being developed
	 I would prefer to wait until many other people have received a COVID-19 vaccine
	\square I do not feel that I personally am at risk from
	COVID-19
	I would rather the vaccine were used for other people who need it more than I do
	☐ I do not believe in vaccinations in general
	☐ Other reason
	☐ Prefer not to answer
Please specify:	
	<u></u>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
10
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

What are your reason(s) for not having the vaccination? Please select all that apply. Please specify:			immuno-compromised, or have other clinical reasor not to be vaccinated I am concerned about the safety or potential side-effects of a COVID-19 vaccine I am not convinced that COVID-19 vaccines will be effective Vaccines may not have been tested thoroughly in all ethnic groups I have had COVID-19 and therefore do not feel I need the vaccine I am taking part in a clinical trial of a COVID-19 vaccine I would prefer one of the other COVID-19 vaccines that are being developed I would prefer to wait until many other people have received a COVID-19 vaccine I do not feel that I personally am at risk from COVID-19 I would rather the vaccine were used for other people who need it more than I do I do not believe in vaccinations in general Other reason Prefer not to answer						
How much do you agree with the fo	ollowing stater	nents about	vaccinations in	general?					
	1 Strongly disagree	2	3	4	5 Strongly agree	Prefer not to answer			
I can rely on vaccines to stop serious infectious diseases	\circ	0	0	0	0	0			
Although most vaccines appear to be safe, there may be problems that we have not yet discovered	0	0	0	0	0	0			
Authorities promote vaccination for financial gain, not for people's health	0	0	0	0	0	0			
Being exposed to diseases naturally is safer for the immune system than being exposed through vaccination	0	0	0	0	0	0			
When, if at all, do you think it will k vaccinate most of the population a		virus?	18 montl2 years fMore thaDo not ke	s from now s from now s from now hs from now hs from now rom now n 2 years					

1	
2	
3	
4	
5	
6	
7	
8	
9	
	0
1	
1	2
1	3
1	4
1	5
1	6
1	7
1	8
	9
2	0
2	1
2	2
2	3
2	4
2	5
	6
	7
	8
	9
3	0
3	1
3	
3	3
3	
	5
	6
3	
	8
	9
4	
	1
4	
4	
4	4
	5
	6
4	1
	8
4 5	
5	
5	
5	
5	_
	4 5
	5 6
5	
	Q
5	8 0
5 5	9
5	9
5 5	9

Section 8/10: Your health and COVID-19
94% complete
The coronavirus pandemic will have many effects in the UK, five of which are shown below. How serious do you think each of them is in terms of its consequences?

Please select the relevant number next to the statement (i.e. if you believe "Effects on economy and jobs" to be the most serious then select '1' for this effect).

You will only be able to select each number once.

If you are answering this questionnaire on a smartphone, you may find it easier to view by rotating the screen.

	1 (Most serious)	2	3	4	5 (Least serious)	Prefer not to answer
Effects on children and their education	0	0	0	0	0	0
Effects on the economy and jobs	0	\bigcirc	\circ	\bigcirc	\circ	\circ
Increasing deaths as a direct result of catching coronavirus	0	0	0	0	0	\circ
Increased deaths due to fewer healthcare resources to identify and treat medical conditions other than coronavirus	0		0	0	0	0
Increased mental health issues	0	0	0	0	0	0
When a vaccine becomes available receive it?	e, would you w	vish to	O Definitel O Probably O Probably O Definitel O Prefer no	Yes No		

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58

Section 8/10: Your health and COVID-19									
96% complete .									
Do you think the coronavirus crisis will increase or decrease the level of inequality in the UK, compared with before the pandemic? O Increase a lot O Increase a bit O Decrease a bit O Decrease a lot O Prefer not to answer									
To what extent do you think the for thoughts, and don't look up the an		nts about COVID-	19 are true or fal	se? Give your imr	nediate				
If you are answering this question	naire on a smartp	hone, you may f	ind it easier to vi	ew by rotating the	e screen.				
	Definitely true	Probably true	Probably false	Definitely false	Prefer not to answer				
A person can be infected twice with coronavirus	0	0	0	0	0				
Coronavirus is less infectious than the influenza virus	0	0	0	0	0				
Coronavirus was created in a laboratory	0	0	0	0	0				
Infection with coronavirus is equally likely in men and women	0	0	0	0	0				
Mortality from coronavirus is higher in men than women	0	0	0	0	0				
Most people in the UK have already had coronavirus without realising it	0	0	0	0	0				
The current pandemic is part of a global effort to force everyone to be vaccinated whether they want to or not	0	0	20	0	0				
The genetic material in a coronavirus is RNA, unlike that of humans which is DNA	0	0	0	0	0				
The number of people reported as dying from coronavirus is being deliberately reduced or hidden by the authorities	0	0	0	0	0				
The symptoms that most people blame on coronavirus appear to be linked to 5G network radiation	0	0	0	0	0				
There is no hard evidence that coronavirus really exists	0	0	0	0	\circ				

Section 9/10: Your approach to life in general

96% complete

People differ in many ways. The questions below cover a range of ways that people can differ from one another, in terms of values, attitudes, and approach to life in general.

For most of the questions there is no right or wrong answer. Do not think too hard about each answer but instead give the one that most immediately seems correct for you, being as honest as you can.





1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	

Section 9/10: Your approach to life in general

96% complete

.

The following questions are about how you see yourself as a person.

Please select the number which best describes how you see yourself where 1 means 'does not apply to me at all' and 7 means 'applies to me perfectly'.

I see myself as someone who...

If you are answering this questionnaire on a smartphone, you may find it easier to view by rotating the screen.

	Does not apply to me at all (1)	2	3	4	5	6	Applies to me perfectly (7)	Prefer not to answer
Is sometimes rude to others	0	\circ	\bigcirc	\circ	\bigcirc	\bigcirc	\circ	\bigcirc
Does a thorough job	0	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
Is talkative	0	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
Worries a lot	0	\bigcirc	\bigcirc	\circ	\bigcirc	\bigcirc	\circ	\bigcirc
Is original, comes up with new ideas	0	0	0	0	0	0	0	0
Has a forgiving nature	\circ	0	\circ	\bigcirc	\bigcirc	\circ	\bigcirc	\bigcirc
Tends to be lazy	\circ	\circ	0	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
Is outgoing, sociable	\circ	0	0	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
Gets nervous easily	\circ	\bigcirc	0	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
Values artistic, aesthetic experiences	0	0	0	0	0	0	0	0
Is considerate and kind to almost everyone	0	0	0	0	0	0	0	0
Does things efficiently	\bigcirc	\bigcirc	\bigcirc	0	\circ	\bigcirc	\circ	\bigcirc
Is reserved	\bigcirc	\bigcirc	\bigcirc	0		\bigcirc	\circ	\bigcirc
Is relaxed, handles stress well	\bigcirc	\bigcirc	\bigcirc	0	0	\bigcirc	\bigcirc	\bigcirc
Has an active imagination	\circ	\bigcirc	\circ	\circ	0	\bigcirc	\circ	\circ

Section 9/10: Your approach to life in general

97% complete

.

For each of the following statements, indicate the extent to which you agree or disagree by selecting a number from 1 (Strongly disagree) to 7 (strongly agree).

If you are answering this questionnaire on a smartphone, you may find it easier to view by rotating the screen.

	1 (Strongly disagree)	2	3	4	5	6	7 (Strongly agree)	Prefer not to answer
My life is determined by my own actions	0	0	0	0	0	0	0	0
I am usually able to protect my personal interests	0	0	0	0	0	0	0	0
I can pretty much determine what will happen in my life	0	0	0	0	0	0	0	0
To a great extent, my life is controlled by accidental happenings	0	0	0	0	0	0	0	0
Often there is no chance of protecting my personal interest from bad luck happenings	0	0	0	0	0	0	0	0
When I get what I want, it's usually because I'm lucky	0	0	0	0	\circ	0	0	0
People like myself have very little chance of protecting our personal interests where they conflict with those of strong pressure groups	0	0	0	0	0	0	0	0
My life is chiefly controlled by powerful others	\circ	0	0	0	0	0	0	0
I feel like what happens in my life is mostly determined by powerful people	0	0	\bigcirc	0	0	0	0	0
If someone is meant to have a serious disease, they will get that disease.	0	0	\circ	0	0	0	0	0
My health is determined by fate.	\circ	\circ	\bigcirc	\bigcirc	\bigcirc	\circ	\circ	\circ
My health is determined by something greater than myself.	\circ	0	0	\circ	0	0	0	\circ
I will stay healthy if I am lucky.	\circ	\circ	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\circ	\bigcirc
I like having a clear and structured mode of life	0	0	0	0	\circ	0	0	\circ

Con	fidential		В	MJ Open					Page 140 of 143 Page 116
1 2 3 4	I would quickly become impatient and irritated if I could not find a solution to a problem immediately	0	0	0	0	0	0	0	0
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 38 39 40 40 40 40 40 40 40 40 40 40 40 40 40	Genes are more important than one's own behaviour in determining one's health								

02/09/2021 15:46 projectredcap.org



1	
2	
3	
4	
5	
6	
7	
8	
9	
1	0
1	1
1	2
1	3
	4
1	5
1	6
1	7
	8
	9
2	0
2	1
2	2
2	
	4
2	5
	6
2	
	8
2	9
	0
3	1
3	
3	3
3	4
2	5
3	
3	7
3	8
3	
4	
4	1
4	2
4	3
4	
4	
4	
4	7
4	
4	
	0
5	
5	2
5	
5	
5	
5	6
5	
5	
5	
6	0

Section 9/10: Your approach to life in general		
98% complete		
How do you see yourself: are you generally a person who is fully prepared to take risks or do you try to avoid taking risks? Please select a number on the scale, where the value 0 means: 'not at all willing to take risks' and the value 10 means: 'very willing to take risks'.	 0 Not at all willing to take risks 1 2 3 4 5 6 7 8 9 10 Very willing to take risks Prefer not to answer 	

Think back to the work you were doing at the end of 2019 or in early 2020 before the UK national lockdown on 23rd March 2020. How well do the following statements describe your typical work environment at that time?

If you had more than one job, think about your main job/role. If you were not working please select "not applicable".

If you are answering this questionnaire on a smartphone, you may find it easier to view by rotating the screen.

	Definitely disagree	Somewhat disagree	Somewhat agree	Definitely agree	Not applicable	Prefer not to answer
There was a real opportunity for me to choose the particular things I worked on	0	0	0	0	0	0
My work colleagues really tried hard to get to know one another	0	0	0	0	0	0
I had a lot of choice about the work I did	0	0	0	0	0	0
I was required to do too many different things	\circ	0	0	0	0	0
My coworkers were supportive and friendly towards me	0	0	0	0	0	0
There seemed to be too much work to get through	0	0	0	0	0	0

Think back to the work you were doing at the end of 2019 or early 2020 before the UK national lockdown on 23rd March 2020. How well do the following statements describe overall the way you felt about your work at that time?

If you had more than one job, think about your main job/role. If you were not working please select "Not applicable".

If you are answering this questionnaire on a smartphone, you may find it easier to view by rotating the screen.

Col	n	fi
-01	•	• •
		-
1		
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		
26		
27		
28		
29		
30		
31		
32		
33		
34		
35		
36		
37		
38		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		

				DIVID OP	-11					Page 118
		Never	A few times a year	Once a month or less	A few times a month	Once a week	A few times a week	Every day	Not applicabl e	Prefer not to answer
	I was exhausted in the morning at the thought of another day at work	0	0	0	0	0	0	0	0	0
	When I was working I forgot everything else around me	0	\circ	0	\circ	0	0	0	0	0
)	I didn't have enough energy for family and friends during leisure time	0	0	0	0	0	0	0	0	0
} -	I was proud of the work that I did	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\circ	\bigcirc
	At work I felt bursting with energy	0	0	0	0	0	0	\circ	0	0
;))										
<u>.</u> ;										
,										
)										
; 										
3										
1										
; ;										
3										
)										
}										

Τ̈́	a	'n
•	ч	=
1		
2		
3		
4		
5		
ر		
6		
7		
8		
9		
1	0	
1	1	
!	!	
1	2	
1	3	
	4	
	5	
1	6	
1	7	
	, 8	
1	9	
2	0	
2	1	
2	2	
2	3	
	4	
2	5	
2	6	
2		
2	/	
	8	
2	9	
	0	
ر	٠	
3	1	
3	2	
3	3	
	4	
3	5	
3	6	
3		
3	8	
3	9	
	0	
4	U	
4		
4	2	
4		
4		
4	5	
4	6	
4		
4	8	
4	9	
5		
5		
5	2	

54

55

56

57

58

59

60

Section 10/10: A few last questions 99% complete contributed to the UK-REACH study.

The guestionnaire is now almost finished, and we are very grateful to you for having completed it so far and having

People filling in questionnaires often feel that although they have answered a lot of questions they often have not had the chance to say what they really feel about issues that have come up. There are therefore three open-ended questions on very broad issues, to do with:

- Why ethnic minorities might be more vulnerable to COVID-19
- How society might change as a result of COVID-19
- How your own future might change as a result of COVID-19

Only if you want to, please type whatever you want to say into the three boxes. You should have more than enough space, and the computer will tell you how much space you have left. Often open-ended comments such as these can provide much of interest to researchers.

Finally, there are two short questions asking for a little feedback on the questionnaire itself, about whether you think it might be useful and whether you think it was far too long.

What are your thoughts on why people from ethnic minorities working in health and care have been more severely affected by COVID-19?	
How do you see society changing as a result of COVID-19?	
How do you see your own future changing as a result of COVID-19?	
Two very last questions:	
We know that the questionnaire was long. Did you think:	 ○ It should have asked about a lot more things ○ It should have asked about some more things ○ It was about the right length ○ It should have been shorter ○ It should have been much shorter
How useful do you think this questionnaire might be for researching and understanding COVID-19 in ethnic minorities?	 ○ Not at all useful ○ Not very useful ○ Fairly useful ○ Very useful ○ Extremely useful

Thank you very much for your assistance in this study, which is very much appreciated.

Information about the progress of the study and the research findings will be placed on the UK-REACH website. If you are affected by any of the issues raised in this questionnaire or are looking for information on COVID-19 (coronavirus) please visit:

- Government guidelines: www.gov.uk/coronavirus
- NHS advice: https://www.nhs.uk/conditions/coronavirus-covid-19/symptoms/
- NHS Where to get urgent help for mental health:

https://www.nhs.uk/using-the-nhs/nhs-services/mental-health-services/where-to-get-urgent-help-for-mental-health/

- Covid-19 Workforce Wellbeing: https://www.practitionerhealth.nhs.uk/covid-19-workforce-wellbeing
- Victim Support support for people affected by crime or traumatic events, including hate crime: https://www.victimsupport.org.uk/
- Samaritans Emotional support for everyone: www.samaritans.org
- Mind Advice and support for anyone with a mental health problem: www.mind.org.uk

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No.
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4,5
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	5,6
		(b) For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8-10
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8-10
Bias	9	Describe any efforts to address potential sources of bias	10
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	10
		(b) Describe any methods used to examine subgroups and interactions	10
		(c) Explain how missing data were addressed	NA
		(d) If applicable, explain how loss to follow-up was addressed	NA
		(e) Describe any sensitivity analyses	NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	NA
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	NA
		(b) Indicate number of participants with missing data for each variable of interest	NA
		(c) Summarise follow-up time (eg, average and total amount)	NA
Outcome data	15*	Report numbers of outcome events or summary measures over time	NA
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear	NA

		which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	NA
		(c) If relevant, consider translating estimates of relative risk into absolute	NA
		risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and	NA
		sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	NA
Limitations	19	Discuss limitations of the study, taking into account sources of potential	NA
		bias or imprecision. Discuss both direction and magnitude of any potential	
		bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives,	NA
		limitations, multiplicity of analyses, results from similar studies, and other	
		relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	NA
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study	13
		and, if applicable, for the original study on which the present article is based	

^{*}Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.